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SUMMARY 
Therapeutic proteins have assumed a key role in the treatment of various diseases such as 
cancer, inflammation, viral infections, metabolic disorders and diseases of the central nervous 
system.1 However, physical and chemical instability present a challenge in the development of 
protein therapeutics. Physical (e.g. unfolding, denaturation, precipitation, aggregation and 
surface adsorption) and chemical (e.g., Asn deamidation, racemization, scrambling, reduction 
or oxidation of disulfides, hydrolysis, or amino acid oxidation) degradation can possibly occur 
during purification, formulation and process development, apart from degradation during 
storage, transport or possibly, compounding and patient administration.1,2 Physical 
degradation includes protein aggregation and proteinaceous (subvisible and visible) particle 
formation. Both have been reported as a potential critical quality attribute, as being 
considered potentially relevant to induce immunogenicity.3 However, to date, the available 
data in literature for investigations of aggregates, subvisible and visible particles 
immunogenicity using in vitro and in vivo experiments is often conflicting and fragmented. 
Some examples of recent studies are briefly described below. 
• Filipe et al. have observed that not all IgG aggregates seem to pose the same 
immunogenic risk after they administered them to transgenic and non-transgenic 
mice.4 They found out that oxidation of aggregates had more impact on 
immunogenicity than any other aggregate features investigated in their work (size, 
amount, structural conformation, hydrophobicity, morphology and type of 
intermolecular linkage). 
• Fradkin et al. could observe that UV treated samples of murine growth hormone have 
shown an immunogenic response in Balb/c or Nude Balb/c mice.5 However, they 
could not find out if the heightened immune response was initiated by chemical 
damage, the presence of microparticulate aggregates, or a combination of both 
features. 
• Although all of the types of murine mAb aggregates tested by Freitag et al. provoked 
the generation of ADAs, not all of them were equally immunogenic in C57BL/6 J and 
BALB/c mice.6 In their manuscript, the most immunogenic aggregates after 
subcutaneous injection were of relatively large and insoluble nature, with perturbed 
non-native structures. Therefore they suggested that the characteristics (e.g., size, 
solubility, extent of chemical modification, conformation) of the aggregates may 
influence their pharmacokinetics and immunogenicity but in this study they also 
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concluded that the size of aggregates is not exclusively responsible for ADA 
formation. 
• In a different study, size enriched fraction in the 5-10 m range of mAb particles 
obtained by sedimentation and FACS following 20h stir stress, were observed by 
Telikepalli et al. to be able to induce relatively high cytokine response in PBMC 
donors compared with other size ranges.7 Those particles presented amorphous 
morphology, contained protein with partially altered secondary structure, elevated 
surface hydrophobicity, and trace levels of elemental fluorine. 
As described before, a number of studies have been reported in the literature but it is still 
difficult to draw sound conclusions from the reported results. A more systematic research of 
different sizes and types of subvisible particles is thus needed in order to understand if a 
correlation of particles to immunogenicity exists and how specific particle species would relate 
to immunogenic effects. A major caveat of the published studies to date is the use of complex 
mixtures of therapeutic protein monomer, various aggregates and particle populations 
spanning a large range of sizes and possibly including a variety of chemical variations. 
However, potential effects generated by individual species (i.e. different size or modification) 
are difficult to delineate in such complex mixtures, as individual species are not easy to obtain. 
Therefore, fractionation methods to obtain subvisible particle fractions having discrete sizes 
may provide significant advantage in further researching distinct species of proteinaceous 
subvisible particles in relevant in vivo or in vitro test systems, possibly being able to identify 
specific subvisible species primarily relevant for a potential biological consequence, if 
occurring.  
Extended sample characterizations are essential to support and better understand the results 
obtained from immunogenicity investigations. Although various techniques for the analysis of 
subvisible particle in parenteral drugs are available on the market (please see Figure 1) with 
methods having been developed successfully over the years, the quantification of particles in 
the submicrometer particle size range still remains a significant challenge.  
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Figure 1: Operation ranges of the more common methods for the analysis of aggregates and 
subvisible/visible particles (adapted from Zölls and Nahri). SEC-HPLC/MALLS, size-exclusion 
chromatography/multi-angle light scattering8-10; AUC, analytical ultracentrifugation11; CE-SDS, sodium dodecyl 
sulfate capillary electrophoresis 12; AF4, asymmetrical flow field flow fractionation13; DLS/SLS, dynamic light 
scattering and static light scattering14, NTA, nanoparticle tracking analysis15; RMM, resonant mass measurement16; 
QLD, quantitative laser diffraction17; FACS, fluorescence activated cell-sorting18,19; CC, coulter counter20; 
MFI/Flowcam, microflow digital imaging21-23; LO, light obscuration24-26; Visual inspection. 
Strengths and weaknesses of the different analytical techniques were evaluated over the last 
years.1,27 The different analytical techniques have different principles and therefore different 
sources of error affecting directly the accuracy and precision of the performed measurements. 
For example, in the field of protein particle analysis, researchers have been using estimated 
density values for sizing using Resonant Mass Measurement principle (RMM also known as 
Archimedes) and for calculating protein particle mass. Such assumptions certainly introduce 
an error into the results. Chapter 1 describes the determination of the density of 
proteinaceous particles, without extrapolation, using RMM. The use of various media with 
different densities allowed to determine the density of artificially generated protein particles 
in a size range < 5 m by using a suspended microchannel resonator. Commercially available 
standard beads (latex, polymethacrylate and melamine) of a defined size and density were 
used to establish a method to determine the density of the studied protein particles (mAb1, 
mAb2 and BSA). This step was required, in order to establish and optimize the method 
parameters. 
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Most of published studies have evaluated immunogenic potential only by using 
heterogeneous-sized aggregated and particulated samples.4,28-31 A major disadvantage of those 
published studies is the use of complex mixtures of protein monomer, aggregates and 
subvisible particles of various sizes. In chapter 2, different techniques were evaluated in order 
to generate preparative well-defined size fractions and isolates of subvisible proteinaceous 
particles. A comparative evaluation study between a differential centrifugation method and a 
fractionation using flow cytometry (preparative fluorescence activated cell sorting – FACS) 
was carried out using a model IgG1. The strengths and weaknesses of each fractionation 
method are discussed. Fractionation of particles is important, as there is a remaining gap 
where the actual particle size associated with immune activation has not been thoroughly 
addressed yet. 
Due to the fact that oxidation might be a relevant modification for proteins and protein 
particles in order to induce immunogenic signals, protocols were generated that selectively 
induce oxidation products that are prominent and known oxidation side products. Based on 
published studies, methionine and tryptophan are the most common modifications found in 
samples generated under forced oxidation reactions (e.g., H2O2, t-BHP, AAPH, Fenton 
reaction, or UV exposure).32,33 However, the effects and the contribution of individual protein 
modifications are difficult to delineate as different amino acids are often oxidized 
simultaneously during those reactions. Chapter 3 describes a method that was developed in 
order to selectively oxidize methionine and tryptophan. The use of oxidants such as H2O2 or 
AAPH, combined with the use of antioxidants (L-methionine or L-tryptophan) and well-
defined reaction conditions (such as incubation temperature and reaction time) allowed us to 
almost selectively oxidize either methionine or tryptophan in our model mAb, in order to 
further study the impact of these modifications on immunogenicity. This approach was 
developed in order to avoid long and complex fractionation processes of oxidized residues. 
In chapter 4 the biological effects of proteinaceous subvisible particles using a transgenic 
mouse model were evaluated. Subvisible particles were generated using artificial heat stress. 
Unfractionated material of subvisible particles and isolated fractions thereof, differing in size, 
were prepared using the developed differential centrifugation method and the preparative 
FACS fractionation method. Non-oxidized subvisible particle samples as well as samples 
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presenting various levels of oxidized Trp-and Met-residues ((a) high Trp and Met oxidation 
combined, (b) high Met oxidation only,(c) high Trp oxidation only and (d) a mixture of 
several oxidized species obtained after UV exposure) were tested in vivo in wild-type and 
transgenic mice after subcutaneous injection. The samples were characterized in detail, using 
particles measuring instruments (light obscuration, micro flow imaging and resonant mass 
measurements) and LC/MS peptide mapping. 28 days post immunization blood sera of both 
wild type and transgenic mice were tested for the presence of anti-drug antibodies (ADAs) by 
ELISA. The protein structure integrity was assessed using Fourier-transform infrared 
microscopy (FTIR). 
Within the present work, techniques were developed that helped to assess potential 
immunogenicity of size fractions of subvisible particles and (selectively) oxidized particles in a 
transgenic mouse model. It was shown that subvisible particles per se, independent of their 
size, were unable to trigger an immunogenic response. However, subvisible particles having 
high extent of chemical modifications (oxidation) were able to break tolerance in the 
transgenic mice.  
In summary, this thesis has shown that artificially generated particles (unfractionated material 
or well-defined fractions) using an IgG1 mAb were not immunogenic in our transgenic 
mouse model, unless extensively oxidized. However, the specific oxidation products required 
to trigger the response in transgenic mice could not be identified yet. More work in the field 
will be needed to understand which specific size and modifications are needed to break 
tolerance and induce an immune response in transgenic mouse models. 
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General introduction  
Protein pharmaceuticals are increasingly used to treat life threatening and chronic diseases, 
such as several forms of cancer and inflammation, viral infections, metabolic disorders and 
central nervous system diseases.34,35 Millions of lives have been improved or saved, since the 
beginning of commercialization of monoclonal antibodies and recombinant therapeutic 
proteins in the 1980s. 1 In the last four years (2010-2014), monoclonal antibodies represented 
more than a quarter of the new biopharmaceutical products approved by the FDA.36 In 2011, 
more than 300 mAb-based therapeutics were in clinical trials.37 Their market value has been 
steadily rising, reaching total cumulative sales value of more than $63 billion for 2013.36 This 
achievement is the result of many years of research and development addressing myriad 
discovery and quality challenges.38 Adverse immune responses severely hamper the successful 
application of therapeutic proteins. 
1.1 Immunogenicity of biotherapeutic products and its assessment using in vitro/in vivo
models  
1.1.1 Adaptive immune response 
Since their launch in the mid-1980s, therapeutic monoclonal antibodies (mAb) have evolved 
from mice, to chimeric and humanized derivatives, to fully human molecules. It was assumed 
that human therapeutic antibodies, or engineering of antibodies to a human form, would 
bypass the immunogenicity problem because of the self-tolerance of human for the constant 
regions of their own antibodies. However, mouse, chimeric, humanized as well as human 
monoclonal antibodies have shown to elicit a high rate of immunogenicity depending on the 
dosing regimen and patient population.3 Some human antibodies developed using phage 
display may have significant anti-drug antibody (ADA) responses.  
Novel structural formats like fusion proteins, multispecific antibodies, single chain fragments, 
single domain antibodies, and specifically engineered antibodies with mutations (in the 
constant or variable regions), may elicit immune responses.3 
Foreign antigens trigger a classical immune reaction that is dependent upon T-cell activation. 
The likelihood of an immunological reaction is higher because of the higher probability of a 
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foreign epitope being recognized by a T cell. To trigger an immune response a therapeutic 
protein interacts with several types of immune cells such as professional antigen-presenting 
cells (APCs), B-cells and T cells.39 APCs (e.g., dendritic cells (DCs), macrophages and B cells) 
have the capacity to take up, process and display linear peptide epitopes from an encountered 
antigen. Moreover, APCs present the ability to signal and direct T cells to respond in an 
appropriate manner. DCs are well established to be the most important cell type for guiding 
immune responses. After the uptake of the antigen, DCs migrate from the peripheral tissues 
(e.g. subcutaneous space) to the spleen and lymph nodes. After the digestion of antigens by 
phagocytosis has occurred, the resulting peptides are presented on their surface to other cells 
of the immune system by major histocompatibility complexes class II (MHC-II). This newly 
assembled peptide-MHC complex is then transported to the surface of the cell for recognition 
by T cell receptors (TCRs) from CD4+ T cells. Beside this first signal mediated by the 
TCR/peptide–MHC interaction, two other signals - co-stimulation and recognition of soluble 
cytokines - have to be presented as well for activation of a naïve CD4+ T cell (also called T cell 
maturation). The same peptide-MHC complex is then recognized by the activated CD4+ T 
cell on a naïve B cell.39 This activation of B cells starts generating antibody-secreting (short- 
and long-lived) plasma B cells. Some of the activated B cells also become memory cells, which 
maintain the pool of long-lived plasma cells and react rapidly to rechallenge by producing 
short-lived plasma cells. This T cell-dependent immune response is thus usually long lasting 
and of high titer, particularly for foreign or exogenous proteins. 
The human immune system is usually tolerant to proteins of human origin. The T cell 
population has been selected to not respond to peptides for self-proteins. In the absence of a 
neoantigen, an immune response against a human protein, though not impossible, is highly 
unlikely unless the protein is presented to the immune system in a fashion that can reverse 
tolerance by the earlier mentioned T-cell–dependent pathway.3 
The elicitation of antibodies towards antigens can also be independent of T cells. Polyvalent 
antigens such as viral capsids and lipopolysaccharides from bacteria are able to crosslink B cell 
receptors (BCRs) due to repetitive epitopes on their surface that are arranged in specific steric 
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distance.40,41 This mechanism seems to be applicable to protein aggregates that have 
multivalent surface structure comparable to bacteria or viruses. 
1.1.2 Antibody induction - relevance of anti-drug antibodies(ADAs) 
The development of unexpected immunogenicity against biotherapeutics poses significant 
clinical, scientific, and manufacturing challenges. This reaction leads to production of anti-
drug-antibodies (ADAs) that can be either neutralizing or non-neutralizing. Non-neutralizing 
ADAs bind to the therapeutic protein and may alter its pharmacokinetic properties by 
building immune complexes with the drug. These complexes can enhance clearance of the 
therapeutic drug from the blood circulation and therefore reduce bioavailability. Neutralizing 
ADAs can directly interfere with the drug biological activity by binding to epitopes that lie 
within the active site or by steric hindrances of sites in close proximity to it.42 
The production of anti-drug-antibodies (ADAs) inactivates the therapeutic effects of the 
treatment and, in rare cases, induces adverse effects. Unexpected immune responses to 
therapeutic protein products may result in adverse events not only by inhibiting the efficacy of 
the therapeutic protein product, but also by cross-reacting to an endogenous protein 
counterpart, leading to loss of its physiological function.43-47 Clinically relevant ADA can 
impact efficacy and/or safety of a biological therapeutic. Despite the development of fully 
humanized mAbs, there can be a high frequency of anti-drug antibodies in patients.48,49 The 
induction of anti-drug antibodies in animals and patients is therefore a key endpoint 
concerning the immunogenicity of biotherapeutics. In worst-case scenarios, formation of 
anti-drug antibodies may pose serious safety concerns, and can even be life-threatening.50 
However, the causes of ADAs induction may be patient-, disease- or product-related.3 The 
prediction of the immunogenic potential of novel protein therapeutics is therefore a challenge 
in biotherapy. 
1.1.3 Potential risk factors inducing immunogenicity – Immunogenicity drivers 
The immunogenic potential of a therapeutic drug is influenced by a variety of factors such as 
the administration mode, the treated disease, the drug dose, the concomitant medication, 
patient genetic factors and other undefined variables.42  
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Beside these clinical factors, the intrinsic characteristics of the biological therapeutic play an 
important role in influencing the development of ADAs. Process related impurities such as 
host cell protein, DNA, protein A, bovine serum and culture media residues may also lead to a 
higher risk of immunogenicity.3 Product related variants including variations in the amino 
acid sequence (e.g. disulfide bond integrity or mismatch, deamidation, oxidation, high 
molecular weight aggregates) or different posttranslational modifications such as 
glycosylation along with neoepitopes generated during protein engineering may induce ADAs 
formation.3 The formation of anti-drug antibodies after injection of aggregated proteinaceous 
material was observed recently in in vivo studies.6,51,52 A breakdown in tolerance following the 
formation of aggregates with repetitive epitopes was suggested to be an important mechanism 
by which ADAs are induced.51 Immunogenicity enhancement by protein aggregates resulting 
of additional T cell-independent activation of B-cells through cross-linking mechanisms by 
repetitive and ordered structures in protein aggregates under native forms is another plausible 
theory.38,53-55 An additional mechanism for enhanced immunogenicity is related to structural 
changes induced by chemical linkages, or other chemical modifications leading to protein 
aggregates.38,51 
1.1.4 Tools to assess immunogenicity  
A range of techniques exist to study the immunogenicity of protein therapeutics which are 
useful for investigating the presence of antigen-specific antibody; these include immunoassays 
that can identify antibodies capable of binding to antigen and bioassays that can distinguish 
between neutralizing and non-neutralizing antibodies. In silico prediction tools are available 
for predicting the T-cell or B-cell epitopes based on protein sequences or structures.56,57 
Experimental approaches, such as in vitro major histocompatibility complex (MHC)-peptide 
binding assays, T-cell proliferation assays are being explored to assess the immunogenicity 
risk.58-61 
Animal models are a potentially useful approach to measure antibody responses to 
biotherapeutics and their degradants.62 Several transgenic animal models have been generated 
for this purpose. Transgenic mice are often the preferred in vivo model to predict 
immunogenicity as they are immune tolerant to the administered human protein and can be 
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used to study the immunogenicity of biotherapeutic aggregates and multiple degradants.4-
6,28,52,63-66 
Although different very useful models are being and were developed, the precise and exact 
immunological mechanisms for unexpected immunogenicity remain relatively poorly defined 
until now. Moreover, data from both animal studies and in vitro assessments are generally not 
predictive of the clinical occurrence or outcome. Indeed, immunogenicity studies in animal 
models do not necessarily predict immunogenicity in humans. In vitro T-cell activation assays 
and studies in genetically engineered animal models are promising but it has to be mentioned 
that no model fully recapitulates the human immune response. Therefore, long-term 
monitoring of immunogenicity in patients during clinical trials and post-marketing is 
essential. 
1.2 Protein stability  
Physical and chemical degradation reactions may occur when products are produced, stored, 
transported or even, during compounding or administration to patients.34 Susceptible 
modifications of the structure of a monoclonal antibody might change its activity. 
Overcoming their limited stability is therefore a major challenge for formulation development 
scientists.38,67,68 Among the various degradation mechanisms a protein can undergo, protein 
aggregation and formation of visible and subvisible protein particles have received significant 
attention recently.69-71 
1.2.1 Protein aggregation 
Protein aggregation is one physical degradation pathway that occurs in nearly all therapeutic 
proteins during long-term storage and/or upon stress (denaturants, high/low temperature, 
agitation, free-thaw, high/low pH).1,2,67,72-75 Protein aggregation refers to a broad range of 
diversified self-associated states of monomer units. Soluble or insoluble aggregates include 
assemblies of protein monomers ranging from dimers to those large enough to be classified as 
subvisible particles to larger, visible particles (description of particles in next paragraph). 
Aggregates that are small enough to remain in solution are classified as soluble aggregates in 
literature.1 Aggregates that are large enough to be centrifuged down or filtered out of solution 
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are called insoluble aggregates.1 Aggregates may be covalent or non-covalently bound. The 
weak non-covalent interactions often lead to the formation of reversible protein aggregates, 
which might be in equilibrium with the monomer in the formulation. In contrary, irreversible 
aggregates are not in equilibrium with the monomer, and they cannot be dissolved by simple 
dilution using placebo buffer. Recently, a very useful and descriptive classification of 
aggregates was published by Narhi et al.76 
Since the first investigation of protein aggregation behavior in the 1960s, different models 
have been introduced to explain their formation.71,77,78,79 A variety of aggregation pathways are 
possible depending on the nature of the protein and its close environment.  
The aggregate end state might be a combination of native monomer, structurally degraded 
monomer, partially or even fully unfolded monomer. 
1.2.1.1 Impact of protein aggregation 
Protein aggregates may show a loss in bioactivity compared to the native protein.80 In 
addition, some types of aggregates are discussed to potentially generate an immune response. 
1,2,38,55,67,81-85 Aggregation has therefore recently received increased interest from industry, 
academia and regulators.1 To date, the data found in literature is contradictory. On one side, 
all of the types of murine mAb aggregates tested by Freitag et al. provoked the generation of 
ADAs, but not all of them have shown the same immunogenic potential in C57BL/6 J and 
BALB/c mice. Whereas, Bessa et al. have shown that only highly modified soluble aggregates 
of human IgG1 (induced by harsh UV-treatment) were able to break tolerance in transgenic 
mice in comparison to non-covalently modified aggregates that did not break tolerance.86 
1.2.1.2 Analytical tools to characterize soluble/insoluble aggregates and particles 
(proteinaceous or foreign) 
No single analytical technique is sufficient for assessing and monitoring protein aggregates 
over the full size range due to the measuring size limitation of each instrument.1,2,76 A 
summary of the different tools that are available on the market with their strengths and 
weaknesses is presented in Table 1.  
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Common and well-established analytical methods like SE-HPLC, AF4, AUC, DLS and 
electrophoresis (capillary or gel) are used for the analysis and/or quantification of protein 
aggregates.15,75,87 These analytical tools are very powerful and versatile widely implemented in 
industry for characterization purposes.2 
For counting and size analysis of particles in the nm and low m-size range, emerging and 
very promising techniques like nano-tracking analysis (NTA), resonant mass measurement 
(RMM) and Coulter Counter (electrical zone sensing method) have been used over the last 
years.15,16,20,87-90 For analysis of particles larger than 1 m, flow imaging technologies (MFI or 
FlowCam) and light obscuration techniques are widely implemented but only light 
obscuration method is cited in the USP until now.22,24-26,91,92 More recently, flow cytometry was 
implemented for the first time to characterize and quantify protein subvisible particles 
without fluorescent labeling.93 Different excellent reviews or scientific articles were published 
to describe in detail those instruments, principles, strength and weaknesses.1,24,27,75 
Beside particles formed only with protein matter, foreign particles might potentially be 
present in biopharmaceutical products.1,75 Particles providing from the packaging material 
(e.g. silicon oil, rubber, and glass) or introduced during production, filling and packaging 
processes (e.g. stainless steel, tungsten or cellulose) might be found in commercial products 
and need to be identified.76 Silicon oil particles – one of the most common contaminant found 
in pharmaceutical products filled in syringes – can be detected using RMM technology due to 
the difference in density between silicon oil and formulation buffer. Indeed silicon oil particles 
have a lower density than the water based buffer and will therefore be counted as positively 
buoyant particles when detected in buffer (whereas proteinaceous particle will be classified as 
negatively buoyant particles due to their higher density).16,88 Using MFI technology, a 
differentiation between silicon oil droplets and protein particles is also possible for particles 
larger than 1 m using a multiparametric image filter as shown recently in literature.88,94 
Further identification of particles in pharmaceutical products by chemical and/or physical 
approaches may be needed for trouble shooting root-cause analysis. For this purpose Raman 
microscopy, Fourier-transform infrared microscopy and/or scanning electron microscopy 
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(coupled with energy-dispersive X-ray spectroscopy) are used.1,95,96 However, this last method 
only provides data on the elemental composition of a sample. 
Table 1: Analytical tools used to characterize aggregates and subvisible/visible particles. 
Size range Analytical technique Advantages Drawbacks
0.001-0.1μm 
Size Exclusion 
Chromatography (SEC) 
Fast
High throughput 
Limited size range  
Impact of mobile phase
Interaction with matrix  
Field Flow Fractionation 
(FFF) High throughput 
Interaction with 
membrane  
SDS-Page Gels 
Possible to run under 
reduced conditions 
Visualization of protein 
bands 
Limited to low amount 
of protein 
Long preparation time  
Capillary electrophoresis 
(CE-SDS) 
High resolution  
Reproducibility  
Rapid data analysis  
Possible to run under 
reduced conditions 
Extensive sample 
preparation 
Analytical Ultra 
Centrifugation (AUC) No matrix interaction Low throughput 
Dynamic light scattering 
(DLS) 
Fast
High throughput Low resolution 
0.03-1μm Nano Tracking Analysis (NTA) 
Tracking of individual 
particles 
High extrapolation 
factor 
Not suitable for 
assessing 
mixtures of particles 
with broad distribution 
of sizes 
0.2-5μm 
Resonant Mass 
measurement 
(Archimedes) 
Single particle 
measurement  
Differentiation between 
proteinaceous particles 
and silicon oil 
Low volume needed 
Low sensitivity to 
particles with density 
close to media  
0.2-10μm Quantitative Laser Diffraction (QLD) 
Concentration 
distributions 
of protein particles in 
the whole 0.2–10μm 
diameter range 
High particle 
concentration can be 
measured (105-109)
Impact of refractive 
index and solvent 
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Size range Analytical technique Advantages Drawbacks
0.6-25μm Label-Free Flow Cytometry Analysis 
Possible to quantify and 
characterize particles 
based on their physical 
properties such as 
density or morphology 
Sensitive to refractive 
index 
0.6-25μm Coulter counter (CC) 
Wide dynamic range  
Individual particles are 
counted 
High conductivity is 
required  
Requires several 
measurement with 
different aperture tube 
to cover the whole size 
range 
1-200μm Flow imaging techniques 
Provide information on 
size, counts and 
morphology  
Pictures for individual 
particles 
Differentiation between 
protein particles, silicon 
oil, and air bubbles 
Difficult to detect 
translucent particles 
Impact of sample 
refractive index 
Fast sedimentation of 
large particles 
1.3-100μm Light obscuration (LO, HIAC) 
Counting of individual 
particles 
High reproducibility  
Robust 
Under-sizing effect for 
proteinaceous particles 
Not reliable for sample 
with high viscosity  
Dilution is needed for 
high particle counts 
Does not work well with 
turbid samples 
>100μm 
Visual inspection 
(Seidenader, Optima 
Lamp, EP box) 
Individual vial inspection 
Highly trained operators 
are needed  
Operator eye fatigue  
Effect of product on 
visual inspection 
outcome 
 
1.2.2 Protein oxidation  
Oxidation is a common degradation pathway that affects therapeutic proteins during 
production, purification, formulation, transportation, storage and product handling. Cysteine, 
histidine, methionine, phenylalanine, tryptophan and tyrosine residues in a protein can act as 
oxidation sites in proteins due to the high reactivity of sulfur atoms and aromatic rings 
towards various reactive oxygen species. Oxidation induced during processing and storage 
might be the result of contaminating oxidants (contained in excipients or derived from 
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surfactant), but it might also be due to the presence of transition metal ions or due to the 
exposure of the product to UV-light.97,98 
1.2.2.1 Impact and consequences of protein oxidation 
Oxidation may extensively modify the primary structure of proteins, by which changes in 
secondary, tertiary and quaternary structure may arise.98 The oxidized products that are 
generated under forced oxidation studies or after long term storage may have different 
consequences. High oxidation levels might change the biological properties of the therapeutic 
drug and potentially enhance the immune response of generated sample.76,77,90  
1.2.2.1.1 Methionine 
Altered biological activity and decreased serum half-life following methionine oxidation was 
reported for insulin, hormones, granulocyte colony-stimulating factor, interferon and other 
type of proteins. Oxidation of methionine located on the Fc fragment of the monoclonal 
antibody decreased binding to FcRn receptor (neonatal Fc receptor), binding affinity to 
protein A/G and also serum half-life.99-101 Beside these effects, changes in secondary and 
tertiary structure leading to aggregation were observed for IgG1 and IgG2 presenting 
methionine oxidation on the Fc fragment.101,102 
1.2.2.1.2 Tryptophan  
Tryptophan oxidation is only reported in few studies where it induced mainly loss of target 
binding and altered biological activity.98,103 
1.2.2.1.3 Other amino acids 
Cysteine oxidation led to generation of new intramolecular and intermolecular covalent 
bonds, as observed for interferon, insulin, calcitonin and oxytocin where formation of dimers, 
trisulfide and tetrasulfide derivatives was reported.98 
Trace metals, acting as catalyzers, are responsible for histidine oxidation leading to altered 
activity or major changes on pharmacokinetic profile for the studied protein as reported for 
hormone and insulin.98,104 
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Tyrosine as well as phenylalanine oxidation leads to tyrosine oxidation products that are very 
prone to addition reaction, inducing aggregate formation through dityrosine covalent linkage 
as found in studies for oxytocin, insulin and interferon.98,105-107 
1.2.2.2 Analytical tools for detection/quantification of oxidation in proteins 
Several methods to detect and/or quantify oxidation in mAbs are described. 
1.2.2.2.1 Methionine oxidation 
Methionine oxidation levels in mAbs can be assessed using affinity chromatography methods 
like analytical Protein-A or Protein-G chromatography.108,109 Eventually, oxidation of 
methionine and tryptophan of an IgG1 can be detected and quantified by hydrophobic 
interaction chromatography (HIC).110 Furthermore, RP-HPLC can be employed to detect 
methionine and tryptophan oxidation in proteins.32,33,111 Mass spectrometry, e.g. peptide 
mapping LC/MS(-MS), is the standard method to identify and quantify amino acid 
modification (such as methionine) at the peptide levels after enzymatic digestions. 
1.2.2.2.2 Tryptophan oxidation 
RP-HPLC was mainly implemented to detect tryptophan oxidation in proteins as well as 
peptide mapping LC/MS(-MS).32,33,111  
1.2.2.2.3 Oxidation of other amino acids and identification of covalent bounds 
Recently, histidine oxidation in an IgG1 was detected and quantified for the first time in the 
Fc part of an IgG1 mAb by mass spectrometry.112  
Tyrosine and phenylalanine oxidation products can be investigated and quantified using 
fluorescence methods or electrospray ionization-mass spectrometry (ESI-MS).  
Dimerization resulting of cysteine oxidation were identified using SEC-HPLC, ESI-MS and 
tryptic digest followed by mass spectrometry in the case of salmon calcitonin.113 LC-MS-MS 
measurements performed following various enzymatic digests, were lastly perfectly used to 
investigate and find out the nature of intermolecular/intramolecular cross-linkers induced by 
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metal catalyzed or UV-light oxidation.105,114 A combination of techniques such as 18O-labeling 
and mass spectrometry yielded the discovery and characterization of a photo-oxidative 
histidine-histidine cross-link in IgG1 antibody.115 
Nevertheless, characterization of protein cross-links remains challenging due to their 
structural complexity despite the rapid advancements in mass spectrometry and data analysis 
algorithms.116 
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Scope 
There is an increased interest from industry, academia and regulators for protein aggregates, 
subvisible and visible particles due to possible biological consequences, such as 
immunogenicity, altered bioactivity and modified pharmacokinetic profiles. Aggregates, 
subvisible and visible particles are important product instabilities, which might be present in 
every formulation of biotherapeutic products like monoclonal antibody solutions. Especially, 
the presence of subvisible particles in biotherapeutic products is currently a hot topic and it 
constantly gains more importance. 
The ultimate goal of this thesis is to develop tools and techniques in order to be able to 
characterize well-defined size fractions of proteinaceous subvisible particles with various 
desired oxidation profiles using in vivo transgenic mouse model. Up to now only a few articles 
were published and the available data from in vitro and in vivo experiments on aggregates and 
subvisible particles is often conflicting and fragmented, which impedes the development of 
sound conclusions. Moreover, complex mixtures of monomers, aggregates, particles and other 
degradants were used to draw conclusions. 
Only estimated values of protein particle density were used up to now in published studies 
although it is required to know the density of the measured particles in order to accurately 
calculate their dimensions and mass. The first aim of this thesis was therefore to develop a 
method to measure experimentally the protein particle density without extrapolation 
(Chapter 1). The density for commercially available standard beads (polystyrene, 
polymethacrylate and melamine) and a large bench of stressed proteinaceous samples was 
determined with the use of the resonant mass measurement instrument (RMM, Archimedes) 
and its ability to measure the buoyant mass of individual particles. Various fluids with 
increasing densities were implemented in order to determine the neutral buoyant mass where 
the particle density equals the fluid density. 
Chapter 2 reports the development of a process to isolate well-defined subvisible fractions 
using differential centrifugation for a model IgG1 antibody. The process to separate four 
fractions in the submicron and micrometer size range was developed and successfully 
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optimized through the use of a design of experiments. The centrifugation technique was 
compared to an already published fractionation method using a preparative fluorescence-
activated cell sorter. Efficiency, advantages and drawbacks for both methods were compared 
and discussed (Chapter 2). 
Oxidation profile of aggregates and subvisible particles seem to be an important attribute 
regarding induced biological consequences. That is why the next goal was to develop a 
method for selective oxidation of methionine and tryptophan residues in a model mAb in 
order to be able to delineate the effects and the contribution of individual protein 
modifications in the primary structure. This included a large set of experiments where 
different reaction conditions such as temperature of incubation, reaction time, type and 
concentration of oxidant (t-BHP, H2O2, AAPH) were evaluated in presence (or not) of a large 
excess of anti-oxidant (free amino acids) in order to protect the corresponding amino acid in 
a model antibody of the IgG1 subtype (Chapter 3).  
To complete the work, unfractionated materials and well-defined size fractions (with well-
established oxidation profile) were prepared using the established tools (Chapter 1-3). Those 
samples were deeply characterized and injected subcutaneously into wild type and transgenic 
mice for immunization. Anti-drug antibody levels were measured following ELISA in order to 
assess the immunogenic potential of those preparations (Chapter 4). 
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Abstract 
One of the analytical tools for characterization of subvisible particles which gained popularity 
over the last years due to its unique capabilities is the Resonance Mass Measurement 
technique. However, a challenge that this technique presents is the need to know the exact 
density of the measured particles in order to obtain accurate size calculations. The density of 
proteinaceous subvisible particles has not been measured experimentally yet and to date 
researchers have been using estimated density values. In this paper, we report for a first time 
experimental measurements of the density of protein particles (0.2-5 m in size) using 
particles created by stressing three different proteins using four different types of stress 
conditions. Interestingly, the particle density values which were measured varied between 1.28 
and 1.33 g/cm3 and were lower than previous estimates. Furthermore, it was found that 
whereas the density of proteinaceous particles was affected to a very low degree by the stress 
conditions used to generate them, there is relatively larger difference between particles 
originating from different classes of proteins (e.g. mAb vs. BSA). 
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Introduction 
The analyses of subvisible and submicron particles in therapeutic protein formulations have 
gained significant attention during the recent years.1 In addition to light obscuration (which is 
the method of choice for quality control of biopharmaceuticals), recently, several additional 
techniques became available for characterization of subvisible particles in therapeutic protein 
solutions. These include flow imaging microscopy, electrical sensing zone measurements, 
nano-tracking analysis, label-free flow cytometry and Resonant Mass Measurement.2-8 
Because most of these additional characterization methods have emerged relatively recently, 
naturally, a number of open questions regarding their performance, utility, strengths and 
deficiencies still remain. 
One of these recently emerged (and very promising) techniques is the resonant mass 
measurement (abbreviated RMM in literature; also known as “suspended microchannel 
resonator system” or “Archimedes”).9,10 In the suspended microchannel resonator system, a 
particle with a diameter between 200 nm and 5 m (vendor’s information) flowing through 
the fluidic channel alters the resonating frequency of the suspended cantilever. This 
momentary shift is associated with the change in mass caused by the passage of a particle of 
differing density than the surrounding media through the cantilever.11 If the particle density is 
lower than the sample fluid density a positive frequency shift is induced (positive buoyant 
particle; e.g. silicon oil droplet in water or placebo buffer) whereas a higher particle density 
than the sample fluid induces a negative frequency shift (negative buoyant particle; e.g. 
protein particle in water or placebo buffer). The frequency shift multiplied by the sensitivity of 
the sensor results in the buoyant mass of the given particle. 
This technique has quickly gained popularity for characterization of subvisible particles in 
biopharmaceuticals owing to its unique abilities to: a) discriminate between different particle 
types based on their density and b) measure particles in the sub-micrometer size-
range.3,4,7,9,10,12-16 One example of the potential application of these novel capabilities of the 
method is the differentiation between silicon oil droplets and protein particles specifically in 
the submicron and low micrometer size range.9,12 RMM was also used for the determination of 
single particle mass in biology.11,17 Burg et al. demonstrated that suspended microchannel 
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resonators can weigh single nanoparticles, single bacterial cells and sub-monolayers of 
adsorbed proteins in water with sub-femtogram resolution. More recently, the adsorbed 
protein mass of BSA on polystyrene beads was determined using RMM.18  
One inherent challenge associated with RMM measurements is the requirement to know the 
density of the measured particles in order to calculate their dimensions (e.g. equivalent 
circular diameter) accurately. This aspect of the analysis is particularly important to avoid 
error in sizing particle populations. Unfortunately, to date the values of the density of 
proteinaceous particles have not been determined experimentally. This is the reason that all 
prior published studies reporting characterization of proteinaceous submicron/subvisible 
particles using RMM utilize estimates of the density of these particles from calculations based 
on crystallographic studies, also assuming that the density of protein particles does not change 
significantly with their size or type.16 The density values used in the literature range between 
1.32 g/cm3 (as suggested by the RMM manufacturer) and 1.35 g/cm3.16,18 
The goal of the current study was to determine the density of proteinaceous subvisible 
particles in the size range between 0.2 – 5.0 m, generated using different stress conditions 
and also using different proteins. For that purpose, the capabilities of the suspended 
microchannel resonator using a modified method for particle density determination used 
previously for other substances were utilized.9 As opposed to the previously reported method 
of linear extrapolation to zero buoyant mass, where the density of the solution matches the 
density of the particle (neutral density)9, we used cesium chloride solutions in order to cover a 
larger density range and be able to determine the particle density experimentally without 
extrapolation.  
To verify the accuracy of the new approach, commercially available and commonly used 
standard beads were studied using RMM: polystyrene (d=1.05 g/cm3), polymethacrylate 
(d=1.19 g/cm3) and melamine (d=1.51 g/cm3). 
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Materials and Methods
Cesium Chloride (purityΨ98%), sodium citrate dihydrate (purity Ψ99%), sodium phosphate 
monobasic monohydrate (purity Ψ99%), disodium phosphate dibasic anhydrous (purity 
Ψ99%) were obtained from Sigma–Aldrich (St. Louis, Missouri, USA). Trehalose dihydrate 
(purity Ψ98%) was obtained from Ferro Pfanstiehl (Waukegan, Illinois, USA). Sodium 
chloride (purity Ψ99.5%), ethanol absolute for analysis from Merck (Darmstadt, Germany) 
and deuterium oxide (D2O, purity=99.96%) from Euriso-top (Saint-Aubin, France) were used. 
Polysorbate 20 and 80 were obtained from Croda (Edison, New Jersey, USA). Duke 
polystyrene microsphere size standards (800 nm, 1 m, 2 m) were purchased from Thermo 
Scientific (Waltham, Massachusetts, USA). 1 m polymethacrylate beads and 2 m melamine 
resin microspheres were purchased from Sigma Aldrich (St. Louis, Missouri, USA). Water 
purified with Milli-Q Advantage A10 from Millipore, with a resistance larger than 18.2 
mΑ.cm at 25°C was used in all experiments. Albumin from bovine serum (purityΨ96%) from 
Sigma–Aldrich (St. Louis, Missouri, USA) was used. A 40 mg/ml solution was prepared in 
PBS. Two monoclonal antibodies (mAb1) and (mAb2) of the IgG1 subtype were provided at 
25 mg/ml in 51 mM sodium phosphate, 6 % trehalose, and 0.04 % polysorbate 20 (pH 6.2) and 
10 mg/ml in sodium citrate dehydrate, 0.9 % sodium chloride, 0.07% polysorbate 80 (pH is 
6.5) by F.Hoffmann-La Roche Ltd. (Basel, Switzerland). mAb1 and mAb2 were initially -
filtered through a 0.22 m Millipore Express plus filter prior use. Millipore 0.22 m Express 
plus filters were used for the filtration of all buffer solutions and media used in the RMM 
measurements before use to avoid contamination with dust or foreign particles.  
The densities of each solution were measured using a densitometer (Anton Paar DMA38, 
Ashland, Virginia, USA) calibrated with water before measurement.  
PCC-54 Detergent from Pierce (Rockford, Illinois, USA) and Tergazyme® from Alconox 
(New-York, USA) were used for cleaning of particle measurement instruments when 
mentioned. 
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DLS measurements 
Different solutions of cesium chloride (0, 20%, 30%, 40%, 50%, 55%) containing increasing 
concentration of protein (between 0 and 10 mg/ml) were prepared and measured for mAb1 
and mAb2 by DLS using a DLS plate reader (Wyatt Technologies Corporation). Sample 
temperature during measurements was set to 20°C. Measurements were made using a 
Corning® 96 well black plate with clear flat bottom polystyrene and 150 ƨl sample in each well. 
10 acquisitions per sample were performed and regularization fit was applied to each sample. 
For determination of hydrodynamic radius the method described by Parmar et al was used.19 
Stress conditions for BSA, mAb1 and mAb2 heat 
1 ml of protein solution was artificially stressed for 3 min at 80°C/1400 rpm using a 
Thermomixer (Eppendorf). The temperature was chosen to be above the melting temperature 
of the protein to ensure formation of large amounts of proteinaceous particles. In order to 
homogenize the artificially generated protein particles, a silicon-oil-free 5 ml luer lock syringe 
(Henke Sass Wolf, Tuttlingen, Germany) was used, mounted with a 27 G needle and 20 draw-
release cycles were applied manually. After centrifugation at 2000 rpm for 1 min to discard the 
largest particles, the supernatant fractions were collected, aliquoted and stored at -80°C until 
needed. Stability of protein particles during -80°C storage and after thaw was demonstrated 
using light obscuration and microflow imaging measurements (data not shown).  
Stress conditions for mAb1 and mAb2 solvent-induced precipitation 
1 ml of mAb solution was poured into 1 ml of pure ethanol to induce precipitation of the 
protein. To homogenize and reduce the size of the formed protein particles, 5 draw-release 
cycles were applied manually using a 5 ml syringe (silicon-oil-free) mounted with a 27 G 
needle. 
Stress conditions for mAb1 shaking stress 
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Shaking stress was applied at a constant 200 rounds per minute (rpm) by placing 2 ml of 
mAb1 solution into 6 ml-vials that were placed horizontally at room temperature for 9 
months, protected from direct light, onto a horizontal moving shaking plate (HS 260 Control 
Model IKA GmbH and Co., Stauffen, Germany). After centrifugation at 2000 rpm during 1 
minute to discard the largest particles, the supernatant fractions were collected, aliquoted and 
stored at -80°C until needed.  
Stress conditions for BSA, mAb1 and mAb2 stirring 
Washed 6 mmௗ×ௗ15 mm Teflon® coated stirrer bars (Semadeni AG, Ostermundigen, 
Switzerland) were placed directly into the 6 ml-vials where 2 ml protein solution was filled. 
The stirring stress was generated at a constant 500 rpm by placing the vials vertically, 
protected from direct light, onto a multi-position magnetic stirrer (RO 15 Model IKA GmbH 
and Co.) at room temperature for 30 h.  
Microflow imaging measurements 
The morphological parameters of different samples were analyzed for by micro flow imaging 
(MFI) using the MFI DPA4200 series instrument (Protein Simple, San Jose, California, USA) 
equipped with a 470 nm LED light source. Particles with equivalent circular diameter (ECD) 
larger than 1 m were analyzed. Size (5 m ThermoScientific Duke Standard) and count 
standards (5 m COUNT-CAL Count Precision Standards, ThermoScientific; USA) were 
used to check the sizing and counting accuracy of the instrument. At the end of the day, the 
system was flushed at maximal speed for 5 minutes and then soaked for 30 minutes with 1 % 
(w/v) Tergazyme®, followed by rinsing with water for 30 min. Flushing with water was 
repeated after each sample for 30 minutes. For these flushing steps, the flow rate was set to 
instrument maximum speed. Optimization of illumination was performed prior to analysis, 
using solutions matching the sample to be analyzed. For measuring, 1 ml of sample was placed 
in a 1 ml dual-filter tip on the inlet port. The first 0.2 ml was discarded, before a volume of 0.6 
ml was analyzed. Each sample was measured in triplicate.
Suspended microchannel resonator measurements (RMM) 
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The RMM measurements were performed on the Archimedes system (RMM0017, generation 
2) from Malvern instruments LTD (Malvern, United Kingdom). Micro sensor chips with 
internal microchannel dimensions of 8 ƨm × 8 ƨm were used for all the experiments. The 
instrument baseline was between 0.010 and 0.015 Hz. The calibration of each sensor was done 
after replacement using a diluted 1 m Duke polystyrene size standards (final 
concentration=106 part/ml in water). The sample was loaded for 40 sec prior to calibration. 
The calibration was finalized after 300 particles were detected as suggested by the 
manufacturer.  
Different volume of each stock solution (standards beads or protein particles) were spiked 
before RMM measurement in the different solutions (water, PBS, D2O, CsCl 20%, CsCl 30%, 
CsCl 40%, CsCl 50%, CsCl 55% w/w) according to initial particle concentration in order to 
reach concentrations larger than 5x106, but not higher than 3x107 particle/ml. Each sample 
was analyzed in triplicate. Prior spiking of artificially produced proteinaceous particles into 
the corresponding media it was ensured that there is no formation of new particles using 
RMM or MFI control measurements.  
The threshold limit (LOD) was manually set to 0.04 Hz for each analysis (based on previous 
experiments, data not shown). A stop trigger of 2000 particles or 1 h measurement time was 
used in order to analyze a representative particle population of each sample. During 
measurement of microspheres and protein samples the “autoreplenish” function was 
automatically activated every 120 sec for duration of 2 sec. During the autoreplenish, fresh 
sample was loaded to the microchannel in order to avoid possible settling down of particles. 
Moreover, the sample volume analyzed when implementing the autoreplenish function is 
larger, improving the reproducibility of each measurement series performed on RMM (data 
not shown here).  
Between runs, sensors were rinsed with formulation buffer and water for 10 min as 
recommended by the manufacturer. The water rinsing step was repeated until a clean 
frequency trace was achieved. At the end of each measurement day, the sensor and the micro 
tubing were rinsed with 1% PCC-54 detergent, by applying high pressure on the sample and 
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reference vials to clean the bypass channels. ParticleLab software (version 1.8.510) provided 
by Affinity Biosensor was used to process all measurement results. 
Determining particle density 
Particle density determinations were performed by evaluating the change in the mean 
buoyant mass of the measured particles relative to changes in solution density. The buoyant 
mass for the different particles was measured in solutions with increasing densities. The 
obtained mean value (n=3) for the buoyant mass (reported by the software in fg) for all 
particles detected during analysis over the full size range was plotted against the 
corresponding solution densities for particles standards. In the case of monotonic 
distributions of particles showing significant populations immediately below the accessible 
size range of the sensor, a restricted size range was used to calculate the mean buoyant mass, 
and the fitting was performed in an iterative manner to avoid artifacts due to differences in 
minimum detectable particle sizes that are a result of differences in solution density. The 
intercept of the linear regression with the Y-axis (where the buoyant mass is equal to zero) 
gave the density of the measured particles.9 At this point, the density of the particle has the 
same density as the fluid and no frequency shift can be detected – i.e. neutral density.9  
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Results and discussion 
The particle measurement capabilities of the RMM system are a valuable complement to 
particle counting and sizing methods currently used in numerous industrial and research 
applications. One advantage of RMM is the ability to directly measure the mass of individual 
particles. The densities of polystyrene, melamine and silicon oil particles were determined 
previously by Patel et al. by linear extrapolation to zero buoyant mass using sucrose solutions 
with increasing densities, but the density for protein particles has never been experimentally 
determined before. The goal of this study was to determine the density of proteinaceous 
subvisible particles, using the suspended microchannel resonator without extrapolation. For 
this purpose, series of cesium chloride solutions were used in order to reach high densities 
and avoid extrapolation. The particle densities were determined by applying linear regression 
to the measured mean buoyant masses of particles in eight different solutions (n=3 in each 
case) with varying densities from 1.00 to 1.65 g/cm3 (water, PBS, D2O, CsCl solutions – for 
more details see Materials and Methods). Measurements were carried out using commercially 
available beads (polystyrene ƭ= 1.05 g/cm3, polymethacrylate ƭ= 1.19 g/cm3 and melamine ƭ= 
1.50 g/cm3) as well as artificially generated protein particles. 
Density determination for particle standards 
 
Figure 1: Particle density of polystyrene microspheres 800 nm. Measurement of the microsphere buoyant mass 
in 8 different surrounding media (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%, CsCl 50% and CsCl 55%) 
with increasing densities allow to find the polystyrene particle density. 
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Figure 2: Particle density of polymethacrylate microspheres (1 ȝm). Measurement of the microsphere buoyant 
mass in 8 different surrounding media (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%, CsCl 50% and CsCl 
55%) with increasing densities allow to find the polymethacrylate particle density. 
 
Figure 3: Particle density of melamine microspheres (2 ȝm). Measurement of the microsphere buoyant mass in 
8 different surrounding media (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%, CsCl 50% and CsCl 55%) with 
increasing densities allow to find the melamine particle density. 
In order to assess the accuracy of the method, the densities of standard beads were measured. 
Three different types of beads with densities covering the range of interest were chosen: 
polystyrene (ƭ= 1.05 g/cm3), polymethacrylate (ƭ= 1.19 g/cm3) and melamine (ƭ= 1.50 g/cm3). 
The beads were spiked into different media with increasing densities from 1.00 to 1.65 g/cm3 
(water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%, CsCl 50%, CsCl 55% w/w), and the 
buoyant masses for each population were measured in triplicate. As explained by Patel et al., 
the density of the measured particles should correspond to the intercept of the regression line 
and the Y axis (the point where the particles become “invisible” for the suspended 
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microchannel resonator).9 The measured values for particle buoyant masses of polystyrene, 
polymethacrylate and melamine beads standards in different media including the respective 
standard deviation (error bars) are depicted in Figures 1 and supplementary Figure 1, Figure 2 
and Figure 3, respectively. The intercepts of the regression lines with the solution density axis 
(Y axis) at zero buoyant mass, the slopes and regression coefficients for the standard beads are 
presented in Table 1. Using this method the experimentally determined density values for the 
polystyrene particles and melamine particles were within 0.4 and 0.5% of the expected value of 
1.05 g/cm3 and 1.51 g/cm3 respectively (no difference in density was observed between 3 
different sizes of polystyrene particles – 0.8 m, 1 m and 2 m), whereas the linear fit for 
polymethacrylate resulted in neutral density of 1.19 g/cm3 which corresponded exactly to the 
expected value. The obtained results for the commercially available standard beads correlated 
very well with published data and supplier information. Unlike the previously reported 
method for determination of particle densities using sucrose solutions, the method applied in 
this study does not use extrapolation to determine the density of particles. Thus, the density of 
relatively dense particles (e.g. melamine: ƭ= 1.50 g/cm3) determined using the new and 
improved method reported here is very close to the expected value (0.5% deviation), whereas 
3.7% deviation was observed in the measurements using extrapolation.9 The significant 
increase of the accuracy can be attributed to the closer match of the media density and the 
density of the measured melamine beads (i.e. between 40% and 50% CsCl). It is interesting to 
notice that for the same reasons, a higher standard deviation for the buoyant mass 
measurements (n=3) was observed for high densities in the case of polystyrene, and for lower 
densities in the case of melamine.  
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Table 1: Summary of linear fit results obtained from the experimental points represented in Figure 1-6 and 
supplementary Figure 1-3. The results are presented for standard beads (polystyrene, polymethacrylate and 
melamine); artificially generated particles obtained using BSA, mAb1 and mAb2. The intercept (i.e. particle 
density; neutral density), the slope of the regression line and the coefficient of determination R-Square are listed 
for the analyzed mAb1 protein particles. 
Sample name 
Intercept Slope 
Adj. R-Square 
Value Standard Error Value 
Polystyrene 800 nm 1.05 0.01 -3.3 x 10-2 0.999 
Polystyrene 1 ȝm 1.05 0.01 -1.8 x 10-3 0.994 
Polystyrene 2 ȝm 1.04 0.01 -2.3 x 10-3 0.997 
Polymethacrylate 1 ȝm 1.19 0.01 -1.4 x 10-3 0.995 
Melamine 2 ȝm 1.50 0.01 -1.4 x 10-3 0.995 
BSA - heat 1.33 0.01 -2.8 x 10-2 0.998 
BSA - stirring 1.31 0.01 -2.4 x 10-2 0.983 
mAb1 - heat 1.28 0.01 -8.8 x 10-2 0.992 
mAb1 - solvent-induced 
precipitation 1.28 0.01 -6.2 x 10
-3 0.995 
mAb1 - shaking stress 1.28 0.01 -7.0 x 10-3 0.995 
mAb1 - stirring 1.28 0.01 -9.0 x 10-3 0.998 
mAb2 - heat 1.28 0.01 -8.3 x 10-3 0.994 
mAb2 - solvent-induced 
precipitation 1.29 0.01 -9.0 x 10
-3 0.990 
mAb2 - stirring 1.28 0.01 -9.2 x 10-3 0.999 
Density determination for protein samples  
A number of samples containing artificially generated proteinaceous particles were prepared 
using three different model proteins – BSA, mAb1 and mAb2 (see Materials and Methods for 
experimental details). The different stress conditions (heat, solvent-induced precipitation, stir 
and shaking) resulted in different amounts of precipitated protein (data not shown). The 
presence of residual monomers bears the risk for potential analytical artefacts, such as further 
aggregation upon contact with high concentrations of cesium chloride and consequent 
undesirable particle formation. To mitigate this risk, the impact of every different medium 
used in these experiments on the mAb solutions regarding particle formation under the 
method conditions was investigated before actually measuring buoyant mass of spiked protein 
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particles in the different media. The protein solutions were diluted 10-fold with each medium, 
and the particle formation was assessed one hour after mixture using flow imaging and RMM 
techniques. It was observed that any aggregation under experimented conditions was 
negligible when pure protein solution was diluted with all media, except for 50% and 55% 
CsCl solutions, where relevant particle formation was observed during RMM and MFI 
measurements (data not shown). Therefore, in order to avoid measurement artifacts, 
measurements of buoyant masses for proteinaceous particles resuspended in 50% or 55% CsCl 
solutions were not performed. In addition, the impact of dilution regarding particle 
morphological parameters for particles obtained following each stress conditions was assessed 
using flow imaging. No impact on any of morphological parameters measured by flow 
imaging was detected upon dilution of protein particles into the media used in the study (data 
not shown).  
 
Figure 4: Particle density of artificially stressed mAb1. Density of mAb1 particles (heat stress) was determined 
by measuring the buoyant mass of each sample in 6 different surrounding media (water, PBS, D2O, CsCl 20%, 
CsCl 30%, CsCl 40%). 
To determine the density of the different populations of stressed model proteins, particles 
were spiked from stock solutions in six different solutions with densities varying from 1.00 to 
1.45 g/cm3 (using water, PBS, D2O, CsCl solutions – for more details see Materials and 
Methods) and the mean buoyant mass of each population was measured in triplicate using 
RMM (maximum one hour measurement time). The mean buoyant mass over a selected size 
range obtained from the iterative calculation as described by Patel et al. was used to plot the 
Figure 4, supplementary Figure 2 for mAb1, Figure 5, supplementary Figure 3 for mAb2 and 
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Figure 6 for BSA particles.9 The size restriction was employed to ensure that the same 
population of particles is analyzed in media of different densities. This size restriction had a 
considerable effect on the standard deviation between triplicate measurements which was 
significantly reduced after application of this procedure. The summary of the linear fit results 
is presented in Table 1 for the three model proteins.  
 
Figure 5: Particle density of artificially stressed mAb2. Density of mAb2 particles (heat stress) was determined 
by measuring the buoyant mass of each sample in 6 different surrounding media (water, PBS, D2O, CsCl 20%, 
CsCl 30%, CsCl 40%). 
It is important to note that the good linear fit to all of the experimental values described 
above, including H2O, PBS and D2O particle dispersions as well as these in increasing 
concentration of CsCl excludes the possibility that changes induced by higher concentrations 
of CsCl (e.g. particle dehydration) have influenced the measurements. In case such influence 
would have been present, a significant deviations from linearity would have been expected, 
which was not the case. This conclusion was also confirmed by the lack of any discernible 
effects on the protein hydrodynamic radius (Rh) upon resuspension into differently 
concentrated CsCl solutions, clearly indicating the absence of potential salt-induced swelling 
or compaction of the protein itself (Supplementary Figure 4). Similar results were described in 
literature by Parmar et al for lysozyme.19 
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Figure 6: Particle density of artificially stressed BSA. Densities of BSA particles ((A) heat, (B) stirring) were 
determined by measuring the buoyant mass of each sample in 6 different surrounding media (water, PBS, D2O, 
CsCl 20%, CsCl 30%, CsCl 40%) with increasing densities. 
Previous estimates of the density of protein particles were largely based on the mean protein 
density calculated from large crystallographic datasets and arbitrary estimation of the likely 
water content of protein particles. These estimates have arrived at average densities of 
proteinaceous particles of about 1.32-1.35 g/cm3.13,18,20,21 Now we offer for the first time 
experimentally measured values for proteinaceous subvisible particles. The experimental 
values that we report here range between 1.28 g/cm3 for immunoglobulin particles and 1.33 
g/cm3 for BSA particles, which on average is lower than the estimated values reported 
previously. Interestingly, we did not observe significant density disparities between the 
particles generated using different stress conditions; however, protein-to-protein differences 
were more substantial. The latter observation likely reflects the strong influence of the 
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molecular geometry on the packing of protein monomers in an aggregate. For example, the 
measured density of BSA (relatively more compact molecular structure) particles generated 
using different stress conditions were between 1.31 g/cm3 and 1.33 g/cm3, whereas the density 
of IgG (relatively more extended molecular structure) particles were between 1.28 g/cm3 and 
1.29 g/cm3. It is reasonable to assume that proteins with more extended structures would pack 
into less dense aggregates – assumption which correlates well with the results reported in this 
manuscript. Of course, in order to make a general conclusion regarding the relationship of 
structure and molecular packing, a much more extensive dataset would be needed. One 
important implication of the results reported here is the apparent necessity to measure the 
density of aggregates when these values are used for calculations (e.g. calculating particle size 
distributions from RMM measurements or calculation of the mass contained in particles 
measured using other methods), particularly when a new structural class of protein is studies. 
The method reported here provides a simple and easy to use tool for such measurements.  
In order to determine the impact of the discrepancy between the newly determined 
experimental density values for protein particles and the density estimation used in the 
literature, the size distribution of the particles in a stressed mAb sample were measured and 
re-calculated using previously estimated values and the newly determined density values. 
Using the newly determined density value of 1.28 g/cm3 for mAb-derived particles instead of 
previously suggested 1.32 or 1.35 g/cm3 has a slight impact on the particle size measured by 
RMM. The impact is different in the different particle size bins as depicted in Figure 7. 
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Figure 7: Impact of protein particle densities on size bins for a proteinaceous sample (mAb1-heat). The 
impact of protein particles densities of 1.28 g/cm3 (black), 1.32 g/cm3 (red) and 1.35 g/cm3 (blue) was investigated. 
Horizontal box plots show 25/75% (box), mean values (squares), median (vertical line) and min/max (whisker). 
It is important to note, that the method for density determination reported here is only 
suitable to measure the density of particles smaller than 5 m due to limitations in the current 
RMM instrumentation. Further studies will be needed to measure the density of larger 
particles. The development of a new type of RMM sensor adapted for larger particles might 
help to answer this question. 
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Conclusion 
We report for the first time the direct measurement of the density of proteinaceous subvisible 
particles (of sizes between 200 nm and 5 m) using a new, RMM method. Interestingly, the 
measured densities for proteinaceous particles (1.28-1.33 g/cm3) originating from three 
different proteins and four different stress conditions were lower than previous calculations. 
Whereas relatively small differences were observed between the densities of particles 
generated using different stress conditions, protein-to-protein particle density differences 
were more pronounced. The new method presented here can be easily applied to any system 
and would allow researchers to accurately measure the density of the subvisible particles 
present in their samples, enabling improved sizing of RMM measurements. 
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Associated content - Supporting information 
 
Supplementary Figure 1: Particle density of polystyrene microspheres (A) 1 ȝm, (B) 2 ȝm. Measurement of 
the microsphere buoyant mass in 6 different surrounding media (buffer, CsCl 20%, CsCl 30%, CsCl 40%, CsCl 
50% and CsCl 55%) with increasing densities allow to find the polystyrene particle density. 
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Supplementary Figure 2: Particle density of artificially stressed mAb1. Densities of mAb1 particles ((A) 
solvent-induced precipitation, (B) shaking stress, (C) stirring) were determined by measuring the buoyant mass of 
each sample in 6 different surrounding media (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%). 
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Supplementary Figure 3: Particle density of artificially stressed mAb2. Densities of mAb2 particles ((A) 
solvent-induced precipitation, (B) stirring) were determined by measuring the buoyant mass of each sample in 6 
different surrounding media (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%). 
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Supplementary Figure 4: Hydrodynamic diameter measured by DLS. The measurements were performed in 8 
different surrounding media (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 40%, CsCl 50%, CsCl 55%) at 5 
different protein concentration (1, 2.5, 5, 7.5 and 10 mg/ml) for mAb1 and mAb2. 
 
Supplementary Figure 5: Representative Flow Microscopy images of mAb1 particles. Those particles were 
generated using different types of stress. A) heat stress B) solvent precipitation, C) shaking stress, D) stirring. 
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Abstract: 
Purpose: The goal of this study was to compare and evaluate two preparative techniques for 
fractionation of proteinaceous subvisible particles. This work enables future studies to address 
the potential biological consequences of proteinaceous subvisible particles in protein 
therapeutic products. 
Methods: Particles were generated by heat stress and separated by size using differential 
centrifugation and FACS (Fluorescence-activated cell sorter). Resulting fractions were 
characterized by size-exclusion chromatography, light obscuration, flow imaging microscopy 
and resonant mass measurement. 
Results: Here we report the optimization and comprehensive evaluation of two methods for 
preparative fractionation of subvisible proteinaceous particles into distinct size fractions in 
the range between 0.25 m and 100 m: differential centrifugation and FACS. Using these 
methods, well-defined size fractions were prepared and characterized in detail. Critical 
assessment and comparison of the two techniques demonstrated their complementarity and 
for the first time – their relative advantages and drawbacks. 
Conclusions: FACS and differential centrifugation are valuable tools to prepare well-defined 
size-fractions of subvisible proteinaceous particles. Both techniques possess unique and 
advantageous attributes and will likely find complementary application in future research on 
the biological consequences of proteinaceous subvisible particles. 
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Introduction 
Protein aggregation takes place to a certain extent in all biotherapeutic formulations. 
Concerns are often raised and debated with regards to the theoretical potential for aggregates 
to cause an immune response in patients.1,2 Because of possible biological consequences, such 
as immunogenicity or altered bioactivity and pharmacokinetics, particles of proteinaceous 
origin have recently received increased interest from industry, academia and regulators.1,3-6 
However, an undisputed general link between relevant clinical endpoints such as 
immunogenicity and subvisible particles in biotherapeutic preparations is still elusive. To 
date, the available data from in vitro and in vivo experiments are often conflicting and 
fragmented, which impedes coming to sound general conclusions. A major caveat of the 
published studies to date is the use of complex mixtures of therapeutic protein monomer, 
various aggregates and particle populations spanning a large range of sizes and possibly 
including a variety of chemical variations. However, potential effects generated by individual 
species (i.e. different size or modification) are difficult to delineate in such complex mixtures, 
as individual species are not easy to obtain. Studies using human interferon beta show that 
particles exposed to extreme artificial conditions e.g. metal oxidation or adsorption to glass 
induced an immune response in a transgenic mouse model.7,8 Clinical data with different 
interferon beta products show an increased anti-drug antibody formation which cannot solely 
attributed to aggregates but also to formulation (can contain HSA), modifications in the 
primary sequence and impurities acting as adjuvants.9 Furthermore, a sound characterization 
of complex mixtures used in these and other studies is often technically difficult or not 
feasible. Additionally, it has not been routinely employed by many groups studying the effects 
of subvisible particles generated by artificial stress conditions in various biological in vitro or 
in vivo models. 
Thus, the reliable preparation of particles of such discrete sizes and their detailed 
characterization may provide significant advantage in further researching distinct species of 
proteinaceous subvisible particles in relevant in vivo or in vitro test systems, possibly being 
able to identify specific subvisible species primarily relevant for a potential biological 
consequence, if occurring. 
62 
 
Aggregation can be induced by a wide variety of stress conditions (especially, when protein is 
not adequately stabilized), including temperature stress, mechanical stress such as shaking 
and stirring, pumping, pH stress and freezing and/or thawing stress.10 Such stresses can also 
lead to proteinaceous particles, which can be in the visible or subvisible size range.10 The effect 
of different types of stress on the induction of protein particles and aggregates has been 
investigated extensively.6,11-14 Depending on the protein and applied stress the resulting 
proteinaceous particles can range in size from nanometers to hundreds of micrometers. To 
characterize (subvisible) particle sizes, several methods have been applied to date and are in 
further assessment. Size exclusion chromatography is usually used for separation of soluble 
oligomeric (i. e. dimeric up to tetrameric) protein aggregates in the nanometer range15,16, and 
is incapable to measure protein particles. For larger protein aggregates (nanometers and 
submicron), the use of asymmetrical flow field-flow fractionation (AF4) has been employed to 
measure proteinaceous particles with sizes between 50 and 250 nm.17-19 However, the 
separation with AF4 and size exclusion chromatography leaves room for improvement in 
terms of size range and partition of protein aggregation. The separation of proteinaceous 
particles in a size range of 1 to 50 m which was reported recently, utilized a fluorescence-
activated cell sorter (FACS).20 Centrifugation for fractionation has been used in various fields 
such as cell biology, bacteriology. or in the soil industry where species in the nm-, m- and 
mm-size range have been successfully separated.21-23 Commonly used centrifugation methods 
to fractionate nanoparticles, blood leukocytes, blood plasma and erythrocytes, cells, bacteria, 
DNA or soils implement sucrose gradient, cesium chloride gradient, iodixanol gradients or 
the use of Ficoll/Percoll.24-30 However, the use of gradients has been shown to lead to 
contamination with new chemicals or residuals in the sample.27  
FACS and centrifugation are two of the most promising techniques for fractionation of 
proteinaceous particles and a most recent report utilized versions of the two approaches to 
enrich proteinaceous particles for follow-up biological characterization.31. However, to date 
these methods have not been comprehensively studied and optimized protocols are not 
available. Here we report the production of several distinctly sized protein nano- and 
micrometer subvisible particle fractions using the methods: a) differential centrifugation 
separation and b) fractionation of particles using a FACS. Both methods enabled preparation 
63 
 
of well-defined size fractions of proteinaceous subvisible particles using a model mAb, as well 
as their detailed characterization. The two approaches were examined in detail and the 
experimental parameters that influence particle isolation, fractionation resolution, fraction 
purity, yield and other attributes were carefully evaluated, which allowed for the first time 
detailed characterization and optimization of these two particle separation strategies. Finally, 
we provide an assessment of the relative advantages and shortcomings of the two techniques. 
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Materials and Methods 
Materials 
One Roche proprietary IgG1 monoclonal antibody (mAb1) was used as model protein for 
these studies. The solution was filtered using 0.22 mm Millex GV (PVDF) syringe filter units 
(Millipore, Bedford, MA) before use. 
Dulbecco’s phosphate-buffered saline (DPBS) from GIBCO (Invitrogen, San Diego, 
California) was used when PBS is mentioned. Glycerol (for molecular biology, Ψ99 %) was 
purchased from Sigma Aldrich (St. Louis, Missouri, USA). 
Stress condition: heat stress 
Thermal/shaking stress was applied using a Thermomixer fitted for 1.5 ml-tubes 
(Thermomixer Comfort, Eppendorf, Germany). 1 ml of the 25 mg/ml mAb1 solution was 
incubated for 3 min at 80 °C with 1400 rpm shaking. The temperature was chosen as being 
way beyond the melting temperature of the mAb1 (data not shown). The sample was then 
resuspended by drawing in and emptying out using a disposable Norm-inject 5 ml luer lock 
silicone free syringe (HENKE SASS WOLF, Tuttlingen, Germany) with attached 27 G x 11/2” 
needle (0.40 × 40 mm) (Braun, Melsungen, Germany) for 20 consecutive times, in order to 
homogenize the solution and the generated insoluble matter. The bulk solution was stored at -
80 °C after stressing. The sample was diluted with PBS to an optimal concentration of 
particles before fractionation using FACS.  
Preparation of subvisible particles by differential centrifugation 
A 5810R table-top centrifuge (Eppendorf, Germany) with a swing-bucket angle A-4-81 rotor 
(R=180 mm) was used for all centrifugation experiments.  
1) Empirical approach: selection of centrifuge time/acceleration/volume/media, multi-step 
preparation 
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For fraction 1 (centrifugation-F1), 100 l of initial stressed sample was overlaid on the top of 
1.7 ml glycerol solution (25 % w/w) using a pipette. The eppendorf tube was then centrifuged 
for 180 sec at 25 × g. The supernatant was discarded, whereas the pellet was resuspended in 
PBS for analysis.  
For the preparation of fraction 2 (centrifugation-F2) 100 l of initial stressed sample was 
overlaid on the top of 1.7 ml glycerol solution (25 % w/w) using a pipette. The first 
centrifugation step was performed for 240 sec at 50 × g. The supernatant was collected in an 
eppendorf tube and centrifuged again for 220 sec at 50 × g. The resulting pellet was 
resuspended in PBS.  
For the preparation of fraction 3 (centrifugation-F3), 1 ml of the initial stressed sample was 
centrifuged for 60 sec at 805 × g. After centrifugation the supernatant was collected and 
analyzed.  
Fraction 4 (centrifugation-F4) was obtained by centrifuging 1 ml of centrifugation-F3 for 7 
min at 1811 × g. The supernatant was then collected for analysis. 
2) Design Of Experiments: Optimizing empirical parameters and refining fractionation 
The experimental parameters to obtain fraction 1-4 were refined using Central Composite 
Face-Centered Designs (CCF) of experiment. The optimization for each fraction is described 
in detail in the supporting information.  
Preparation of subvisible particles by preparative flow cytometry (FACS) 
A BD FACS Aria IIu preparative cell sorter (BD Biosciences, San Jose, California) was used 
with BD FACSDiva v 6.1 software, applying the low-angle FSC detector equipped with a 
488/10 band pass filter for the 488 nm laser. A flow cytometry size calibration kit (1, 2, 4, 6 10, 
and 15 m) from Molecular Probes (#F-13838; Life Technologies, Zug, Switzerland) with 
non-fluorescent microspheres was used for the calibration and definition of the sorting gates. 
For all experiments, autoclaved PBS (pH 7.2) was used as sheath fluid, prepared using 10× 
stock solutions and deionized water. To eliminate contaminating particles from the sheath 
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fluid, the sheath line was equipped with 0.22 ƨm filter. Five milliliter 12 x 75 mm 
polypropylene round-bottom tubes (#352063, Corning Inc.) were used for fraction collection. 
All samples were filtered through 40 ƨm cell strainer (#352235, Corning Inc.) before sorting. 
Size exclusion chromatography (SE-HPLC) 
Samples were analyzed by UV absorbance detection at 280 nm. A TSK G3000 SWXL column 
(5 ƨm, 250 Å, 7.8 x 300 mm) from Tosoh was used for separation. The mobile phase (200 mM 
sodium phosphate, 250 mM KCl, pH 7.0) was pumped at a flow rate of 0.5 ml/min. Sample 
size for analysis was 25 g. The stationary phase was kept at 25 ± 2 °C. 1 ml of each sample 
was centrifuged for 10 min at 14000 rpm before injection of the obtained supernatant. For 
each sample 25 l was injected. 
Light obscuration 
A HIAC ROYCO instrument model 9703 (Pacific scientific, New Jersey, USA) was used for all 
light obscuration (LO) measurements. A small volume method using a rinsing volume of 0.4 
ml and 4 runs of 0.4 ml each was applied, as described previously14. Flow rate was set to 10 
ml/min. The first run was discarded and the average ± standard deviation of the last 3 runs 
was reported for each sample. Blank measurements were performed at the beginning of the 
measurements and in between samples using fresh particle-free water. The acceptance 
criterion for blanks was: “less than 5 particles > 1 m”. The system suitability test consisted of 
the measurement of count standards of 5 m (Thermo Fisher count standards) with 
acceptance limits of ± 10 % the reported concentration for particles bigger than 3.0 m was 
performed in the beginning of each measurement day. 
Flow imaging microscopy  
The initial samples as well as all collected fractions were analyzed by flow imaging microscopy 
(FI) using a MFI DPA4200 series instrument (ProteinSimple, Santa Clara, California) 
equipped with a 470 nm LED light source. All particles larger than 1 m in equivalent circular 
diameter were reported, considering the lower limit of detection of equipment. Size and count 
standards (ThermoFisher, Reinach, Switzerland) were used to check consistency of the sizing 
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and counting accuracy of the instrument on the day of each measurement. The system was 
cleaned (before each measurement day) using 1 % (w/v) Tergazyme® (Sigma Aldrich, St. 
Louis, Missouri), followed by rinsing with water for 10 min. For these flushing steps, the flow 
rate was set to “maximum speed”. Flushing with water was repeated after each sample. The 
“optimization of illumination” routine was performed prior to analysis, using filtered sample 
or PBS matching the buffer composition of the sample to be analyzed (e.g. filtered sample for 
measuring after heat stress or PBS to measure FACS fractions). For measuring, 1 ml of sample 
was placed in a 1 ml dual-filter tip on the inlet port. 
Resonant mass measurement (RMM, Archimedes)  
Resonant Mass Measurements (RMM) were performed using Archimedes system (RMM0017, 
generation 2) from Malvern instruments LTD (Malvern, United Kingdom). Micro sensor 
chips with internal microchannel dimensions of 8 ƨm × 8 ƨm were used for all the 
experiments. The calibration of the sensor was done using 1 m Duke polystyrene size 
standards (Waltham, Massachusetts, USA) diluted in water to approximately 106 part/ml. The 
calibration was finalized after 300 particles were detected as recommended by the 
manufacturer. The particle density for proteinaceous particles was defined as 1.28 g/ml. 
Before measurement, one ml of the sample to be analyzed was centrifuged 5 min at 1258 ×g in 
order to remove large particles that could block the sensor during RMM. The influence of the 
additional centrifugation step on the particle concentration can be seen in Supplementary 
Figure 7. Measurements were performed in triplicates and the sensor was filled with fresh 
sample during 40 sec before each measurement. The limit of detection (also called threshold) 
was manually set to 0.015 Hz for each analysis. Each measurement stopped either after one 
hour of measurement or when a total of 4000 particles were detected. During measurement, 
the “autoreplenish” function was automatically activated every 500 sec for 5 sec to load fresh 
sample and avoid settling down of particles in the sensor and tubings. 
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Results 
The aim of this study was the development, comprehensive evaluation and comparison of 
methods for the preparative fractionation of proteinaceous subvisible particles, with diameters 
ranging from hundreds of nanometers to approximately hundred micrometers. Two different 
methods were evaluated. Besides the two reported methods, other techniques such as 
sequential filtration, gravitation, asymmetrical flow field-flow fractionation or gel 
chromatography were initially also tested for their applicability to isolate different size 
fractions. However, these methods had limitations in their usable size range or sample 
amount. 
First, a differential centrifugation fractionation of proteinaceous particles was developed and 
carried out to obtain a number of discrete fractions of various sizes spanning the range 
mentioned earlier. In order to optimize the method and process parameters, a statistical 
design of experiments approach (DoE) was applied. Second, fractionation of proteinaceous 
particles using preparative FACS strategy, comparable to the method reported elsewhere, was 
applied.20 The factors influencing the quality of separation in both methods were examined in 
detail. Light obscuration (LO), Flow Imaging (FI), flow cytometry and Resonant Mass 
Measurements (RMM) were used to measure the particle size distributions of the resulting 
fractions. The digital images generated by the FI measurements allowed an approximate 
calculation of ratio of protein particles contained in these fractions. RMM was used for the 
detection and quantification of submicron particles. 
Generation and characterization of subvisible proteinaceous particles 
In order to generate sufficient amounts of proteinaceous particles for method assessment, a 
starting solution of therapeutic IgG1 protein product with concentration of 25 mg/ml was 
heated to 80 °C for 3 min which lead to the extensive particle formation. After this treatment, 
the relative protein monomer content in the supernatant was below 0.05 % and no nanometer 
aggregate formation could be detected by size exclusion chromatography. After heat stress, 
the resulting samples contained particles in a broad size range (see Figure 1A). The harsh 
treatment described above generated numerous very large particles which were broken up 
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into smaller species by drawing and pushing these through a 27G x 1.5“ needle mounted on a 
5 ml disposable syringe, resulting in a typical decay distribution with increasing size (see also 
Figure 1B). The proteinaceous particles prepared using this technique demonstrated adequate 
stability upon dilution in PBS and in the media used in all experiments (measured by flow 
imaging microscopy – see Supplementary Figure 8). Furthermore, the particles produced 
using the procedure described above were sufficiently stable upon freeze/thaw and storage at -
80 °C (Supplementary Figure 8), to allow sample storage. 
 
Figure 1: Size-distribution obtained suing MFI of the sample after heat/shake stress (A) and consequent 
application of 20 syringe draw and release cycles (B). 
Fractionation of subvisible proteinaceous particles using differential centrifugation  
An empirical approach for centrifugation using adapted Stokes law [T =9ln/(2r2(ƭp-ƭs)Ƶ2R] 
where T represents the centrifugation time, r is the radius of a sphere, ƭp is the density of the 
particle, ƭs stands for the density of the solution, Ƶ is the angular velocity of the centrifuge and 
R is the rotor radius, was used to isolate four different fractions of high purity (approximate 
mean diameters; 0.4 m, 1.5 m, 15 m and 40 m). These experiments informed the 
definition of the critical experimental parameters that might have an impact on the 
fractionation performance. 
In order to extend centrifugation times to practical length, to slow down the sedimentation of 
large particles and prevent co-sedimentation of particles of different sizes, we noticed that it 
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was necessary to increase the viscosity of the medium. This was achieved by the addition of 
glycerol to varying concentrations (see Table 1). A content of 25 % glycerol (w/w) was 
sufficient to maintain large particles (>15 m) in suspension and avoid rapid sedimentation. 
To verify that the use of glycerol did not impact the morphology of the particles flow imaging 
microscopy measurements were carried out. Indeed, particles which were in contact with 
glycerol during the fractionation procedure and consequently resuspended in PBS did not 
show any measurable difference in their size, circularity, aspect ratio and object intensity 
parameters in comparison to particles that did not have contact with glycerol (data not 
shown). Moreover, the amount of glycerol remaining after centrifugation and resuspension of 
pellets in PBS was estimated (based on pellet/fraction volumes) to be relatively low 
(approximately 2.5 % (w/w)). To arrive at these initial parameters for the empirical approach, 
a broad screen was carried out in a large number (~1000) of experiments which explored the 
following parameter ranges: centrifugation time in the range of 30 seconds to 6 hours, 
acceleration in the range of 8 ×g to 3226 ×g, and glycerol concentrations from 0 to 100 % . As 
a guide to future experiments, we would suggest the user to begin with the parameters 
outlined in Table 2 and adapt them in order to fulfill their requirements. 
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In a second step, a design of experiments (DoE)-approach was used to further optimize and 
refine the fractionation parameters. For this approach a response surface methodology (RSM) 
and a Central Composite Face-Centered Designs (CCF) were utilized due to their flexibility, 
efficiency and the fact that the experiments could be run sequentially. The empirically 
optimized fractionation parameters in the first step of the method development served as 
center points of each DoE. The aims of the DoE optimization (optimal responses) were high 
purity and high particle concentration in the desired size range. Therefore, the variables (i.e. 
acceleration, centrifugation time and glycerol concentration) and responses were selected in 
each case as described in Table . Each optimal point was confirmed experimentally to verify 
the predicted optimal conditions. After each successful confirmatory run the respective 
fractionation using those optimal conditions was repeated in larger scale in order to perform 
the full analytical characterization (SE-HPLC, RMM, FI, LO).  
Using the DoE optimization it was possible to refine the experimental parameters in order to 
obtain higher particle concentration and/or reach size targets for four different fractions as 
described in Table  and Figure 2. The proportion of the variation of the response described by 
the model (R2) shows in all the cases that the data was accurately modeled (see Supplementary 
Figure 2B, Supplementary Figure 3B, Supplementary Figure 4B, and Supplementary Figure 
5B). The high values obtained for the proportion of the variation of the response predicted by 
the model according to cross validation (Q2) allow good model prediction in each case. 
Moreover, the models were deemed to be valid as demonstrated by validity values larger than 
0.25 for each model (indicating no lack of fit) as depicted in Supplementary Figures 2B to 5B. 
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Figure 2: Particle concentration (solid lines) and integrated mass (dashed lines; see Materials and Methods 
for detailed description of the calculations) for fraction 1 (A), fraction 2 (B), fraction 3 (C), fraction 4 (D) 
obtained by centrifugation with optimized conditions. Results from RMM are shown in black, FI measurements 
in blue and LO - in red. 
The size distributions of the four DoE optimized fractions described above were measured 
using LO and the additional characterization methods FI and RMM (see Figure 2). Besides the 
minor discrepancy between the distributions reported by LO and flow imaging microscopy 
(observations also previously reported in literature).the results presented in Figure 2 
demonstrate that the resulting fractions had high particle concentrations in the targeted size 
ranges, high purity as indicated by low content of small particles in large fractions 
(centrifugation-F1 and centrifugation-F2) and low content of large particles in the small 
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fractions (centrifugation-F3 and centrifugation-F4).32,33 Representative FI images of particles 
from the different fractions can be found in Supplementary Figure 6. 
As seen in Figure 2, defining features (and major advantages) of the differential centrifugation 
approach were: a) the relatively high concentrations of particles that can be achieved in the 
final fractions and b) the broad size range that can be accessed using this method. 
Resuspension of the pellet (for fractions containing large particles) allowed adjusting the 
particle concentration and the buffer composition to user requirements. Moreover, 
contamination of large size fraction with nanoparticles was nearly completely eliminated by 
adding glycerol during the centrifugation process. 
Fractionation of subvisible proteinaceous particles using FACS 
For the preparation of micrometer-sized subvisible proteinaceous particles, the same starting 
material was used as for the centrifugation approach (see Materials and Methods section). In 
principle, preparation of nanometer-sized particle fractions by FACS is also possible, although 
using this approach restricts the sample to low final protein concentrations. These low 
concentrations may present challenges for follow-up biological characterization studies. The 
sizes of the target fractions were estimated using a FACS size calibration kit containing beads 
with an approximate diameter of 2, 4, 6 and 15 ƨm and the Forward Scatter (FSC-A) signal. 
The cell sorter used in this study (see Materials and Methods section) allows simultaneous 
sorting of four different size-fractions. The position and the broadness of gates were set to 
achieve very narrow size-fractions (see Figures 3 and Figure 4.). However, it needs to be 
pointed out that narrow gates require more material and longer sorting times (see 
Supplementary Figure 1). The particles were sorted (with settings “4-way purity”) applying 
the gate limits defined above. After sorting, all fractions were measured using flow cytometry 
(see Figure 3) The polystyrene beads, as well as the sorted proteinaceous particles where 
measured using FI (for representative images see Figure 3 B and C). As seen in Figures 3 and 4 
all fractions were in excellent agreement with the polystyrene beads of similar size and the 
final size distributions matched the pre-determined gates which was confirmed by the 
additional analytical methods applied.  
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The first experimental parameter explored in detail was the nozzle size. Using different nozzle 
sizes influenced the particle concentration of the sorted fractions. As expected, larger nozzle 
sizes lead to larger drops containing more sheath fluid (PBS) and sample buffer (also PBS). 
Thus, the risk of coincidence of two or more particles per drop is higher for larger drops and 
the drop frequency is much lower compared to streams from smaller nozzles. In addition, 
larger nozzle sizes require less pressure and exert a less harsh mechanical treatment to 
particles. Conversely, some of the disadvantages of smaller nozzle size are the higher tendency 
for clogging of the orifice and also spraying of the stream by partial blocking and the resulting 
diversion of the stream. Larger particles may cause a deflection of the stream by partial 
blocking the nozzle and therefore mis-sorting when passing through the nozzle. After testing 
all three available nozzles, the 100 ƨm nozzle was chosen as optimal for the target fractions, 
because it applied the softest conditions in matters of pressure and mechanical stress from 
passing the nozzle. 
The optimal number of events per second (i.e. number of particles) in FACS is a quarter of the 
overall drops per second (manufacturer’s recommendation). Therefore, in the case of the 70 
ƨm nozzle with a drop rate of 90 kHz, the optimal rate is ~22000 events/sec and for the 100 
ƨm nozzle with a drop rate of 30 kHz the optimal rate is ~7500 events/sec. In cases where 
higher concentrations of particles in the starting solution were used, a higher discard rate of 
drops by the instrument was observed, which resulted in an increased probability of 
coincidence of two or more particles in one drop (not separated). Therefore, the 
concentrations of particles in the starting material were adjusted below 7500 events/sec by 
dilution with PBS (sheath fluid). It needs to be pointed out that using a buffer different from 
the sheath fluid may lead to false positive results due to differences in the refractive indices or 
in rare cases foaming. 
76 
 
 
Figure 3: Fractions sorted using FACS and re-analyzed with flow cytometry (A). Flow imaging microscopy 
images of the size-standards used in the FACS experiments for gate determination (B). Representative FI 
images of protein fractions after FACS sorting (C). 
The resulting sorted fractions were analyzed using flow cytometry (Figure 3A), LO and FI (to 
quantify the particles larger than 1 ƨm) and RMM for submicrometer particles (Figure 4A-D). 
The results from all size-distribution measurements were consistent between all methods with 
a small shift to smaller sizes in the case of LO measurements. This minor undersizing effect 
has been described previously in reports that have reported smaller and fewer particles in LO 
as compared to flow imaging microscopy.32,33 The content of submicrometer particles in all 
four FACS fractions determined by RMM was several million particles per ml (Figure 4). 
These smaller particles could not be measured and fractionated by FACS due to the technical 
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limitation of this method to detect only scattered light of particles larger than the laser 
wavelength. All particles smaller than this threshold cannot be detected and end up in all 
FACS-sorted fractions. Therefore, after sorting, the samples did contain not only particles of 
the desired size but also a small amount of “contaminating” particles of smaller 
(submicrometer-sized) and larger sizes. This can be attributed either to a) the possible break-
up or aggregation of particles upon sorting due to the mechanical forces that are applied 
apart, b) coincidence of two particles in one drop or c) partial blocking of the nozzle by large 
particles causing diversion of the stream. One strategy to increase the purity of the fractions is 
by resorting the already sorted fractions20. However, it was found that resorting only led to a 
small increase in the purity, but in a large decrease in the concentration of particles. In 
comparison to a previous study20, the purity of the individual initial fractions in the current 
report was very high and therefore, a resorting was not justified. The relatively high purity 
after the first sort was attributed to the higher stability of the particles as compared to the 
previous report. Data regarding the stability (reversibility) of fractions after freeze/thaw can be 
found in Supplementary Figure 8 (FACS fraction 1 and fractions generated by differential 
centrifugation given as examples). A comparison of the fractions generated by centrifugation 
and FACS can be found in Table 3. 
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Figure 4: Particle concentration (solid lines) and integrated mass (dashed lines; see Materials and Methods 
for details on calculation) for fraction 1 (A), fraction 2 (B), fraction 3 (C), fraction 4 (D) isolated by FACS. 
Results from RMM are shown in black, FI measurements in blue and LO - in red. 
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Discussion  
In this study a number of method attributes were evaluated in order to understand the 
applicability of the individual methods and define a toolkit for characterization of 
proteinaceous subvisible particles that researchers can use in future studies. The size-range, 
resolution, purity and yield and some additional factors were systematically assessed. 
Size-range 
Naturally, both methods examined in this study are restricted in their working size-range by 
physical limitations related to the separation principle or the instrumentation used. For 
example, the smallest particles that FACS can theoretically separate have a diameter of 0.5 ƨm. 
The lower detection limit could in principle be improved by increasing the angle of the 
forward scattering (FSC) detectors because particles with sizes near and below the laser 
wavelength (nanometer-sized particles) scatter proportionally more light at larger angles.34 
The limit is also dependent on the instruments settings for the detector voltage of the forward 
and side scatter detectors. It has been shown that detector voltage settings for detection of 
very small particles (0.5 to 3 ƨm) are not suitable to distinguish between larger sizes (larger 
than 3 ƨm) and settings for larger particles (larger than 1 ƨm) results in the loss of sensitivity 
for particles smaller than 1 ƨm35. The upper size-limit of FACS instruments is dependent on 
the nozzle size. As a general recommendation the manufacturer suggests not to exceed an 
object size of 50 ƨm for this specific instrument.  
In contrast to FACS, centrifugation-based separations are less restricted in their working size-
range. As a consequence, the differential centrifugation method described here can be used to 
preparatively separate a much broader size range of particles as compared to FACS-particles 
between the sizes of 0.2 m and 100 m can be easily separated. Therefore, one major 
advantage of differential centrifugation is its suitability for preparation of submicrometer 
particle fractions. In addition, as demonstrated in this study (see Figure 2A.), particles larger 
than 40 m can be easily separated as well. The possibility to obtain particle fractions of 
different sizes ranging from low-nanometer to larger than 100 m in the same experiment is a 
major advantage of differential centrifugation. However, it needs to be mentioned that 
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obtaining multiple size-fractions in a single experiment requires the use of an additive to 
increase the viscosity of the medium (i.e. glycerol or sucrose) in order to avoid cross-
contamination of the different fractions.  
Resolution 
A major difference between both methods is the resolution of prepared fractions. With flow 
cytometry it was possible to prepare particles in a very narrow size window, e.g. 2 ƨm (Figure 
4). The differential centrifugation method allowed isolating fractions with approximate mean 
diameters of 0.4 m [0.2-0.8 m], 1.5 m [0.2-2.5 m], 15 m [1-30 m] and 40 m [10-60 
m], whereas FACS fractionation method separated fractions with mean diameters of 2 m, 
[1-3 m] 4 m [3-5 m], 6 m [5-7 m] and 15 m [5-25 m]. With exception for submicron 
fractions, the centrifugation method generated rather broad size distributions. For example, 
comparison of the 15 ƨm fractions generated by FACS (Fraction 1, Figure 4A) and differential 
centrifugation (Fraction 2, Figure 2B) show a very broad distribution for the fraction using the 
second method. In contrast, the 15 ƨm fraction generated by flow cytometry was much 
narrower in size range. Very narrow fractions of 2, 4 or 6 ƨm mean particle diameter have also 
been generated using FACS, which was not possible with the centrifugation method. Whereas 
obtaining fractions of discrete sizes using centrifugation was challenging and might need 
further development. In principle, the FACS method can be used to generate even more 
narrow fractions than the ones reported here. Naturally, one drawback associated with such 
efforts would be the requirement for more material and longer fractionation run times. The 
time for sample preparation with both methods is very different and depends highly on the 
initial sample and its preparation. As stated in Table 3, differential centrifugation uses more 
time than FACS mainly because of the higher sample amount requirements. The fractionation 
run time (i.e. the instrument time that was needed for either centrifugation or FACS, not 
counting the time for sample preparation or setup of the instrument) for 1 ml of both 15 ƨm 
fractions is 8 min for centrifugation and 5 min with FACS. Any changes in size range of the 
desired fraction and particle concentration of the initial sample can significantly change these 
time frames. 
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Table 4: Comparison of the attributes of FACS and differential centrifugation methods with respect to the 
generation of micrometer-sized subvisible particle fractions 
Attribute                Method 
 Differential centrifugation FACS
Presence of nanoparticles low high 
Resolution medium high 
Yield high low 
Size range large medium 
Preparation time long medium 
Additives needed yes no 
Purity and yield 
One drawback of the FACS fractionation method is the inability to detect particles smaller 
than 0.5 ƨm due to physical limitations in the detection with laser light scattering. This leads 
to contamination of all FACS fractions with small particles which can be detected using 
alternative methods (e.g., RMM, FI). Indeed, RMM confirmed the presence of nanoparticle 
contaminants in the FACS fractions (Figure 4A-D). Although, resorting of the initial fractions 
did minimize the nanoparticle contamination, the improvement was attributed largely to the 
dilution effect rather than specific removal of submicrometer particles. More importantly, the 
differential centrifugation method does not have this limitation. Figures 2A and 2B show a 
very low content of submicrometer particles in the micrometer fractions (Fraction 1 and 2). 
This also suggests an interesting approach to achieve very pure and also narrowly sized 
fractions – a combination between FACS and centrifugation fractionation. More specifically, a 
first-pass centrifugation step could be applied to remove the nanoparticles present in a 
sample. As a second step the micrometer centrifugation fractions can be separated using 
FACS to generate well-defined fractions of specific sizes. Alternatively, the approach can be 
reversed centrifuging FACS-generated fractions to separate micrometer from nanometer 
particles. However, the latter approach may be impractical due to the necessity for viscosity 
additives (e.g., glycerol). 
Although some of the fractions generated in this study did contain certain amounts of 
“contaminating” nanoparticles, if calculated in terms of protein mass the impact of this 
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contamination was negligible. Flow imaging microscopy and RMM data can be used to 
perform such calculations of the total protein mass of the particles present in every sample 
based on the digital image analysis (taken in Flow imaging microscopy) or on the buoyant 
mass (RMM).36-37 Such calculations for the fractionation experiments presented here showed 
practically no influence of the submicrometer particles on the protein content of micrometer 
fractions generated by FACS and centrifugation (Figure 4A-D and Figure 2A-B). However, 
the mass calculations reveal an important practical aspect of the fractionation of subvisible 
particles – i.e. the fractions of the smaller-sized particles contain much less protein than the 
larger-sized fractions. This effect is a natural consequence of the power relationship between 
size and volume (e.g. sphere=ସଷ ߨݎଷ). Interestingly, the impact of this effect seems to be larger 
in the FACS fractionation method, which can be attributed to the higher purity of the 
individual fractions. 
The particle concentration generated by FACS is limited by the fact that the flow cytometer 
sorts drops of buffer and sheath fluid of the same size. Drops with smaller particles therefore, 
contain relatively more sample fluid than large drops that almost fill out the whole drop. This 
can also be seen at the particle concentration measured by FI of the FACS fractions 1 to 3 
indicating that the same number of particles is present in the same volume. Fraction 4 has a 
lower particle concentration due to the detection limit of the FI instrument. Therefore, FACS 
cannot be used to create concentrated fractions, but might be combined with centrifugation to 
concentrate and also to remove submicron contamination from the fractions as described 
above. Using centrifugation it would possible to reach even larger protein concentrations 
(than those presented here) for fractions including the resuspension of a pellet (Fraction 1 and 
2). Indeed, each pellet was resuspended in 1 ml of PBS in our study but for some other 
purposes the number of pellets or the initial volume could have been increased and 
resuspended in smaller volumes (data not shown). Although the primary target was purity of 
the fractions, we calculated the recovery yield for both 15 m fractions generated with FACS 
and centrifugation. The initial sample contains 86 million particles/ml in the size range 
between 5 and 25 m which is diluted 1 to 5. The FACS fraction 1 contains only 60000 
particles/ml, i.e. 0.35 %. For centrifugation fraction 2 the initial sample was diluted 1 to 10 and 
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contains 150 000 particles/ml, i.e. 1.75 %. However it needs to be pointed out that 1 ml of 
initial sample yields more than 1 ml after FACS sorting. 
Other factors 
An important consideration in setting up fractionation of subvisible particles using the 
methods described in this study is the particle concentration in the samples. For example, in 
flow cytometry the number of particles should not exceed the number of drops per second 
(e.g. 7500 events per sec with the 100 m nozzle) in order to avoid coincidence of two or more 
particles in the same drop. Thus, high particle concentrations can lead to either mis-sorting 
and/or to slower sorting rates because of discarded drops containing multiple particles. In the 
case of centrifugation we only tested experiments using protein solutions with concentrations 
of up to 25 mg/ml. It is conceivable, that higher concentrations might need to be diluted 
before centrifugation to prevent an interaction between large and small particles. 
The centrifugation-based approach to fractionation of particles larger than 5 ƨm requires the 
addition of viscosity modifiers (e.g., glycerol) to reduce the sedimentation speed and improve 
the fraction purity. In fact, it is exceedingly difficult to isolate proteinaceous particle fractions 
of large mean diameter (e.g. 30-40 m) without the use of glycerol. Our first attempts to 
generate such fractions without glycerol always contained a large number of smaller particles 
(0.2 to 2 m). Of course, the use of glycerol may potentially result in additional complications 
– for example, the addition of glycerol may induce changes in the particle size- or morphology 
distributions. This was not the case in the experiments reported here and such changes were 
not observed or reported in the literature, but it remains a theoretical possibility which needs 
to be carefully controlled. A further practical aspect of the use of glycerol for fractionation by 
centrifugation is the fact that small amounts of glycerol are carried over after resuspension of 
the fraction pellet into working medium (buffer) resulting in the presence of glycerol in the 
final fractions (albeit in very low concentrations, i.e. 2.5 % w/w). Conversely, for the 
preparation of FACS fractions no additives are necessary, which may be an additional factor 
in choosing a fractionation method. The dilution of the samples fractioned by FACS can be 
done using any buffer, which in turn can be used as a sheath fluid in the FACS instrument 
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with the only caveats that the buffer should not foam and needs to contain a sufficient amount 
of ions for charging and deflection. 
Another major difference between both methods is the type of physical stress that is applied to 
the particles during the fractionation process. During centrifugation the samples experience 
centrifugal forces and perhaps shear stress; during flow cytometry fractionation several 
different types of stress are present. For example, in the flow cell a pressure of up to 70 psi 
(4.82 bar) is applied (depending on the nozzle size), which could impact the sample in either 
way. It has been reported that high pressure can be used to dissociate aggregates and refold 
protein, however, the pressure used in that study was significantly higher (2000 bar) and 
therefore such effect is likely irrelevant.38 In the flow cell of the flow cytometer the particles 
pass through laser beams and the surrounding liquid is repeatedly charged negative and 
positive using electrical potential of ± 40 to 80 V. After exiting the flow cell, the particles pass 
through a small orifice and return to atmospheric pressure, experiencing shear and 
cavitational forces. Afterwards, the sample is accelerated to 20 m/sec and passes through an 
electric field of 3 to 5 kV/cm before hitting a liquid surface or a solid tube wall. There are 
alternative cell sorters available that divert the particles mechanically or by an air stream 
instead of electrostatics, but these instruments have a maximal drop rate of 2 kHz and 
therefore 10 fold slower than the instrumentation used in this study. As a side note an 
instrument using air stream (Union Biometrica, Inc.) for sorting is capable to sort particles up 
to 1,500 ƨm as advertised by the manufacturer. In relation to the physical stress it needs to be 
mentioned that the stability of the particles to be fractionated (their ability to remain intact, 
i.e. irreversibility) is important. Although particle stability in FACS sorting was shown for stir 
stress31 as well as syringe shear-cavitation stress20, particles generated under different 
conditions with other proteins might demonstrate different stability behavior. For example, 
our experience with particles of the same IgG used in this study produced by stir stress was 
that they were not suitable to create fractions larger than 5 m because these particles were 
fragile for this particular protein and this particular stress condition. 
All technical challenges of mechanical, electrical or chemical nature mentioned above may 
have impact on the proteinaceous particles. Depending on the further use of the generated 
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fractions, (e.g. in vivo or in vitro biological assays) it might be necessary to assess possible 
physico-chemical changes induced by the separation process, particularly if the protein is 
sensitive to the types of stress exerted during fractionation. In such cases, additional 
investigations should be taken into consideration. It is recommended to consider CE-SDS to 
check degradation and covalent linkage, and RP-HPLC and peptide mapping to check for 
modifications like oxidation or deamidation of amino acid residues.39 Furthermore, it may be 
relevant to assess potential changes in the secondary and tertiary structure using spectroscopic 
techniques such as circular dichroism (CD), Fourier transform infrared- (FTIR), and 
Fluorescence- or Raman spectroscopy. For the subsequent use in in vivo or in vitro assays it 
may also be important to check the endotoxin content. In principle both methods can 
produce fractions that have low endotoxin content if the necessary precautions are taken. A 
procedure to prepare a FACS for endotoxin-free sorting has been published recently31 and is 
also available from some instrument manufacturers (e.g. BD: prepare for aseptic sort). Finally, 
it should be pointed out that irrespective of the separation method particle size-fractions 
though enriched in size may still contain conformational or chemically heterogeneous 
populations. 
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Conclusions 
Here we report a comprehensive evaluation and optimization of the experimental parameters 
of two new methods for fractionation of proteinaceous subvisible particles of sizes between 
approximately 0.2 m and 100 m: differential centrifugation and FACS. Applying the 
optimized method parameters size-fractions of proteinaceous subvisible particles were 
isolated using both techniques and the methods’ attributes such as size-range, resolution, 
fraction purity and yield were assessed. It was found that both techniques present advantages 
and disadvantages (see Table  for a summary) and will likely find complementary use in the 
research practice. Further research will focus on assessing immunogenicity in in vitro models 
of various fractions of protein aggregates and particles. 
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Associated content - Supporting information: Optimizing fraction 1-4 (obtained by 
centrifugation) with a Design of Experiments  
Fraction 1: 
The time length (60 to 300 sec), the acceleration (8 × g to 50 × g) and the glycerol 
concentration (10-40 % w/w), were identified as critical parameters for this single 
centrifugation step, based on previous experience. A Central Composite Face-Centered 
Design (CCF) of experiment was used including three center point experiments which 
resulted in 17 runs (see Supplementary Table 1). After each run, the pellet was resuspended in 
1 ml of PBS and analyzed. 
Fraction 2: 
Fraction 2 was obtained in two steps that were evaluated separately in two separated designs 
of experiments (DoE). For the first centrifugation step the time length (60 to 420 sec), the 
acceleration (8 to 129 × g) and the glycerol concentration (10 to 40 % w/w) were considered in 
a CCF design including three center point experiments, resulting in a total of 17 experiments. 
Once the optimum was set for step 1, supernatant of different tubes were pooled in order to 
optimize step 2.  
Development for step 2 also utilized a CCF design (2 parameters, 11 experiments including 
three center point experiments). The time-length (60 to 300 sec) and the acceleration (8 to 129 
× g) were considered for the experiments. After each run, the pellet was resuspended in 1 ml 
of PBS and analyzed. 
Fraction 3: 
One single centrifugation step using a CCF design (11 experiments including three center 
point experiments) with variation of the time length (60 to 180 sec) and of the acceleration 
(453 to1258 × g) was used to obtain fraction 3. After each run, the supernatant was analyzed. 
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Fraction 4: 
An additional centrifugation step was performed using fraction 3 as starting material in order 
to obtain fraction 4. CCF design (11 experiments including 3 center point experiments) with 
changes in time length (3 to 11 min) and acceleration (805 to 3220 × g) was used for this 
optimization. Resonant Mass Measurements (RMM) were performed on the supernatant after 
each run.  
For each fraction, optimal points were defined using the optimizer function of the DoE-
software Modde (Version 10) but also the presented contour plots (manually chosen). 
Description of DoE results: 
As seen in Supplementary Figure 2A for centrifugation- fraction 1 the optimal conditions 
(regions in red) for the total particle concentration and for the mean diameter did not overlap 
when superimposing the contour plots, i.e. no conditions can be found to satisfy both 
requirements. Therefore, the obtained particle size and concentration requirements were 
balanced. The particle concentration of the resuspended pellets was measured using FI, (see 
Supplementary Table 1). Additionally, the contents of particles in the submicron size-range 
were measured using RMM. These measurements demonstrated that the content of 
nanometer-sized particles was very low (4 × 104 particle/ml) when using the optimal 
conditions. 
To obtain the second fraction (centrifugation fraction 2) with a targeted mean diameter of 15 
m, particles between 10 and 25 m were enriched, particles larger than 40 m or smaller 2 
m eliminated. In summary, two centrifugation steps were needed for this and treated in two 
different DoE assessments. The first step (for details, see   
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Supplementary Table 2) was implemented to discard the largest particles. The optimum 
conditions for step 1 to obtain the supernatant maximized concentration of particle between 
10-25 m and minimized the concentration of larger particles than 40 m. After setting the 
optimum for step 1 (centrifugation for 240 sec with an acceleration of 50 × g using a glycerol 
solution of 25 %), the experiments for the second DoE were performed as described in 
Supplementary Table 3 in order to get rid of particles in the low submicrometer range. The 
short centrifugation time (180 sec) at a high acceleration (72 × g) resulted in fraction 
containing (after reconstitution of the pellet) high number of particles between 10-25 m and 
a mean diameter around 15 m as depicted in Figure2B. In addition, only 2 × 104 particle/ml 
in the low micrometer size range were measured after optimization in fraction 2 using RMM.  
One single centrifugation step was sufficient to generate centrifugation fraction 3 
(approximate mean size of 1.5 m) from the initial stock solution. The total particle 
concentration and the mean diameter of the resulting supernatant were selected as responses 
for the DoE. Using the contour plots, optimal conditions were found in order to reduce the 
mean diameter (from 1.33 to 1.25 m). However, the longer centrifugation time implemented 
after optimization (160 sec against 60 sec before optimization) induced a decrease of the 
particle concentration present in the supernatant by two times. The total particle 
concentration below 3 m measured by FI and RMM remains reasonably high as depicted 
Figure 2C.   
To obtain a fraction with a diameter smaller than 0.5 m (centrifugation fraction 4), an 
additional centrifugation step was performed using fraction 3 as a starting material in order to 
remove the largest particles present in this fraction. This optimal centrifugation run using a 
higher acceleration and a longer centrifugation time allowed a decrease of the mean diameter 
from 0.43 to 0.36 m but induced a decrease from 4.1 × 106 to 2.1 × 106 particles per ml. The 
presence of particle in the m-range is relatively low as expected (see Figure 2D). 
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Supplementary Figure 1: Influence of smaller gate sizes on size distribution of particle fractions 
 
Supplementary Figure 2: Fraction 1 DoE Contours plots at 48 × g for the particle concentration and mean 
diameter measured by flow imaging microscopy as a function of centrifugation time and glycerol 
concentration in specific ranges (A). Summary of fit for fraction 1 response surface methodology (RSM) 
obtained model (B). 
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Supplementary Figure 3 Fraction 2 DoE Contours plots for the particle concentration 1-2 μm and 10-25 μm 
and also for the mean diameter given by flow imaging microscopy analysis in function of centrifugation time 
and acceleration (A). Summary of fit for fraction 2 RSM obtained model (B). 
 
Supplementary Figure 4: Fraction 3 DoE Contours plots for the total particle concentration 1-100 μm and 
for the mean diameter given by flow imaging microscopy analysis in function of centrifugation time and 
acceleration (A). Summary of fit for fraction 3 RSM obtained model (B). 
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Supplementary Figure 5: Fraction 4 DoE Contours plots for the total particle concentration 0.2-5 μm and 
for the mean diameter given by RMM analysis in function of centrifugation time and acceleration (A). 
Summary of fit for fraction 4 RSM obtained model (B). 
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Supplementary Figure 6: FI pictures of the three different fractions generated by differential centrifugation. 
  
Fraction F1 (40 ȝm) 
Fraction F2 (15 ȝm) 
Fraction F3 (1 ȝm) 
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Supplementary Figure 7: Influence of sample preparation (centrifugation for 5 min at 1258 × g) on the 
particle concentration measured by RMM. 
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Supplementary Figure 8:Stability of starting material (diluted) that was used for fractionation and of the 15 
ȝm FACS and centrifugation fractions sorting after freezing at -80 °C and thawing measured with FI. 
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Supplementary Table 1: Experimental design for optimization of fraction 1 obtained by centrifugation. 
Run 
Order 
Time 
(sec) 
Acceleration 
(× g) 
Glycerol 
concentration (%) 
Particles/ml  
(1-100 μm) 
Mean diameter 
(μm) 
11 60 8 10 7.8 x 105 10.7 
6 300 8 10 1.3 x 106 14.1 
13 60 50 10 1.1 x 106 13.0 
10 300 50 10 1.6 x 106 10.5 
16 60 8 40 5.7 x 102 15.7 
12 300 8 40 1.9 x 104 40.1 
9 60 50 40 2.0 x 104 42.5 
1 300 50 40 2.0 x 105 38.8 
3 60 25 25 5.7 x 104 42.7 
2 300 25 25 1.8 x 105 38.0 
5 180 8 25 5.8 x 104 41.6 
17 180 50 25 1.8 x 105 39.1 
15 180 25 10 1.4 x 106 10.8 
14 180 25 40 4.0 x 104 41.8 
7 180 25 25 1.7 x 105 36.2 
8 180 25 25 1.6 x 105 39.2 
4 180 25 25 1.1 x 105 38.9 
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Supplementary Table 2: Experimental design for optimization of fraction 2 obtained by centrifugation (step 
1/2). 
Exp 
No 
Run 
Order 
Time 
(sec) 
Acceleration 
(× g) 
Glycerol 
concentration (%) 
Particles/ml 
10-25 μm 
Particles/ml
40-100 μm 
1 9 60 8 10 1.6 x 105 2.3 x 104 
2 6 420 8 10 6.5 x 105 2.7 x 104 
3 8 60 129 10 1.1 x 106 3.0 x 105 
4 13 420 129 10 3.2 x 104 2.3 x 105 
5 3 60 8 40 3.2 x 105 3.3 x 105 
6 1 420 8 40 2.8 x 105 1.3 x 105 
7 2 60 129 40 2.7 x 105 2.1 x 105 
8 12 420 129 40 2.0 x 105 4.9 x 104 
9 7 60 50 25 2.6 x 105 6.4 x 104 
10 11 420 50 25 1.5 x 105 1.1 x 104 
11 14 240 8 25 2.6 x 105 9.0 x 104 
12 16 240 129 25 1.3 x 105 1.4 x 104 
13 15 240 50 10 6.8 x 104 5.7 x 104 
14 4 240 50 40 2.2 x 105 5.0 x 104 
15 17 240 50 25 1.8 x 105 1.2 x 104 
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Supplementary Table 3: Experimental design for optimization of fraction 2 obtained by centrifugation (step 
2/2). 
Exp 
No 
Run 
Order 
Time 
(sec) 
Acceleration  
(× g) 
Particles/ml (FI)
10-25 μm 
Mean 
diameter 
(μm) 
Particles/ml
1-2 μm 
1 8 60 8 1.1 x 104 13.2 1.9 x 103 
2 6 300 8 2 x 104 14 2.6 x 103 
3 3 60 129 4 x 104 15.1 3.0 x 103 
4 11 300 129 1.5 x 105 14.2 8.3 x 103 
5 2 60 50 2.3 x 104 13.7 3.2 x 103 
6 5 300 50 9.4 x 104 15 5.2 x 103 
7 1 180 8 8.1 x 103 12.8 1.7 x 103 
8 7 180 129 1.3 x 105 14.8 7.0 x 103 
9 10 180 50 5.3 x 104 15.3 4.5 x 103 
10 9 180 50 5.8 x 104 15.1 4.0 x 103 
11 4 180 50 6.2 x 104 15.5 3.7 x 103 
 
Supplementary Table 4: Experimental design for optimization of fraction 3 obtained by centrifugation. 
Exp No 
Run 
Order 
Time 
(sec) 
Acceleration (× g ) Particles/ml (FI) 
Diameter
(μm) 
1 3 60 454 2.3e+6 1.94 
2 10 180 454 1.2e+6 1.51 
3 7 60 1260 1.3e+6 1.58 
4 5 180 1260 3.2e+5 1.25 
5 2 60 806 1.3e+6 1.47 
6 6 180 806 3.5e+5 1.24 
7 9 120 454 1.8e+6 1.81 
8 8 120 1260 4e+5 1.27 
9 1 120 806 7.7e+5 1.33 
10 4 120 806 8.5e+5 1.29 
11 11 120 806 7.6e+5 1.36 
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Supplementary Table 5: Experimental design for optimization of fraction 4 obtained by centrifugation. 
Exp 
No 
Run 
Order 
Time (min) Acceleration (× g) 
Particles/ml 
(RMM) 
Diameter 
(μm) 
1 5 3 806 8.6e+6 0.537 
2 8 11 806 4.7e+6 0.432 
3 7 3 3226 5e+6 0.455 
4 2 11 3226 1.5e+6 0.345 
5 1 3 1814 6.7e+6 0.503 
6 4 11 1814 3e+6 0.392 
7 3 7 806 6.6e+6 0.482 
8 10 7 3226 1.9e+6 0.352 
9 11 7 1814 3.8e+6 0.427 
10 9 7 1814 4.2e+6 0.427 
11 6 7 1814 4.3e+6 0.445 
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Supplementary Table 6: Parameters and responses selected for the optimization of fractions obtained by 
centrifugation. 
Fractions Selected variables for the DoE Selected responses for the DoE 
centrifugation-F1 
Acceleration, Centrifugation 
time, Glycerol concentration 
Particles per ml total (1-100 μm) 
Mean diameter (μm) 
centrifugation-F2 
Acceleration, Centrifugation 
time 
Glycerol concentration 
Step1: 
Particles per ml 10-25 μm 
Particle concentration 40-100 μm 
Acceleration, Centrifugation 
time 
Step2: 
Particles per ml 10-25 μm 
Mean diameter (μm) 
Particles per ml 1-2 μm 
centrifugation-F3 
Acceleration, Centrifugation 
time 
Particles per ml total(1-100 μm)  
Mean diameter (μm) 
centrifugation-F4 
Acceleration, Centrifugation 
time 
Particles per ml (RMM) 
Mean diameter (μm) 
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Abstract 
Oxidation of methionine and tryptophan are common degradation pathways for monoclonal 
antibodies (mAbs) and present major analytical challenges in biotechnology. Generally, 
protein oxidation is detectable in stability and/or stressed samples (e.g., exposed to hydrogen 
peroxide, UV light or metal ions). The induced chemical modifications may impact the 
biological activity of antibodies and may have biological consequences. However, these effects 
and the contribution of individual protein modifications are difficult to delineate as different 
amino acids are often oxidized simultaneously and accompanied by other degradants such as 
aggregates, especially in forced degradation studies. Here, we report a new method to obtain 
selective oxidation of methionine or tryptophan by using oxidation reagents combined with 
large excess of free tryptophan or methionine, correspondingly. More specifically, using 
hydrogen peroxide (H2O2) or tert-butyl hydroperoxide (t-BHP) in combination with addition 
of free tryptophan allowed for selective oxidation of methionine. Conversely, the use of 2,2-
azobis(2-amidinopropane) dihydrochloride (AAPH) in combination with free methionine 
resulted in selective tryptophan oxidation whilst methionine oxidation was not significantly 
altered. This novel stress model system may prove to be valuable tool in future mechanistic 
studies of oxidative degradation of protein therapeutics. 
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Introduction 
Oxidation is a common degradation pathway that may occur during the life cycle of proteins 
and peptides.1-5 The resulting chemical modifications may affect in vitro stability and in vivo 
biological functions.5-17 The position of oxidized amino acids in the protein sequence is crucial 
for their impact on protein structure, function and biological response, especially in the case 
of monoclonal antibodies where binding properties are essential to reach target antigen. It has 
been previously reported that oxidation of methionine from the Fc region can reduce binding 
to the neonatal Fc receptor and biological half-life of the concerned mAb.8,10,11 Such a change 
in the pharmacokinetic profile is highly dependent on the position of the oxidation. A recent 
study, reported that M252 oxidation was the dominant contributor to PK impairment 
observed in mice transgenic for the human FcRn receptor. In this study, an increased plasma 
clearance was only observed if both IgG HCs were oxidized at M252.17 Moreover, the 
formation of oxidized methionine or tryptophan in the complementary-determining regions 
(CDRs) may induce loss of potency and antigen binding capabilities.14,15  
During the last thirty years cysteine, histidine, methionine, phenylalanine, tryptophan and 
tyrosine residues were identified as major oxidation sites in proteins due to the high reactivity 
of sulfur atoms and aromatic rings towards various reactive oxygen species.5,18 Oxidation 
might be induced during production, processing or storage, e.g. due to the possible reactive 
impurities present or formed in excipients (e.g. polyethylene glycol or polysorbate).19,20 The 
generation of peroxides through auto-oxidation of these polymeric compounds might favor 
oxidation of these amino acid residues. The presence of transition metals may also lead to 
oxidation, e.g. via the Fenton reaction.21,22 One option to minimize or prevent oxidation of the 
active protein is the addition of antioxidants, chelating agent or radical scavengers to the 
formulation buffer, if acceptable from a toxicological and regulatory perspective and thus, if 
considered acceptable and safe to clinical use.20,22,23  
In order to assess the potential susceptibility of protein products to oxidation, different 
oxidation stress conditions have been studied, such as H2O2, t-BHP, AAPH, transition metal 
ions, or UV exposure. 15,22-25 Such relatively harsh treatments often result in a myriad of 
modifications on several amino-acid residues like histidine, phenylalanine, and tyrosine, for 
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example.5,22,26 However, methionine and tryptophan are the residues that are oxidized most 
commonly and to the highest extent when exposed to such conditions.23,24,27-29  
In recent investigations, antibody samples containing both methionine and tryptophan 
oxidation products were used to draw conclusions regarding impact on target binding and 
reduced binding affinity.14-16 Still, one major impediment to the interpretation of such studies 
is the fact that frequently both methionine and tryptophan residues are oxidized concurrently, 
making the definition of the individual contribution of these residues to the overall effects 
difficult to delineate. Thus, the preparation of proteins in which methionine and tryptophan 
have been selectively oxidized would be very helpful, in order to improve the understanding 
of the relationship between structure and functional consequences.  
In a recent report it has been demonstrated that the addition of free L-methionine and L-
tryptophan to forced oxidation reactions of parathyroid hormone can effectively limit the 
oxidation of methionine and tryptophan residues, respectively.22 However, so far this 
observation has not been further tested and reported when mAbs are used. In the present 
study we demonstrate the utility of this competition approach using a new method for 
selective oxidation of methionine or tryptophan residues in a model monoclonal antibody 
from the IgG1 subclass (the experimental strategy is depicted in Figure 1). In order to achieve 
this aim, a large excess of free amino acids was added to the reaction conditions, in order to 
protect the corresponding amino acid in the mAb when applying different oxidants (t-BHP, 
H2O2, AAPH). Different reaction conditions such as incubation temperature, reaction time 
and oxidant concentration were evaluated. Oxidation products in the model IgG1 were 
characterized using size-exclusion chromatography, Protein A-based affinity 
chromatography, reversed phase-HPLC and mass spectrometry. 
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Figure 1: Schematic representation of experimental strategy to generate selectively oxidized antibody 
species. Combination of hydrogen peroxide (H2O2) or tert-butyl hydroperoxide (t-BHP) with addition of free 
tryptophan under well-defined experimental conditions leads to selective oxidation of methionine residues. 
Combination of 2,2-azobis(2-amidinopropane) dihydrochloride (AAPH) with addition of free methionine allows to 
selective tryptophan oxidation under well-defined experimental conditions.  
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Materials and Methods 
An IgG1 therapeutic monoclonal antibody (mAb) was chosen as a model protein for the 
present study. The mAb (IgG1) solution was provided at 25 mg/ml in 51 mM sodium 
phosphate, 6 % trehalose, and 0.04 % polysorbate 20 (pH 6.2) by F. Hoffmann-LaRoche Ltd, 
Basel, Switzerland. 
H2O2, t-BHP, AAPH, EDTA, DTT (dithiothreitol), iodoacetic acid, cysteine were purchased 
from Sigma–Aldrich (St. Louis, Missouri) and Dulbecco’s phosphate-buffered saline (DPBS) 
10× from GIBCO (Invitrogen, San Diego, California). Guanidine hydrochloride (Gdn-HCl) 
from AppliChem (Darmstadt, Germany) was used during the study. 
Trifluoroacetic acid (TFA), formic acid (FA), acetic acid (AcOH), acetonitrile, hydrochloric 
acid (HCl), potassium chloride (KCl) and sodium chloride (NaCl) were purchased from 
Merck (Whitehouse Station, New Jersey). Tris(hydroxymethyl)-aminomethan (Tris) was used 
from Ajinomoto (Raleigh, North Carolina). 
Papain from Carica papaya (10 mg/ml) was delivered by Roche Diagnostic (Indianapolis, 
Indiana). Trypsin Proteomics grade was provided by Roche Diagnostics GmbH (Penzberg, 
Germany). 
L-tryptophan was purchased from Sigma–Aldrich (St. Louis, Missouri) and was dissolved 
directly in mAb solution to reach a final tryptophan concentration of 4 mg/ml in solution 
(19.6 mM). H2O2 or t-BHP were used as oxidants and added into the mAb solution with or 
without prior addition of free tryptophan to obtain final concentrations of oxidants between 
0% and 5%. 
L-methionine was purchased from Sigma–Aldrich (St. Louis, Missouri) and was dissolved 
directly in mAb solution to reach a final methionine concentration of 40 mg/ml in solution 
(0.26 M). As oxidant, AAPH was then added into the mAb solution in presence or absence of 
free methionine to final oxidant concentrations between 0% and 5% (see Table 1). 
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Table 1: Experimental parameters for artificial oxidation of model IgG1. The oxidant, oxidant concentration, 
antioxidant, incubation temperature and time were varied to find optimal condition for selective oxidation of 
methionine or tryptophan respectively. The mAb concentration was kept constant for the complete set of samples. 
Parameter Value/range 
Oxidant H2O2, t-BHP, AAPH 
Oxidant concentration 0.0, 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0% 
Antioxidant 
None 
L-methionine (0.26M) 
L-tryptophan (19.6mM) 
Incubation temperature 5, 25, 40°C 
Incubation time 1, 6, 24, 120h 
model mAb concentration 18.5 mg/ml 
The final mAb concentration for each prepared sample was 18.5 mg/ml. Samples were 
incubated under protection from direct light at 5°C, 25°C or 40°C and aliquots were collected 
at 1, 6, 24 or 120 h. A control sample, without oxidant, was also incubated and analyzed for 
each time point and temperature. The oxidation was stopped by buffer exchange using 
disposable PD-10 desalting columns (GE Healthcare, Buckinghamshire, UK). 
Instrumentation and Sample analysis 
A Waters Alliance 2695 high-pressure liquid chromatographic (HPLC) system equipped with 
a 2487 UV detector and Empower2 software (version 7) (Waters, Milford, Massachusetts) was 
used throughout the study. The determination of protein concentration before injection was 
performed on a SoloVPE spectrometer from C-Technologies (Bridgewater, New Jersey). 
SE-HPLC (Size-Exclusion Chromatography) 
Samples were analyzed by UV absorbance detection at 280 nm. A TSK G3000 SWXL column 
(5 ƨm, 250A, 7.8 x 300mm) from Tosoh was used for separation. The mobile phase (200 mM 
phosphate, 250 mM KCl, pH 7.0) was pumped at a flow rate of 0.5 ml/min. Sample size for 
analysis was 25 g. The stationary phase was kept at 25 ± 2°C. 
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Protein A Chromatography  
Analytical Protein A chromatography was performed, as described previously on a POROS® A 
(4.6 × 50 mm) column (Applied Biosystems, Foster City, California).12 The stationary phase 
was kept at 23 ± 2°C. 
RP-HPLC (Reversed-Phase Chromatography) 
Protein samples were diluted to a final concentration of 1 mg/ml in Tris buffer (0.1 M Tris, 4 
mM EDTA, and 1 mM cysteine, pH 7.4). 50 ƨl of 0.1 mg/ml papain was added to 500 l of the 
mAb1 solution before incubation at 37°C for 2 h. Following incubation, 11 ƨl of 1 M DTT was 
added to each tube and samples were incubated for another 30 min at 37°C. Analysis of 
oxidized and intact mAb was carried out using a BioBasic Phenyl column (5 ƨm, 300A, 2.1 x 
250 mm) from Thermo Fischer Scientific. Mobile phase A was 0.09% TFA in water. Mobile 
phase B was 0.08% TFA in acetonitrile. Flow rate was 0.45 ml/min. The chromatography was 
performed using a linear gradient from 35 to 40% solvent B in 16 min. 40% of mobile phase B 
was maintained during 4 minutes and finally 35% solvent B was pumped during 10 min. 
Sample size for analysis was 8 ƨg. The fragment elution was monitored by UV absorption at 
215 nm. As the method described above cannot be used to identify the tryptophan oxidation 
site in the protein sequence, it was utilized only as a rapid screening tool for tryptophan 
oxidation present in the fragment antigen-binding part of the heavy chain (HC-Fab). The 
tryptophan oxidation fraction was calculated by dividing the area of the pre-peak by the total 
peak area of the HC-Fab peaks. 
Proteolytic digest of mAb 
For detection and quantification of oxidized amino acids, the mAb was digested with trypsin. 
First, the protein was denatured in 0.4 M Tris-HCl, 8 M Gdn-HCl, at pH 8.5 by diluting 350 
ƨg of oxidized mAb in a total volume of 300 l. For reduction, 10 l of 100 mg/ml DTT were 
added and incubated at 50°C for 1 h. After alkylation of free cysteines by adding 10 l of 330 
mg/ml iodoacetic acid and incubation at room temperature in the dark for 30 min, the buffer 
was exchanged to digestion buffer (0.1 M Tris-HCl, pH 7.0) by using a NAP5 gel filtration 
column. Subsequently, NAP5-eluate (500 l) was mixed with 10 ƨl of a solution of 0.25 mg/ml 
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trypsin in 10 mM HCl and incubated at 37°C for 18 h. The digestion reaction was stopped by 
adding 50 l of a 10% TFA solution. 
The tryptic peptide mixture was separated by reversed phase-UPLC (ACQUITY, Waters, 
Manchester, UK) on a C18 column (BEH C18 1,7 m, 2,1 x 150 mm; Waters, Manchester, 
UK) and the eluate online analyzed on a Q-TOF SYNAPT G2 instrument (Waters, 
Manchester, UK). The mobile phases of RP-HPLC consisted of 0.1% FA in water (solvent A) 
and 0.1% FA in acetonitrile (solvent B). The chromatography was performed using a linear 
gradient from 1 to 35% solvent B in 45 min and finally from 35 to 80% solvent B in 3 min 
using a flow rate of 300 ƨl/min. 3 g digested protein was applied. UPLC-system and mass 
spectrometer were connected by PEEK capillary tubes. Data acquisition was controlled by 
MassLynxTM software (Waters, Manchester, UK).  
MS/MS experiments were performed on a LTQ Orbitrap Velos electrospray mass 
spectrometer (Thermo Scientific, Dreieich, Germany) using the chromatographic system 
described above in order to identify the oxidized peptides. The fragmentation was induced by 
low-energy CID using helium as collision gas (“top5” mode). Data acquisition was controlled 
by Xcalibur software (Thermo Fisher Scientific) using a manual acquisition mode. Oxidized 
amino acids were identified from the MS/MS-data using the software Proteomics Discoverer 
(Thermo Fisher Scientific). The collision energy was adjusted according to stability and mass 
of the parent ion. 
Peptides of interest were identified manually by searching for their theoretical m/z-values 
within the experimental mass spectrum. For their quantification, specific ion current (SIC) 
chromatograms of peptides of interest were generated on the basis of their monoisotopic mass 
and detected charge states using GRAMS AI software (Thermo Fisher Scientific). Relative 
amounts of non-oxidized and oxidized peptides were calculated by manual integration of the 
corresponding peaks.  
Besides the summarized large number of methionine and tryptophan oxidation sites (see 
Table 2 and Tables S1 and S2) no significant levels of additional amino acid oxidations events 
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(e.g. at histidine residues) were detected by careful inspection of the experimental mass 
spectra. 
Table 2: LC-MS results for the oxidation with H2O2 or t-BHP with or without addition of free tryptophan. 
The mAb was denatured and the disulfide bridges were reduced using DTT. Alkylation of free cysteines was 
performed using iodoacetic acid. After a buffer exchange, the mAb was finally digested with trypsin. LC stands for 
light chain, HC stands for heavy chain. Methionine (M) and tryptophan (W) oxidation levels were quantified. 
OXIDATION WITH/WITHOUT TRYPTOPHAN PROTECTION 
Modified Amino 
Acids Control 
1% H2O2 
5°C 24h  
1% H2O2 
5°C 24h  
with 
tryptophan 
2% t-BHP 
25°C 120h 
2% t-BHP 
25°C 120h  
with 
tryptophan 
LC M4ox 0.3 4.4 0.9 4.1 3.8 
HC M34ox 0.7 7.4 2.5 6.9 7.4 
HC M83ox 0.6 4.1 0.7 4.2 4.0 
HC M258ox 4.4 99.6 99.6 99.7 99.7 
HC M364ox 0.4 90.8 92.9 91.0 91.6 
HC M434ox 1.2 96.1 96.1 96.1 96.7 
LC W35ox+4 0.2 0.6 0.5 0.6 0.5 
LC W35ox+16 0.0 0.0 0.0 0.0 0.0 
LC W96ox+4 0.1 0.3 0.2 0.4 0.2 
LC W96ox+16 0.1 0.2 0.1 0.2 0.2 
HC W50ox+4 0.1 0.2 0.2 0.2 0.2 
HC W50ox+16 0.2 0.3 0.2 0.3 0.3 
HC W50ox+32 0.0 0.0 0.0 0.0 0.0 
HC W108ox+4 0.0 0.0 0.0 1.5 0.3 
HC W108ox+16 0.2 0.3 0.2 2.6 0.6 
HC W108ox+32 0.1 0.1 0.1 0.1 0.1 
HC W283ox+4 0.1 0.1 0.1 0.2 0.1 
HC W283ox+16 0.1 0.2 0.2 0.2 0.2 
HC W319ox+4 0.1 0.2 0.1 0.2 0.2 
HC W319ox+16 0.4 0.8 0.6 0.8 0.7 
HC W319ox+32 0.0 0.0 0.0 0.0 0.0 
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Results and discussion 
In forced oxidation studies of therapeutic proteins widely varying extents of methionine 
oxidation (from 0% to 100%) were reported. In these reports the most commonly used 
oxidative reagents were H2O2 and t-BHP with reaction conditions spanning a broad range, 
including different temperatures (room temperature or 40°C), different concentrations of the 
oxidative agent (0.0005% to 0.2% for H2O2, 0.05% to 5% for t-BHP) and different reaction 
times (6 h to 7 days).12-14,22 One drawback of such oxidation studies is the possible co-
oxidation of tryptophan and methionine. This effect was reported for the oxidation of a 
recombinant antibody performed with 0.05% t-BHP at room temperature for 7 days where 
65% methionine oxidation and 25% tryptophan oxidation were detected in the same sample.14 
One other example of co-oxidation of tryptophan and methionine was shown during the 
reaction of parathyroid hormone with AAPH. Indeed, incubation of 0.1mg/ml parathyroid 
hormone with 0.1 M AAPH at 40°C for 24 h resulted in 84% of tryptophan oxidation and 58% 
of methionine oxidation.22 After reacting human growth hormone with AAPH, Steinmann et 
al. reported a multitude of oxidized residues, including 20% tryptophan oxidation and 
significant methionine oxidation (100% M14; 80% M125; 70% M170).30 
Indeed, the use of established conditions for forced oxidation available in literature did not 
allow us to selectively oxidize neither methionine nor tryptophan amino acids in a 
monoclonal antibody model protein as depicted in Figure 2, 3 and 4, and Supplementary 
Table 1 and 2. Instead, extensive co-oxidation of both methionine and tryptophan was present 
under these conditions. 
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Figure 2: Analysis of oxidized and non-oxidized mAb species by analytical Protein A chromatography. (A) 
The chromatogram overlay shows the elution profile of control material (black), mAb oxidized in the presence of 
1% H2O2 for 24 h at 5°C with (blue) or without addition of free tryptophan (red). The red and blue curves are 
perfectly overlapping. (B) The chromatogram overlay shows the elution profile of control material (black), mAb 
oxidized in the presence of 2% t-BHP for 120 h at 25°C with (blue) or without addition of free tryptophan (red). 
The red and blue curves are perfectly overlapping. (C) The chromatogram overlay shows the elution profile of 
control material (black), mAb oxidized in the presence of 5% AAPH with (blue) or without addition of free 
methionine (red) for 120 h at 40°C.  
To identify optimal conditions leading to selective oxidation of methionine or tryptophan in a 
mAb, a large set of parameters were evaluated based on published studies and previous in-
house experiments (data not shown).12,14,22 A model IgG1 was incubated with different 
116 
 
oxidants while the reaction times and incubation temperatures were varied as described in 
Table 1. To curtail oxidation of the amino acids methionine or tryptophan, the corresponding 
free amino (L-methionine or L-tryptophan) acids were added to the reaction mixtures. After 
completion of all reactions, samples were screened for total oxidation levels using Protein A 
analytical chromatography and RP-HPLC. Selected samples were further analyzed using LC-
MS and LC-MS/MS in order to identify and semi-quantify the methionine and tryptophan 
oxidation sites in the amino-acid sequence. 
In the model IgG1 used in this study several methionine residues were identified as 
susceptible to oxidation (M4, M34, M83, M258, M364 and M434). Basal levels of oxidation of 
these susceptible residues were identified in the starting material (see Table 2). From the 
oxidized tryptophan identified by LC-MS/MS (W35, W50, W96, W108, W283, W319) only 
surface exposed W50 and W108 showed significant changes between unstressed and stressed 
samples.  
Selective methionine oxidation  
Oxidation levels of Fc methionine were first quantified by Protein A chromatography. The 
non-oxidized antibody species eluted at 23 min (Figure 2). The oxidized species formed upon 
incubation with oxidant eluted earlier (before 19.8 min) because of the lower affinity of 
oxidized Fc methionine to Protein A.7,12 As depicted in Figure 2A and 2B, the incubation of 
the mAb with 1% H2O2 for 24 h at 5°C as well as the incubation with 2% t-BHP for 120 h at 
25°C allowed for the nearly complete oxidation of the methionine residues from the Fc region.  
The extent of methionine oxidation was also determined by selected ion current 
chromatogram analysis of the oxidized peptides (see Table 2). We found more than 91% 
oxidation for M364, 96% oxidation for M434 and 99% oxidation for M258 according to LC-
MS results. 
In order to assess the total tryptophan oxidation of the HC-Fab, the oxidized samples were 
first digested with papain and then the disulfide bridges were reduced with DTT. The 
generated LC, HC-Fc and HC-Fab were then separated by RP-HPLC (for details see Materials 
and Methods) as presented in Figure 3A and the tryptophan oxidation of the HC-Fab was 
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quantified. The oxidized species due to tryptophan oxidation elute before the HC-Fab peaks. 
The peak with a retention time of 19.5 min represents in that case mainly oxidized tryptophan 
W108 of the HC-Fab (Figure 3B and 3C, signal labeled as “Trp-ox”).  
 
Figure 3: Overlay of RP-HPLC chromatograms used to quantify tryptophan oxidation present in the heavy 
chain Fab part (HC-Fab) of studied IgG1 for control material vs oxidized samples. The analyses were 
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performed after papain digest followed by DTT reduction. (A) Complete RP-HPLC chromatogram for control 
material (black). (B) Zoom in of HC-Fab region; control material (black), 1% H2O2 oxidation for 24 h at 5°C with 
(blue) or without addition of free tryptophan (red). (C) Zoom in of HC-Fab region; control material (black), 2% t-
BHP oxidation 120 h at 25°C with (blue) or without addition of free tryptophan (red). (D) Zoom in of HC-Fab 
region; control material (black), 5% AAPH oxidation for 120 h at 40°C with (blue) or without addition of free 
methionine (red). 
As previously reported, the oxidation of mAb with H2O2 or t-BHP induced relatively low 
tryptophan oxidation levels (please, see Figure 3B and 3C).22 The well-resolved signal with a 
retention time of 19.5 min (corresponding to tryptophan oxidation products) increased not 
only with increasing H2O2 or t-BHP concentrations but also when increasing the reaction time 
and the temperature of incubation (data not shown). In order to exclude the possibility of 
metal ion contamination resulting in Fenton-like reactions, protein oxidation reactions were 
carried out in the presence and absence of EDTA. As no differences in the oxidation levels of 
Trp were detected (data not shown) the mechanism of Trp oxidation in these reactions 
remains unclear. To avoid this unwanted tryptophan oxidation, reaction conditions were set 
as H2O2 oxidation at 5°C for 24 h and t-BHP oxidation at 25°C for 120 h. Moreover, the 
tryptophan oxidation could be inhibited using addition of free tryptophan at concentrations 
of 19.6 mM during the incubations as depicted in Figure 3B and 3C (for detailed LC/MS 
results see Table 2). 
LC-MS analyses confirmed the low abundance of tryptophan oxidation (see Table 2), and as a 
consequence the protective effect of free tryptophan against tryptophan oxidation. According 
to LC-MS results, the total oxidation of W50 and W108 was lower than 1% when adding free 
tryptophan before oxidation with t-BHP (2%-25°C-120 h). In the case of H2O2 oxidation (1%-
5°C-24 h), where tryptophan oxidation products were present at very low level (< 1%), the 
addition of free tryptophan could not protect against the formation of low levels of residual 
tryptophan oxidation products (see Table 2).  
In addition to free tryptophan, which has been shown to protect tryptophan residues in 
proteins from oxidation, other antioxidants could potentially be used to avoid tryptophan 
oxidation.20,21 However, the addition of antioxidant should be investigated in detail before use 
to avoid unexpected effects.31  
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SE-HPLC was used to assess the sample integrity after oxidation. Both H2O2 (1%-5°C-24 h 
with free tryptophan) or t-BHP (2%-25°C-120 h with free tryptophan) oxidation induced only 
minimal changes in aggregate and fragment formation. In comparison to the reference 
material, the incubation with 1% H2O2 induced 0.8% soluble aggregates, whereas the 
oxidation with 2% t-BHP induced 1.4% soluble aggregates (Figure 5A). Thus, the application 
of the developed model stress system does not significantly impact molecular integrity and the 
biological consequences of selective methionine oxidation could be further analyzed by 
functional testing.  
Selective tryptophan oxidation 
AAPH is a reagent that has been used for forced tryptophan oxidation studies.22 In our hands 
the simultaneous oxidation of several tryptophan residues upon stress (mass additions of +4, 
+16, +32, +48, +64) resulted in a complex mixture of reaction products that were difficult to 
separate well by RP-HPLC (Figure 3D). The pre-peaks were broad and poorly resolved. 
Nevertheless, it was possible to detect tryptophan oxidized species in the oxidized sample as 
early-eluting peaks (retention times from 16 to 19.6 min in Figure 3D) and to identify the 
different tryptophan oxidation sites by subsequent LC-MS analyses. Upon incubation at 40°C 
for 120 h with AAPH (0-5%) a considerable tryptophan oxidation (between 12 and 95%) was 
observed, as seen in Supplementary Table 2 and 3. 
As reported in previous studies, the reaction of proteins with alkyperoxyl radicals (generated 
by AAPH that reacts with oxygen) induced also methionine oxidation.22,32 As seen in Figure 
2C and 4A, oxidation with 5% AAPH lead to almost complete oxidation of Fc methionine 
measured by Protein A chromatography and LC-MS peptide mapping.  
The addition of a large excess of free methionine into solution before oxidation at 40°C for 
120 h, allowed protection of Fc methionine as seen in the Protein A chromatogram (Figure 
2C). As depicted in Supplementary Figure 1 and 2, the low levels or absence of peptide signal 
in the TIC plots and extracted ion chromatograms for M258ox (RT=12.65 min), M364ox 
(RT=1.78 min) and M434ox (RT=18.45 min) when adding free methionine into the mAb 
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solution before oxidation with 5% AAPH (at 40°C for 120 h) is a clear confirmation of the 
protective effect of free methionine against methionine oxidation. 
The results from LC-MS analyses of AAPH oxidized samples are presented in Table 1 and 2 of 
the Supplementary material. These results clearly demonstrate that methionine residues 
otherwise susceptible to oxidation by AAPH can be selectively protected by addition of free 
methionine, even in the harshest reaction conditions used in this study (longest incubation 
time [120 h], highest oxidant concentration [5%] and highest temperature of incubation 
[40°C]). This specific sample showed 10.3% oxidation for M258 whereas the same sample 
without methionine addition showed oxidation of 99.7%. Similarly 6.3% versus 98.8% 
M434ox was verified by LC-MS. The oxidation of M364 was lower than 1% in the protected 
sample (99% oxidation in the sample without addition of free methionine). It has to be 
mentioned that 4.5% M258ox, 0.4% M364ox and 1.1% M434ox were found in the non-
stressed reference material (Figure 4A). 
Figure 4A, 4B and 4C show a comparison of the methionine (M258, M364 and M434) and 
tryptophan (W50 and W108) distribution between AAPH stressed samples with and without 
addition of free methionine. Over and above the decrease of methionine oxidation, the 
presence of free methionine in the mAb solution for AAPH incubation slightly changed the 
oxidation profile of tryptophan residues as seen in Figure 4B and 4C. As already observed in 
the RP-HPLC data, the total amount of tryptophan oxidation (as quantified by LC-MS) 
slightly decreased but remained considerable when adding free methionine to the solution 
(Figure 8 and 9). On the one hand a higher percentage of hydroxytryptophan (+16) for W50 
and W108 was measured in the samples containing free methionine. A lower percentage of N-
formylkynurenine (+32) was found for W50 and W108 when adding free methionine 
(Supplementary Figure 3 and 4). Presumably, this effect is related to shift in the equilibrium 
between reaction intermediates caused by the addition of the antioxidant. Further elucidation 
of this mechanism may be of interest as a topic of future studies.  
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Figure 4: Comparison of the relative abundance of methionine and tryptophan residues susceptible to 
oxidation quantified by LC/MS peptide map. The oxidation was performed with 5% AAPH at 40°C for 120 h 
with or without addition of free methionine. Relative abundance is calculated as relative % using specific ion 
current chromatogram analysis of tryptic peptides for M258, M364 and M434 (panel A), W50 (panel B) and W108 
(panel C). The tryptophan modifications kynurenine (+4), hydroxytryptophan (+16) and N-formylkynurenine 
(+32) are represented in panel B and C. 
Significant formation of soluble aggregates was detected by size exclusion chromatography 
(SEC) correlating well with the increase in AAPH concentration. The addition of free 
methionine however, had a protective effect against aggregation as seen in Figure 5B. This 
effect correlates well with overall reduction on oxidation. The monomer content represented 
30% of the total area in the AAPH sample without methionine addition whereas 65% of 
monomers were still present in the sample containing free methionine during incubation with 
5% AAPH for 120 h at 40°C. The content of soluble fragments remained below 0.3% for the 
control and the stressed samples in all studies. The correlation between Met oxidation and 
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protein aggregation observed in this study was not unexpected, as such correlation has been 
reported previously by others and studied in some detail.11,33 These studies have demonstrated 
that Met oxidation in mAbs may result in changes of the secondary and tertiary structure and 
in turn affect significantly the physical stability of the protein resulting in increased 
aggregation propensity. Thus, the decrease of aggregation upon the addition of free Met can 
be attributed to the oxidation protective effect of Met.  
 
Figure 5: SE-HPLC chromatograms of control material vs. oxidized samples. Monomer peak elutes at 17 min. 
The aggregated species elute below 15.5 min. (A) The chromatogram overlay shows the elution profile of control 
material (black), 1% H2O2 oxidized sample for 24h at 5°C with tryptophan addition (blue) and 2% t-BHP oxidized 
sample for 120h at 25°C with tryptophan addition (red). The blue and red curves overlap the black curve. (B) The 
elution profile of control material (black) is represented with the aggregation profile of 5% AAPH oxidation for 
120 h at 40°C with (blue) or without addition of free methionine (red).  
The experimental approach of using combinations of oxidative reagents and antioxidants 
presented here provided an efficient strategy for selective oxidation of Met and Trp residues in 
therapeutic IgG molecules. Although residual low levels of undesirable oxidation were 
detected in some cases (which presumably would need to be accounted for follow-up 
biological studies), we believe that this approach will find broad application in studying the 
biological effects of protein oxidation.  
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Conclusions
Free methionine and/or tryptophan are used as pharmaceutical antioxidants due to their 
protective action against oxidation of amino acids in protein therapeutics. In the present 
report, we explore the potential of these antioxidants to selectively generate methionine- or 
tryptophan oxidized residues. A combination of oxidative (H2O2, t-BHP and AAPH) and 
protective (free tryptophan or methionine) components will serve as a strategy to address 
questions related to the impact of oxidation-induced changes on the biological properties of 
protein therapeutics (e.g., bioactivity, PK/PD, immunogenicity etc.). Such mechanistic studies 
will be instrumental to better understand and control oxidative degradation of antibodies. 
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Associated content - Supporting information 
Supplementary Figure 1: Comparison of total ion current chromatogram. LC-MS analysis performed after 
tryptic digest, of control material (black), 5% AAPH oxidation for 120 h at 40°C with addition of free methionine 
(blue) or without (red). Arrows show the corresponding peak for oxidation product of M258, M364 and M434. 
 
Supplementary Figure 2: LC-MS peptide map extracted ion chromatograms for oxidation product (+16) of 
M258, M364 and M434. The control material (black) is compared with the 5% AAPH oxidized samples for 120 h 
at 40°C with (blue) or without addition of free methionine (red). 
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Supplementary Figure 3: LC-MS peptide map extracted ion chromatograms for oxidation residues of W50 
(+4, +16, +32). The control material (black) is compared with the 5% AAPH oxidized samples for 120 h at 40°C 
with (blue) or without addition of free methionine (red). 
Supplementary Figure 4: LC-MS peptide map extracted ion chromatograms for oxidation residues of W108 
(+4, +16, +32). The control material (black) is compared with the 5% AAPH oxidized samples for 120 h at 40°C 
with (blue) or without addition of free methionine (red). 
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Supplementary Table 1: LC-MS results for the oxidation of mAb with AAPH (0-5%) without addition of 
free methionine. The mAb was denatured and the disulfide bridges were reduced using DTT. Alkylation of free 
cysteines was performed using iodoacetic acid. After a buffer exchange, the mAb was finally digested with trypsin. 
LC stands for light chain, HC stands for heavy chain. Methionine (M) and tryptophan (W) oxidation levels were 
quantified. 
AAPH OXIDATION WITHOUT METHIONINE PROTECTION 
Modified Amino 
Acids Control 
0.05% 
AAPH 
40°C 120h 
0.5% 
AAPH 
40°C 120h 
1% AAPH
40°C 120h 
2% AAPH 
40°C 120h  
5% AAPH
40°C 120h 
LC M4ox 0.3 1.6 2.3 6.1 8.1 23.3 
HC M34ox 0.6 10.7 16.8 23.3 24.1 26.7 
HC M83ox 0.7 6.6 7.9 12.0 14.4 28.3 
HC M258ox 4.5 98.4 99.7 99.7 99.7 99.7 
HC M364ox 0.4 43.1 98.8 99.2 98.9 98.5 
HC M434ox 1.1 93.8 97.3 95.9 97.3 98.8 
LC W35ox+4 0.2 0.6 1.1 2.2 3.2 3.2 
LC W35ox+16 0.0 1.0 2.1 4.9 7.2 9.9 
LC W96ox+4 0.3 0.9 0.8 2.1 2.6 2.6 
LC W96ox+16 0.1 5.0 5.6 5.1 5.4 9.0 
HC W50ox+4 0.1 1.4 3.5 5.0 4.6 3.2 
HC W50ox+16 0.9 7.7 15.1 19.1 22.1 22.9 
HC W50ox+32 1.1 4.2 11.6 12.8 13.0 12.3 
HC W108ox+4 0.7 3.7 7.4 6.0 8.3 5.4 
HC W108ox+16 2.1 47.4 47.7 55.1 52.6 64.9 
HC W108ox+32 1.8 22.5 26.2 30.2 31.8 24.7 
HC W283ox+4 < 1 
HC W283ox+16 0.0 0.4 2.3 3.6 2.9 5.8 
HC W319ox+4 < 1 
HC W319ox+16 0.4 0.5 1.3 2.4 2.6 5.7 
HC W319ox+32 < 1 
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Supplementary Table 2: LC-MS results for the oxidation of mAb with AAPH (0-5%) with addition of free 
methionine. The mAb was denatured and the disulfide bridges were reduced using DTT. Alkylation of free 
cysteines was performed using iodoacetic acid. After a buffer exchange, the mAb was finally digested with trypsin. 
LC stands for light chain, HC stands for heavy chain. Methionine (M) and tryptophan (W) oxidation levels were 
quantified. 
AAPH OXIDATION WITH METHIONINE PROTECTION 
Modified Amino 
Acids Control 
0.05% 
AAPH 
40°C 120h 
with 
methionine 
0.5% 
AAPH 
40°C 120h 
with 
methionine 
1% AAPH
40°C 120h 
with 
methionine 
2% AAPH 
40°C 120h 
with 
methionine 
5% AAPH
40°C 120h 
with 
methionine 
LC M4ox 0.3 1.5 0.9 0.8 0.9 2.0 
HC M34ox 0.6 2.5 1.9 1.4 1.7 2.6 
HC M83ox 0.7 1.5 0.9 0.7 0.9 1.8 
HC M258ox 4.5 7.7 8.2 8.5 8.7 10.3 
HC M364ox 0.4 0.4 0.5 0.7 0.9 2.1 
HC M434ox 1.1 5.1 3.0 2.7 3.5 6.3 
LC W35ox+4 < 1 
LC W35ox+16 < 1 
LC W96ox+4 < 1 
LC W96ox+16 0.1 0.6 0.9 0.9 0.9 1.3 
HC W50ox+4 0.1 2.2 4.7 5.3 5.8 6.3 
HC W50ox+16 0.9 8.9 21.7 25.9 28.3 29.2 
HC W50ox+32 1.1 2.8 3.2 2.4 2.8 2.1 
HC W108ox+4 0.7 2.9 6.7 6.6 6.9 6.1 
HC W108ox+16 2.1 45.5 57.6 61.1 60.9 65.8 
HC W108ox+32 1.8 6.5 8.0 10.4 11.1 10.2 
HC W283ox+4 < 1 
HC W283ox+16 < 1 
HC W319ox+4 < 1 
HC W319ox+16 < 1 
HC W319ox+32 < 1 
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Abstract 
Purpose: The formation of aggregates and particles may lead to an unwanted increase in 
immune response. The aim of this study was to find out which specific characteristics are 
needed for well-defined fractions to break tolerance in our transgenic mouse model.
Methods: Fractionation of proteinaceous subvisible particles in well-defined size fractions 
using differential centrifugation and fluorescence activated cell sorter (FACS) were executed. 
Each sample was extensively characterized using light obscuration, microflow imaging, 
resonant mass measurement, Fourier-transform infrared microscopy (FTIR) and LC/MS 
peptide mapping. In this study we investigated the immunogenic properties of subvisible 
particles (unfractionated material and well-defined size fractions) using a transgenic mouse 
model expressing a mini-repertoire of human IgG1.
Results: The immunization with proteinaceous subvisible particles generated by artificial 
stress (thermal stress) conditions demonstrated that only very extensive modifications within 
the primary amino acid structure of subvisible particles were able to induce a breakage of the 
immune tolerance in our mouse model.
Conclusions: Proteinaceous particles generated using specific IgG1 were not immunogenic in 
our transgenic mouse model unless highly chemically modified (i.e. following chemically 
induced oxidation or harsh UV exposure).
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Introduction  
Particles and aggregates are present in all biotherapeutic formulations in clinical trials or on 
the market. Protein aggregation can occur during many stages of production (i.e. purification, 
formulation, and filling), or during long-term storage and shipping.1-6 Particles of 
proteinaceous origin have recently received increased interest from industry, academia and 
regulators due to possible biological consequences, such as immunogenicity or altered 
bioactivity and pharmacokinetics.7-9 The current understanding of the immunogenicity of 
aggregates and particles is based on studies from vaccine development and on 
immunogenicity of protein assemblies.10-12 Although there are theoretical concerns that 
proteinaceous particles are a potential risk factor for immunogenicity, their biological effects 
are still unclear. Immunogenic effects, after drug administration, refer to formation of anti-
drug antibodies (ADAs) specific for the protein of interest.13 The unwanted immunogenicity 
of a protein product might therefore induce inefficacy of the therapeutic drug. 
However, a link between immunogenicity in the clinics and subvisible particle content in 
biotherapeutic preparations is still lacking. To date, the available data from in vitro and in vivo 
experiments is often conflicting and fragmented, which impedes the development of sound 
conclusions. A major caveat of the published studies is the use of not well-described mixtures 
of monomer, various aggregates and different particle populations.10,14-17 More specific, studies 
with human interferon beta, where samples have been exposed to extreme artificial conditions 
(e.g. metal oxidation or adsorption to glass) lead to an increased immune response in a 
transgenic mouse model.18,19 Interestingly, clinical data with different interferon beta products 
showed an increased anti-drug antibody formation, which cannot solely be attributed to 
aggregates but might be attributed also to formulation (can contain HSA), modifications in 
the primary sequence and impurities acting as adjuvants.20 However, reduction or removal of 
protein aggregates has been claimed to reduce immunogenic effects.9,21-23 A potential effect, if 
any, generated by an individual species, i.e. different size or chemical modification, cannot be 
isolated in these mixtures. To differentiate between the potential immunogenicity of 
aggregates and particles with different size, an increased interest and effort can be noticed in 
the field. Several studies describing methods for fractionation, which were subsequently used 
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for evaluation of immunogenicity in in vitro or in vivo model systems, were recently 
published.24-28 While these studies are giving more insight about the impact of particle size, 
they neglect the influence of chemical modifications. Recently, an investigation using a novel 
human IgG1 transgenic mouse model and thoroughly characterized soluble IgG1 aggregates 
showed that the presence of neoepitopes is needed to observe immunogenic responses.29 
Moreover, the size of these soluble aggregates might be an enhancer of immunogenicity 
although only a small size range from dimers to large oligomers was investigated.  
Here, we present the generation of well-defined size fractions with the recently reported 
methods; differential centrifugation and fluorescence activated cell sorter (FACS) that was 
recently published.25,28 The mean size of these fractions ranged from 1 to 40 m including 
chemically unmodified material as well as oxidized material obtained after different UV 
exposure and chemically induced oxidation (i.e. hydrogen peroxide and 2,2-azobis(2-
amidinopropane) dihydrochloride). The samples prepared for immunization were extensively 
characterized regarding their particle size distribution, biochemical properties and chemical 
modifications using LC/MS peptide mapping and CE-SDS techniques. All samples were then 
tested in a human IgG1 transgenic mouse model. 
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Materials and Methods 
An IgG1 therapeutic monoclonal antibody (mAb) was chosen as a model protein for the 
present study. The mAb solution was provided at 25 mg/ml in 51 mM sodium phosphate, 6 % 
trehalose, and 0.04 % polysorbate 20 (pH 6.2) by F. Hoffmann-LaRoche Ltd (Basel, 
Switzerland). The solution was filtered using 0.22 m Millex GV (PVDF) syringe filter units 
(Millipore, Bedford, MA) before use.  
H2O2, AAPH, EDTA, DTT (dithiothreitol), iodoacetic acid, cysteine were purchased from 
Sigma–Aldrich (St. Louis, Missouri) and Dulbecco’s phosphate-buffered saline (DPBS) 10× 
from GIBCO (Invitrogen, San Diego, California). Guanidine hydrochloride (Gdn-HCl) from 
AppliChem (Darmstadt, Germany) was used during the study. 
Trifluoroacetic acid (TFA), formic acid (FA), acetic acid (AcOH), acetonitrile, hydrochloric 
acid (HCl), potassium chloride (KCl) and sodium chloride (NaCl) were purchased from 
Merck (Whitehouse Station, New Jersey). Tris(hydroxymethyl)-aminomethan (Tris) was used 
from Ajinomoto (Raleigh, North Carolina). 
Papain from Carica papaya (10 mg/ml) was delivered by Roche Diagnostic (Indianapolis, 
Indiana). Trypsin Proteomics grade was provided by Roche Diagnostics GmbH (Penzberg, 
Germany). 
L-tryptophan was purchased from Sigma–Aldrich (St. Louis, Missouri) and was dissolved 
directly in mAb solution to reach a final tryptophan concentration of 4 mg/ml in solution 
(19.6 mM).  
L-methionine was purchased from Sigma–Aldrich (St. Louis, Missouri) and was dissolved 
directly in mAb solution to reach a final methionine concentration of 40 mg/ml in solution 
(0.26 M). 
Stress conditions 
The thermal stress was applied with a thermomixer (Eppendorf, Germany). For mAb1 1 ml of 
the 25 mg/ml solution was incubated for 3 min at 80 °C with 1400 rpm shaking. The solution 
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was then resuspended by drawing in and emptying out for 20 consecutive times using a 
disposable Norm-inject 5 ml luer lock silicone free syringe (HENKE SASS WOLF, Tuttlingen, 
Germany) with attached 27 Gx11/2” needle (0.4 x 40 mm) (Braun, Melsungen, Germany). The 
bulk solution was stored at -80 °C after stressing. 
For generating chemically modified samples, the protein solutions were treated with UV or 
chemicals before applying heat/thermal stress. For UV stress, glass vials containing 16 ml 
formulated antibody solution were kept under the UV–VIS light (Irradiance Energy 765 
W/m2) for 30 h using a SunTest XLS+ device. Chemical stress was applied by adding 2,2-
azobis(2-amidinopropane) dihydrochloride (AAPH) or H2O2 to the mAb solution. Samples 
were incubated under protection from direct light with either 5 % AAPH at 40 °C for 120 h 
(with or without L-methionine addition) or 1 % H2O2 for 24 h at 5 °C with L-tryptophan 
addition. Incubation with H2O2 in combination with free tryptophan resulted in selective 
methionine oxidation. Incubation with AAPH in combination with free methionine resulted 
in selective tryptophan oxidation as described in detail by Folzer et al..28 
Preparation of size fractions of mAb particles by preparative flow cytometry (FACS) 
For the preparation of the subvisible particle fractions a BD FACS Aria III preparative cell 
sorter (BD Biosciences, San Jose, California) was used with BD FACSDiva v 6.1 software, 
applying the low-angle FSC detector equipped with a 488/10 band pass filter for the 488 nm 
laser. A flow cytometry size calibration kit (2, 4, 6 and 15 ƨm) from Molecular Probes (#F-
13838; Life Technologies, Zug, Switzerland) with non-fluorescent microspheres was used for 
the calibration and definition of the sorting gates. For all experiments, autoclaved PBS (pH 
7.2) was used as sheath fluid, prepared using 10× stock solutions and deionized water. To 
eliminate contaminating particles from the sheath fluid, the sheath line was equipped with 
0.22 ƨm filter. All samples were filtered through 40 ƨm cell strainer (#352235, Corning Inc.) 
before sorting. The instrument was used with a 70 ƨm and the sheath pressure was set to 70 
Psi (4.83 bar) and a drop rate of 90 kHz. 
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Preparation of size fractions of mAb particles by differential centrifugation 
The different fractions were prepared using the optimized condition published earlier by our 
group.28 
Light obscuration 
A HIAC ROYCO instrument model 9703 (Pacific scientific, New Jersey, USA) was used for all 
light obscuration measurements. A small volume method using a rinsing volume of 0.4 ml 
and 4 runs of 0.4 ml each was applied. Flow rate was set to 10 ml/min. The first run was 
discarded and the averageௗ±ௗstandard deviation of the last 3 runs was reported for each 
sample. Blank measurements were performed at the beginning of the measurements and in 
between samples using fresh particle-free water. The acceptance criterion for blanks was: “less 
than 5 particlesௗ>ௗ1 ƨm”. The system suitability test consisted of the measurement of count 
standards of 5 ƨm (Thermo Fisher count standards) with acceptance limits ofௗ±ௗ10% the 
reported concentration for particles bigger than 3.0 ƨm was performed in the beginning of 
each measurement day.  
Flow imaging microscopy  
The initial samples as well as all collected fractions were analyzed by flow imaging microscopy 
using a MFI DPA4200 series instrument (ProteinSimple, Santa Clara, California) equipped 
with a 470 nm LED light source. All particles larger than 1 m in equivalent circular diameter 
were reported. Size and count standards (ThermoFisher, Reinach, Switzerland) were used to 
check the sizing and counting accuracy of the instrument on the day of each measurement. 
The system was cleaned (before each measurement day) using 1 % (w/v) Terg-a-zyme® (Sigma 
Aldrich, St. Louis, Missouri), followed by rinsing with water for 30 min. For these flushing 
steps, the flow rate was set to “maximum speed”. Flushing with water was repeated after each 
sample. The “optimization of illumination” routine was performed prior analysis, using 
filtered sample or PBS matching the product to be analyzed. For measuring, 1 ml of sample 
was placed in a 1 ml dual-filter tip on the inlet port. 
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Resonant mass measurement (RMM, Archimedes)  
Resonant mass measurements (RMM) were performed using Archimedes system (RMM0017, 
generation 2) from Malvern instruments LTD (Malvern, United Kingdom). Micro sensor 
chips with internal microchannel dimensions of 8ௗ×ௗ8 ƨm were used for all the experiments. 
The calibration of the sensor was done using 1 ƨm Duke polystyrene size standards (Waltham, 
Massachusetts, USA) diluted in water to approximately 106 particles/ml. The calibration was 
finalized after 300 particles were detected as recommended by the manufacturer. The particle 
density for proteinaceous particles was defined as 1.28 g/ml. Before measurement, one ml of 
the sample to be analyzed was centrifuged 5 min at 1258ௗ×ௗg in order to remove large particles 
that could block the sensor during RMM. Measurements were performed in triplicates and 
the sensor was filled with fresh sample during 40 s before each measurement. The limit of 
detection (also called threshold) was manually set to 0.015 Hz for each analysis. Each 
measurement stopped either after 1 h of measurement or when a total of 4000 particles were 
detected. During measurement, the “autoreplenish” function was automatically activated 
every 500 for 5 s to load fresh sample and avoid settling down of particles in the sensor and 
tubings.  
LC/MS peptide mapping analysis, proteolytic digest of mAb 
For detection and quantification of oxidized amino acids, the mAbs were digested with 
trypsin. First, the protein was denatured in 0.4 M Tris-HCl, 8 M Guanidinium-HCl, at pH 8.5 
by diluting 350 ƨg of oxidized mAb in a total volume of 300 l. For reduction, 10 l of 100 
mg/ml DTT were added and incubated at 50 °C for 1 h. After alkylation of free cysteines by 
adding 10 l of 330 mg/ml iodoacetic acid and incubation at room temperature for 30 min, 
the buffer was exchanged to digestion buffer (0.1 M Tris-HCl, pH 7.0) by using a NAP5 gel 
filtration column. Subsequently, NAP5-eluate (500 l) was mixed with 10 ƨl of a solution of 
0.25 mg/ml trypsin in 10 mM HCl and incubated at 37°C for 18 h. The digestion reaction was 
stopped by adding 50 l of a 10% TFA solution. 
The tryptic peptide mixture was separated by reversed phase-UPLC (ACQUITY, Waters, 
Manchester, UK) on a C18 column (BEH C18 1,7 m, 2,1 x 150 mm; Waters, Manchester, 
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UK) and the eluate online analyzed on a Q-TOF SYNAPT G2 instrument (Waters, 
Manchester, UK). The mobile phases of RP-HPLC consisted of 0.1 % FA in water (solvent A) 
and 0.1 % FA in acetonitrile (solvent B). The chromatography was performed using a linear 
gradient from 1 to 35 % solvent B in 45 min and finally from 35 to 80 % solvent B in 3 min 
using a flow rate of 300 ƨl/min. 3 g digested protein was applied. UPLC-system and mass 
spectrometer were connected by PEEK capillary tubes. Data acquisition was controlled by 
MassLynxTM software (Waters, Manchester, UK).  
MS/MS experiments were performed on a LTQ Orbitrap Velos electrospray mass 
spectrometer (Thermo Scientific, Dreieich, Germany) using the chromatographic system 
described above in order to identify the oxidized peptides. The fragmentation was induced by 
low-energy CID using helium as collision gas (“top5” mode). Data acquisition was controlled 
by Xcalibur software (Thermo Fisher Scientific) using a manual acquisition mode. Oxidized 
amino acids were identified from the MS/MS-data using the software Proteomics Discoverer 
(Thermo Fisher Scientific). The collision energy was adjusted according to stability and mass 
of the parent ion. 
Peptides of interest were identified manually by searching for their theoretical m/z-values 
within the experimental mass spectrum. For their quantification, specific ion current (SIC) 
chromatograms of peptides of interest were generated on the basis of their monoisotopic mass 
and detected charge states using GRAMS AI software (Thermo Fisher Scientific). Relative 
amounts of non-oxidized and oxidized peptides were calculated by manual integration of the 
corresponding peaks. 
Endotoxin 
Endotoxin levels were measured in all samples using a Limulus Amoebocyte Lysate (LAL) 
assay kit according to the manufacturer’s instructions. 
Fourier-transform infrared microscopy (FTIR) measurements 
Samples at 25mg/ml after stress were analyzed by FTIR in ATR mode. Spectra were collected 
from 4000 cm-1 to 850 cm-1 with a resolution of 4 cm-1. 64 scans were averaged for each sample 
139 
 
measurement. Each spectrum was background corrected and vector normalized on the amide 
I band. Finally, the second derivatives of the spectra were calculated and smoothened on 25 
points according to the Savitzky-Golay algorithm. 
Mice and Immunization 
The creation of the transgenic mouse model was published recently by our colleagues.29 
Human IgG transgenic mice on C57BL/6 background used was heterozygous for human Ig. 
Wild type C57BL/6 littermates were used as controls. All mice were kept in an animal facility 
at F. Hoffmann-La Roche, Basel. Experiments were conducted in accordance with protocols 
approved by the Veterinary Office of Kanton Basel. IgG1 particle samples were administered 
subcutaneously twice a week for a total of seven injections (10 ƨg per injection on the side of 
the abdomen). 
ELISA 
For determination of ADAs, ELISA plates (Nunc Immuno MaxiSorp, Rochester, NY) were 
coated overnight with the respective mAb (5 ƨg/ml) that was used for injection and ELISA 
was performed according to standard protocols using alkaline phosphatase-conjugated goat 
anti-mouse IgG (Fc gamma specific) from Jackson Immuno Research. For quantification of 
human IgG1 heavy chain, plates were coated with mouse anti-human IgG (heavy chain 
specific) and detected with biotin mouse anti-human IgG1 followed by alkaline phosphatase-
conjugated streptavidin. Optical densities were read in the ELISA reader at 405 nm. 
Antibodies were purchased from BD Biosciences. 
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Results and discussion 
The aim of this study was to evaluate the immunogenicity of well-characterized subvisible 
proteinaceous particles (presented as unfractionated material or as well-defined fractions) in a 
human IgG1 transgenic mouse model. The mouse model was recently described by Bessa and 
al.29 In our study, a model humanized IgG1 therapeutic antibody was artificially stressed (heat 
stress). Unfractionated material containing protein particles with diameters ranging from 
hundreds of nanometers to approximately hundred micrometers were compared with well-
characterized proteinaceous fractions having distinct mean sizes. The fractions were isolated 
from those unfractionated materials. The methods -fluorescence activated cell sorter (FACS) 
and differential centrifugation- to obtain the several fractions were published recently by our 
group.28 Additional to the investigation of the influence of the particle size, different oxidized 
samples were generated (prior thermal stress) to investigate the impact of specific 
modifications. 
Generation of specific oxidation profile for the different samples 
The initial IgG1 solution was oxidized either by UV treatment or chemically using recently 
published methods, in order to generate samples with various and well-defined oxidation 
profiles.30 More specifically, using hydrogen peroxide (H2O2) in combination with addition of 
free tryptophan allowed for selective oxidation of methionine. The use of 2,2-azobis(2-
amidinopropane) dihydrochloride (AAPH) in combination with free methionine resulted in 
selective tryptophan oxidation whilst methionine oxidation was not significantly altered. 
Oxidation of methionine and tryptophan was achieved using AAPH. A mixture of various 
oxidation species was generated using harsh UV exposure. Those oxidized protein solutions 
were then exposed to heat stress followed by fractionation steps, either by centrifugation or by 
fluorescence activated cell sorter (FACS). 
Generation and characterization of subvisible proteinaceous particle fractions 
An IgG1 molecule was used as a model for this study. To obtain the unfractionated materials 
the initial solution was heat stressed for 3 minutes at 80°C (in addition to 1400 rpm shaking 
during the thermal stress). Then, the samples were homogenized by drawing in and emptying 
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out for 20 consecutive times the solution using a disposable syringe mounted by a needle (see 
material and method for details). The applied stress for this study is considered to be highly 
artificial and not representative of particles found in real marketed product, due to high 
temperature used to generate particles. This stress was used due to its reproducibility and its 
faculty to generate stable particle that we were able to fractionate into fractions of well-defined 
sizes. 
Table 1: Description of the different treatments applied to the IgG1 model to generate the unfractionated 
materials. 
Name Treatment 
Heat stressed unfractionated 
material 
1) 3 minutes 80°C + shaking at 1400rpm + homogenization 
through a syringe mounted with a needle 
UV treated unfractionated 
material 
1) 30 hours at 25°C exposed to light with an irradiance energy 
of 765 W/m2 (using a SunTest XLS+ device) 
2) 3 minutes 80°C + shaking at 1400rpm + homogenization 
through a syringe mounted with a needle 
H2O2 oxidized 
unfractionated material +  
free tryptophan 
1) Treatment with 1% of H2O2 for 24 hours at 5°C in presence 
of an excess of free tryptophan 
2) 3 minutes 80°C + shaking at 1400rpm + homogenization 
through a syringe mounted with a needle 
AAPH oxidized 
unfractionated material  
1) Treatment with 5% of AAPH for 120 hours at 40°C  
2) 3 minutes 80°C + shaking at 1400rpm + homogenization 
through a syringe mounted with a needle 
AAPH oxidized 
unfractionated material + 
free methionine 
1) Treatment with 5% of AAPH for 120 hours at 40°C in 
presence of an excess of free methionine 
2) 3 minutes 80°C + shaking at 1400rpm + homogenization 
through a syringe mounted with a needle 
Fractionation of unfractionated material into well-defined size-fractions was executed using 
either fluorescence activated cell sorter (FACS) or differential centrifugation. The FACS 
method was used here to generate one unique size fraction per unfractionated material 
(reported as Fraction 1 FACS through this manuscript). The details to the isolation by FACS 
of this fraction were published recently by our group.28 Briefly, the particles were sorted 
applying the gate limits as defined by the size standard. 
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Three fractions (Fraction 1-3 centrifugation) per unfractionated material were isolated by 
differential centrifugation using the parameters described recently in our last publication.28 
Table 2: Summary of properties of samples used in in vivo tests. 
Sample 
Flow imaging 
particles/ml 
(1-200 μm) ± 
SD 
Light 
obscuration 
particles/ml 
(1.3-100 μm) ± 
SD 
RMM 
particles/ml 
(0.2-5 μm) ± 
SD 
Mean 
diameter 
measured by 
FI (μm) 
Endotoxin 
content 
EU/ml 
Unfractionated 
material after  
heat stress 
1.4 × 106  
± 5.7 ×103 
1.6× 104  
± 5.1×101 
2.1× 107  
± 3.7 ×106 
10.3 < 0.5 
UV exposed 
unfractionated 
material  
heat stress 
2.8 × 106  
± 1.1 ×105 
1.0× 104  
± 4.3×101 
3.4 × 107  
± 8.3 ×106 
10.8 < 0.5 
Unfractionated 
material 
H2O2 (1%-24h-
5°C with free 
tryptophan) heat 
stress 
2.9 × 106  
± 9.6 ×103 
2.2 × 103  
± 2.6×101 
1.1 × 107  
± 2.8 ×106 
6.3 < 0.5 
Unfractionated 
material 
AAPH
heat stress 
2.2 × 106  
± 1.7 ×104 
1.3 × 104  
± 1.9 ×101 
2.7 × 107  
± 5.7 ×106 
9 < 0.5 
Unfractionated 
material 
AAPH
(5%-40°C-120h 
with free 
methionine) heat 
stress 
2.8 × 106  
± 9.8 ×104 
1.3 × 104  
± 1.6 ×101 
1.4 × 107  
± 2.5 ×106 
8 < 0.5 
Fraction 1  
Centrifugation 
8.0 × 105  
± 3.5 ×103 
9.6× 104  
± 4.1×101 
3.3 × 107  
± 3.4 ×106 
1.4 < 0.5 
Fraction 1  
UV exposed 
Centrifugation 
3.6 × 106  
± 1.0 ×105 
8.4× 104  
± 2.9×101 
2.7 × 107  
± 1.2 ×106 
1.4 < 0.5 
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Sample 
Flow imaging 
particles/ml 
(1-200 μm) ± 
SD 
Light 
obscuration 
particles/ml 
(1.3-100 μm) ± 
SD 
RMM 
particles/ml 
(0.2-5 μm) ± 
SD 
Mean 
diameter 
measured by 
FI (μm) 
Endotoxin 
content 
EU/ml 
Fraction 1 
H2O2 with free 
tryptophan 
Centrifugation 
1.6 × 106  
± 4.2 ×104 
6.6× 104  
± 4.2×102 
3.5 × 107  
± 6.1 ×106 
1.3 < 0.5 
Fraction 1 
AAPH
Centrifugation 
9.9 × 105  
± 2.8 ×104 
4.9× 104  
± 8.4×101 
2.7 × 107  
± 1.1×107 
1.3 < 0.5 
Fraction 1  
AAPH with free 
methionine  
Centrifugation 
1.2 × 106  
± 1.6 ×104 
7.1× 104  
± 5.6×102 
2.5 × 107  
± 1.8×106 
1.3 < 0.5 
Fraction 2  
Centrifugation 
2.9 × 105  
± 7.5 ×103 
2.4× 105 
± 9.7×102 
9.3 × 104  
± 5.4×104 
16.5 < 0.5 
Fraction 2  
UV exposed 
Centrifugation 
2.5 × 105  
± 4.4 ×103 
2.0× 105 
± 6×102 
9.7 × 103  
± 1.2×104 
17.5 < 0.5 
Fraction 2 
H2O2 with free 
tryptophan 
Centrifugation 
2.6 × 105  
± 7.5 ×103 
2.0× 105 
± 1.1×103 
1.4 × 104  
± 1.1×104 
15.9 < 0.5 
Fraction 2 
AAPH
Centrifugation 
3.0 × 105 
 ± 1.7 ×103 
2.3× 105 
± 2.8×103 
1.7 × 105 
 ± 5.7×104 
15.7 < 0.5 
Fraction 2  
AAPH with free 
methionine  
Centrifugation 
2.4 × 105  
± 2.1 ×103 
1.9× 105 
± 1.4×103 
5.1 × 104  
± 4.8×104 
16.9 < 0.5 
Fraction 1 
FACS 
7.3× 105  
± 8.4 ×103 
1.4 × 104  
± 4.3 ×101 
2.7 × 105  
± 1.1 ×105 
12.7 < 0.5 
Fraction 1  
UV exposed 
FACS 
5.9 × 105  
± 6.5 ×103 
1.7 × 104  
± 2.5 ×102 
4.3 × 105  
± 4.4 ×103 
12.2 2.0 
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Sample 
Flow imaging 
particles/ml 
(1-200 μm) ± 
SD 
Light 
obscuration 
particles/ml 
(1.3-100 μm) ± 
SD 
RMM 
particles/ml 
(0.2-5 μm) ± 
SD 
Mean 
diameter 
measured by 
FI (μm) 
Endotoxin 
content 
EU/ml 
Fraction 1 
H2O2 with free 
tryptophan 
FACS  
1.0 × 106  
± 1.3 ×104 
6.7 × 105  
± 3.0 ×103 
3.7× 107  
± 4.2 ×106 
10.1 9.9 
Fraction 1 
AAPH
FACS  
1.2 × 106  
± 8.7 ×103 
9.4× 105  
± 1.4 ×103 
7.8 × 107  
± 3.9 ×105 
9.1 128 
Fraction 1 
AAPH with free 
methionine 
FACS  
1.2 × 106  
± 9.1 ×103 
1.0 × 106  
± 1.3 ×104 
8.8 × 107  
± 2.3 ×106 
9 37.6 
Fraction 3  
Centrifugation 
7.4 × 104  
± 2.7 ×103 
6.7× 104  
± 8.2 ×102 
3.4 × 104  
± 3.2×104 
36.1 < 0.5 
Fraction 3  
UV exposed 
Centrifugation 
6.4 × 104  
± 3.9 ×103 
5.0× 104  
± 1.1 ×103 
1.8 × 104  
± 1.1×104 
36.2 < 0.5 
Fraction 3 
H2O2 with free 
tryptophan 
Centrifugation 
5.3 × 104  
± 4.2 ×103 
4.7× 104  
± 3.7 ×102 
1.4 × 105  
± 7.4×104 
39.1 < 0.5 
Fraction 3 
AAPH
Centrifugation 
5.1× 104  
± 2.7 ×103 
4.4× 104  
± 8.6 ×102 
1.4 × 105  
± 4.2×104 
38.6 < 0.5 
Fraction 3  
AAPH with free 
methionine  
Centrifugation 
5.7× 104  
± 3.9 ×103 
4.5× 104  
± 7.5 ×102 
1.9 × 105  
± 1.0×104 
38.4 < 0.5 
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Figure 1: Size distribution of unfractionated materials measured by RMM. Heat stressed unfractionated 
material (black line), UV-treated unfractionated material (red line), H2O2 oxidized unfractionated material with 
addition of free tryptophan (blue line), AAPH oxidized unfractionated material (pink line) and AAPH oxidized 
unfractionated material with addition of free methionine (green line) are shown. Error bars represent standard 
deviation of three measurements. 
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Figure 2: Size distribution of unfractionated materials measured by MFI (panel A) and corresponding zoom 
in (panel B). Heat stressed unfractionated material (black line), UV-treated unfractionated material (red line), 
H2O2 oxidized unfractionated material with addition of free tryptophan (blue line), AAPH oxidized unfractionated 
material (pink line) and AAPH oxidized unfractionated material with addition of free methionine (green line) are 
shown. Error bars represent standard deviation of three measurements. 
 
The isolated fractions (4 per treatment, i.e. 20 in total) as well as the 5 unfractionated 
materials were characterized using light obscuration, micro flow imaging (MFI) and resonant 
mass measurements (RMM) to obtain their particle size distributions. Table 2 summarizes the 
characteristics of the unfractionated materials and the corresponding fractions. As expected 
for the unfractionated materials, the particles are broadly distributed over the full size range. 
However, distinct differences can be observed between the size distribution of the different 
unfractionated materials measured by RMM and by MFI as depicted in Figure 1 and 2. Larger 
particles were measured for oxidized unfractionated samples in comparison to the untreated 
unfractionated material obtained only after thermal stress. As a direct consequence, the 
resulting mean size measured by MFI was impacted and differences were noticed in the mass 
profile of the different unfractionated materials (data not shown here). The oxidized IgG1 was 
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not as stable as the unmodified IgG1 and formed therefore larger particles faster during 
thermal stress. 
 
Figure 3: Size distribution of Fraction 1 (centrifugation) measured by RMM (panel A) and MFI (panel B). 
Heat stressed (black line), UV-treated (red line), H2O2 oxidized with addition of free tryptophan (blue line), AAPH 
oxidized (pink line) and AAPH oxidized with addition of free methionine (green line) samples are shown. Error 
bars represent standard deviation of three measurements. 
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Based on those observations, the use of unfractionated material to compare the potential 
immunogenicity of differently treated samples might only be partially informative due to the 
differences in their size profiles. This is why well-defined size fractions were prepared. Only 
slight differences can be seen between size distributions of fractions isolated by differential 
centrifugation as seen in Figure 3, Figure 4 and Figure 6 where RMM and MFI results are 
presented. The mean sizes obtained from MFI measurements are comparable and the size 
profiles are similar except with regard to the presence of nanoparticles in some of the Fraction 
2 and 3 (obtained after isolation by centrifugation). The higher count of nanoparticles present 
in some of those fractions might be attributed to a possible manual handling mistake during 
the centrifugation steps where the separation of the supernatants from the pellets occurred 
several times to achieve the right volume and concentration. This contamination through 
nanoparticles remains low (105 particles per ml) and those differences did not impact the mass 
distribution of the fractions because one large particle represents much more protein than a 
small particle, but the differences were visible when comparing only size profiles obtained by 
RMM. However, the concentrations of nanoparticles in the Fractions 2-3 isolated by 
centrifugation are minimal in comparison to contaminations in Fractions 1 collected by 
FACS, where more than 107 particles per ml could be detected. The RMM measurements 
showed that those fractions contained relatively high amounts of contaminating nanoparticles 
(see Figure 5). Possible explanations for the presence of those nanoparticles were discussed in 
our last publication.28 This can be attributed either to (1) the possible break-up or aggregation 
of particles upon sorting due to the mechanical forces that are applied apart, (2) coincidence 
of two particles in one drop or (3) partial blocking of the nozzle by large particles causing 
diversion of the stream.28 A resorting by FACS of the isolated Fractions 1 would have led to 
higher purity but the resulting protein concentration would have been too low for the 
subsequent in vivo biological experiments. Therefore, resorting of the different fractions was 
not performed. The presence of nanoparticle is one major difference between similar size 
fractions (Fraction 1 FACS, and Fraction 2 Centrifugation). For further studies, the 
purification of those FACS fractions will need to be achieved, in order to obtain similar 
properties as obtained after isolation by centrifugation regarding levels of contaminating 
nanoparticles. A combination of both methods could be a good option to optimize this point. 
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Figure 4: Size distribution of Fraction 2 (centrifugation) measured by RMM (0-1 μm) and MFI (1-100 μm). 
Fraction 2 heat stressed (black line), UV-treated (red line), H2O2 oxidized with addition of free tryptophan (blue 
line), AAPH oxidized (pink line) and AAPH oxidized with addition of free methionine (green line) are shown. 
Error bars represent standard deviation of three measurements. 
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Figure 5: Size distribution of Fraction 1 (FACS) measured by RMM (0-1 μm) and MFI (1-100 μm). Fraction 
1 heat stressed (black line), UV-treated (red line), H2O2 oxidized with addition of free tryptophan (blue line), 
AAPH oxidized (pink line) and AAPH oxidized with addition of free methionine (green line) are shown. Error bars 
represent standard deviation of three measurements. 
 
Beside the characterization regarding the size of the particles, the secondary structure of the 
IgG1 was investigated using Fourier transform infrared spectroscopy (FTIR). The applied 
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combination of stresses (i.e. oxidation and/or thermal stress) did not lead to a substantial 
alteration of the secondary structure of the antibody as depicted in Figure 7. No differences of 
the secondary structure between control material in solution (i.e. initial sample before heat 
stress) and unfractionated materials (chemically modified or not) were observed. The spectra 
are dominated by the strong valley at 1615 cm-1, associated with the typical intramolecular ƞ-
sheet structure of antibodies.  
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Figure 6: Size distribution of Fraction 3 (centrifugation) measured by RMM (0-1 μm) and MFI (1-100 μm). 
Fraction 3 heat stressed (black line), UV-treated (red line), H2O2 oxidized with addition of free tryptophan (blue 
line), AAPH oxidized (pink line) and AAPH oxidized with addition of free methionine (green line) are shown. 
Error bars represent standard deviation of three measurements. 
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Figure 7: Second derivative - Fourier transform infrared spectroscopy (FTIR) spectra. Second derivative 
FTIR curves of control material (dashed black line), heat stressed unfractionated material (black line), UV-treated 
unfractionated material (red line), H2O2 oxidized with addition of free tryptophan unfractionated material (blue 
line), AAPH oxidized unfractionated material (pink line) and AAPH oxidized unfractionated material with 
addition of free methionine (green line). 
LC/MS peptide mapping was used to characterize the chemical modifications present on the 
protein primary structure. The summary of the obtained results is depicted in Table 3. FACS-
fractions present higher oxidation levels than fractions obtained by differential centrifugation. 
The stresses/treatments that protein particles are exposed to during the flow cytometry 
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fractionation process seem to induce additional modifications on the protein primary 
structure. This will need to be investigated in detail in a further study. During flow cytometry 
fractionation, the particles are exposed to several different types of stress (i.e. mechanical, 
chemical and electrical) that may induce modifications on the protein primary structure. 
The first goal regarding oxidation was to generate samples presenting high levels of 
methionine oxidation (with low level of tryptophan oxidation). This could be achieved by 
using chemical treatment with H2O2 with addition of free tryptophan in solution as described 
elsewhere by Folzer et al..30 Indeed, the tryptophan oxidation was protected by the free 
tryptophan in solution and the corresponding oxidation remained very low after chemical 
oxidation (see Table 3). This remained valid after additional thermal treatment. Secondly, 
samples presenting high levels of tryptophan oxidation (with low level of methionine 
oxidation) needed to be generated. This part could be achieved by using AAPH with the 
addition of free methionine, as a protective agent, before performing chemical oxidation. The 
oxidation of methionine in these samples remained very low in comparison to tryptophan 
oxidation that was dominant. Last but not least, samples presenting high oxidation levels of 
methionine and tryptophan could be produced by using AAPH (without protection) or UV 
treatment. Besides methionine and tryptophan modifications, other modifications were 
detected in the UV-treated samples which could not be further identified yet (unknown 
peaks) due to the complexity of possible interaction products (identification is ongoing). 
Moreover, CE-SDS (reduced and non-reduced) experiments to assess the presence of covalent 
linkage in the various samples were performed. Clear presence of covalent bounds was visible 
in UV-treated samples (data not shown here). 
 
Table 3: Summary LC/MS peptide mapping results of the different unfractionated materials and 
corresponding fractions for each different treatment. The mAb was denatured and the disulfide bridges were 
reduced using DTT. Alkylation of free cysteines was performed using iodoacetic acid. After a buffer exchange, the 
mAb was finally digested with trypsin. LC stands for light chain, HC stands for heavy chain. Methionine (M) and 
tryptophan (W) oxidation levels were quantified.  
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Species
unfractionated 
material after 
heat stress
Fraction 1 
Centrifugation
Fraction 2 
Centrifugation
Fraction 1
FACS
Fraction 3
Centrifugation
LC M4 ox 3.0 1.4 1.0 1.6 2.1
HC M34 ox 6.7 2.2 2.2 3.0 3.8
HC M83 ox 8.1 2.2 3.1 2.0 6.3
HC M258 ox 6.1 4.1 4.4 8.6 6.1
HC M364 ox 1.4 0.2 0.4 0.2 1.1
HC M434 ox 3.3 2.5 2.1 3.0 2.9
LC W96 ox 6.1 1.3 1.2 0.1 5.6
HC W50 ox 8.5 2.2 2.0 1.6 4.5
HC W108 ox 4.0 12.5 3.7 2.3 6.9
Species
UV exposed 
unfractionated 
material 
heat stress
Fraction 1 
UV exposed 
Centrifugation
Fraction 2 
UV exposed 
Centrifugation
Fraction 1 
UV exposed 
FACS
Fraction 3
UV exposed 
Centrifugation
LC M4 ox 1.0 13.9 2.9 6.1 1.0
HC M34 ox 5.2 18.9 6.4 6.2 3.6
HC M83 ox 3.0 21.1 6.2 3.7 1.3
HC M258 ox 87.9 82.4 80.8 60.2 59.3
HC M364 ox 9.7 9.5 7.1 7.0 7.8
HC M434 ox 71.9 69.3 66.3 71.2 71.7
LC W96 ox 2.1 19.4 3.1 0.8 0.9
HC W50 ox 20.3 37.4 17.7 20.9 19.5
HC W108 ox 41.3 5.6 35.9 38.4 47.1
Species
unfractionated 
material
H2O2 heat stress
Fraction 1
H2O2
Centrifugation
Fraction 2
H2O2
Centrifugation
Fraction 1
H2O2
FACS 
Fraction 3 
H2O2
Centrifugation 
LC M4 ox 1.3 1.2 1.2 5.9 1.3
HC M34 ox 3.1 3.3 3.0 13.9 3.0
HC M83 ox 1.2 1.2 1.2 8.6 1.3
HC M258 ox 66.8 66.5 66.7 63.7 67.4
HC M364 ox 88.5 88.2 89.5 88.4 87.4
HC M434 ox 97.1 97.0 97.0 96.7 97.1
LC W96 ox 0.3 0.1 0.2 0.5 0.2
HC W50 ox 1.5 1.7 1.4 3.0 1.4
HC W108 ox 4.3 2.5 3.1 4.1 3.0
Species
unfractionated 
material
AAPH
heat stress
Fraction 1
AAPH
Centrifugation
Fraction 2
AAPH
Centrifugation
Fraction 1
AAPH
FACS 
Fraction 3 
AAPH
Centrifugation 
LC M4 ox 4.9 4.7 4.9 5.2 4.5
HC M34 ox 4.9 4.9 4.9 6.7 4.9
HC M83 ox 5.2 4.6 5.0 4.9 4.5
HC M258 ox 62.8 63.6 64.2 64.6 65.3
HC M364 ox 6.1 5.7 5.6 6.3 5.4
HC M434 ox 72.6 73.2 72.2 73.4 72.2
LC W96 ox 0.8 0.7 0.8 0.8 0.8
HC W50 ox 17.6 17.9 17.9 17.7 17.7
HC W108 ox 71.8 74.5 77.5 71.8 77.2
Species
unfractionated 
material
AAPH
(5%-40°C-120h 
with free 
methionine) 
heat stress
Fraction 1 
AAPH with free 
methionine 
Centrifugation
Fraction 2  
AAPH with free 
methionine
Centrifugation
Fraction 1
AAPH with free 
methionine
FACS 
Fraction 3 
AAPH with free 
methionine
Centrifugation
LC M4 ox 1.1 1.2 1.3 5.1 1.3
HC M34 ox 1.2 1.3 1.4 12.8 1.3
HC M83 ox 0.8 1.0 1.1 7.4 1.0
HC M258 ox 7.9 10.2 9.0 18.2 7.9
HC M364 ox 0.2 0.2 0.2 0.4 0.2
HC M434 ox 2.3 2.4 2.3 6.6 2.0
LC W96 ox 0.4 0.4 0.4 2.2 0.4
HC W50 ox 19.1 19.7 19.0 33.7 19.2
HC W108 ox 65.9 68.0 62.9 76.3 56.2
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Since endotoxins are known to induce severe immune responses or even septic shock in 
patients, the samples were checked for endotoxins. Endotoxin levels were higher for FACS-
fractions than for unfractionated materials and fractions isolated by centrifugation (see Table 
1).31 The presence of endotoxin in samples and corresponding effects were tested in previous 
study of our group and no undesirable immune responses triggered by pyrogens was shown to 
bias the results.29 We assume that this remains true for the FACS fractions of this study. 
Moreover, investigations are performed at the moment to reduce the endotoxin levels in 
samples obtained after FACS.  
Immune responses in human IgG1 transgenic mice and wild type mice 
The transgenic mouse model developed by Bessa et al. was used for our investigation.29 The 
same immunization protocol was applied for our experiment as the one used by our 
colleagues in their previous study.29 An immunization protocol using repeated subcutaneous 
applications of 10 ƨg protein per injection (twice a week; for a total of 7 injections) was used. 
A total of 5 wild type mice and 5 transgenic mice were immunized with each sample 
(unfractionated or fractions; total of 25 samples). After 28 days, humoral responses under the 
form of anti-drug antibodies (ADAs) were characterized by ELISA for both the wild type and 
the transgenic mice. In order to assess the ADAs production for each individual mouse, the 
optical densities at 405 nm in the serum were measured (after dilution) and compared to the 
buffer control. Injected samples presented level of particles tested that were considerably 
higher than one would measure in marketed product. Indeed, hundred percent of the protein 
amount contained in the sample was present under the form of particles. Such a sample would 
definitely not go through analytical testing performed before delivery to the market. 
In contrast to the antibody response observed in wild type non-transgenic littermate C57BL/6 
control mice, human IgG1 transgenic mice were clearly unresponsive to thermal stressed 
unfractionated material (generated only by artificial heat stress). Immunization with 
unmodified corresponding fractions revealed that whereas all five samples were highly 
immunogenic in wild type animals, no response was observed in the transgenic mouse model 
(only one transgenic mouse elicited a low immune response in the case of Fraction 3 
centrifugation – large particles). 
157 
 
No significant differences between immune responses for the different stresses obtained after 
injection into wild type animals were observed. All five samples (unfractionated materials and 
fractions) per type of treatment were highly immunogenic and broke tolerance in wild type 
animals as depicted in Figure 8 for all oxidized samples obtained after the different treatments 
(UV, H2O2, AAPH and AAPH with addition of free methionine). However, the immune 
responses are clearly lower for oxidized samples injected into the transgenic animals than 
responses obtained after injection into wild type animals (see Figure 8).  
158 
 
 
159 
 
Figure 8: Immune responses induced by heat stressed samples (panel A), UV-treated samples (panel B), 
H2O2 oxidized with addition of free tryptophan samples (panel C) AAPH oxidized samples (panel D) and 
AAPH oxidized with addition of free methionine samples (panel E). Specific IgG responses were determined 
by ELISA 28 days post the first immunization in wild type animals (black triangles, wt) and transgenic animal (red 
triangles, tg). Data shown represent mean IgG ELISA titers ± SEM of 5 mice per group. 
A maximum of two transgenic animals responded to oxidized samples in the case of 
unfractionated materials or fractions isolated by centrifugation whereas the level of responses 
is higher for FACS fractions, where up to five transgenic animals (out of 5) showed a breakage 
of tolerance, for example in the case of AAPH oxidations (panel D and E, Figure 8). FACS 
fractions always showed higher immune responses than almost similar size-fractions 
separated by differential centrifugation (Fraction 3 centrifugation) as presented in Figure 8. 
High level of contaminating nanoparticles in the FACS fractions and not in the centrifugation 
fractions is the only difference beside higher level of oxidation observed in FACS fractions. 
This has to be kept in mind for the interpretation of the immune responses because small 
particles might potentially be taken up easily and faster than large particles. 
As a general remark when looking at the in vivo results (Figure 8), the explanation offered by 
Bessa et al. that the immunogenic potential of soluble aggregates of human IgG1 strongly 
depends on the presence of neoepitopes resulting from harsh stress conditions, i.e. extensive 
exposure to artificial light or in our case harsh chemical treatment seem to remain valid for 
subvisible particles as well.29 It is likely that the chemical amino acid modifications were 
rendering oxidized samples more immunogenic than their unmodified counterpart. Indeed, 
samples carrying a high degree of chemical modifications (neoepitopes) within the primary 
structure were more immunogenic than unmodified samples in the transgenic mice. Oxidized 
subvisible particles may mimic immune complexes and may bind to FcƟR on antigen-
presenting cells (APCs) allowing presentation of chemically modified epitopes. Moreover, B 
cells specific for both modified and native structures of IgG1 particles are present in 
transgenic mice. By challenging transgenic mice with native IgG1, they will not be activated 
due to the absence of auto reactive T-cells specific for native IgG1 epitopes. However, CD4+ 
T-cells specific for neoepitopes can be activated in transgenic mice. Once activated they will 
provide help to B cells recognizing IgG1 that will lead to plasma cell differentiation and ADAs 
production.29 
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Nevertheless, it has to be mentioned that the immunogenic response using UV-treated 
subvisible particles (panel B, Figure 8) was drastically lower than in the case of UV-treated 
oligomers observed by Bessa et al. using the same IgG1 model and the same transgenic mouse 
model.29 This is again a hint, to say that specific aggregate and particle sizes may potentially 
enhance the immune response triggered by the neoepitopes as already observed between 
monomers, dimers and oligomers. The uptake seems to be different according to sizes but this 
needs surely to be verified in future studies. 
In our study the immunization was done subcutaneously. In the case of micrometer-sized 
particles, it might not be the most favorable injection method because large particles will have 
difficulties for being taken up in the blood steam and lymphatic system. A protein depot 
might change or alter the pharmacokinetic profile. In literature, higher immunogenicity in 
comparison to subcutaneous injection was observed for recombinant murine growth 
hormone subvisible particles injected intravenously.32 Injection of labelled size fractions (with 
and without chemical modifications in their primary structure), would be very useful in order 
to identify the uptake mechanism and assess if there is a size-dependency or not. The method 
of injection as well as a detailed pharmacokinetic profile should also be investigated in the 
future, especially in the case of large subvisible particles. 
As already mentioned in literature, other factors beside the extent of chemical modifications, 
like the hydrophobicity, the solubility and the conformation of aggregates or protein particles 
may also play an important role in influencing the pharmacokinetic and their related 
immunogenicity.33 To understand all those attributes, further investigations are clearly 
needed.  
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Conclusions 
This study showed that unmodified subvisible particles (unfractionated or well-defined size 
fractions) obtained after highly artificial heat stress were not immunogenic in transgenic mice 
expressing a mini-repertoire of human IgG1 antibodies, whereas corresponding artificially 
generated subvisible particles presenting high levels of chemical modifications in their 
primary structure resulting of UV-treatment or chemical oxidation with H2O2 or AAPH prior 
to heat stress were immunogenic and a break of tolerance was visible. The immune response 
of modified samples is however quite low in comparison to the response induced in a previous 
study using light exposed oligomers (see Bessa et al.).29 For the moment, with the available 
results, it is not possible to understand whether the immune response is size-dependent or 
not. Nevertheless, one plausible hypothesis, would lead us to say that the observed immune 
response seem to depend on the extent of chemical modifications present in the protein 
primary structure. This point remains hypothetical due to the fact that no specific 
modification could be identified as enhancer of the immune response and because of the 
presence of modifications which were not quantifiable (i.e. stayed as unknown peaks in the 
LC/MS peptide mapping analysis). Further investigation will be needed to understand why 
FACS fractions have always shown higher immune responses than similar size-fractions 
separated by differential centrifugation.  
The use of this transgenic mouse model will hopefully be a very useful tool in the future, 
allowing the identification of potentially immunogenic modifications in subvisible particles. 
Last but not least, it would be very interesting to identify how much particulated material of a 
defined size is really needed to break tolerance.  
As different antibodies react differently upon stress conditions, the use of a single IgG1 as a 
model mAb for our experiments is limiting the general nature of our findings.15 Experiments 
using a second IgG1 molecule and different stresses are currently ongoing in our lab. 
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FINAL CONCLUSIONS 
With respect to quality of protein biotherapeutics, protein aggregation and particle formation 
have recently received increased interest from industry, academia, and regulators because 
some aggregates and/or particles may have biological consequences such as unexpected 
immunogenicity, altered bioactivity and/or altered pharmacokinetics. Besides many other 
factors, unexpected immunogenicity is particularly supposed to be related to aggregates and 
particles which are suspected to activate the immune system and to initiate the elicitation of 
antibodies by B cells.8-10 However, it is still unknown, if aggregates/particles in general or only 
some particular structures are responsible for the activation of the immune system.  
The overall aim of this thesis was to investigate the potential immunogenicity of well-
characterized protein subvisible particles using an in-house previously established in vivo 
mouse model.15 In order to achieve this goal; some tools had first to be developed.  
Chapter 1: Determination of the density of protein particles using a suspended 
microchannel resonator 
Chapter 1 describes the method development for determination of the density of 
proteinaceous particles without extrapolation using RMM as known as Archimedes. 
Unfortunately up to now, the density of proteinaceous particles, as a crucial particle 
parameter for weight-based techniques like RMM, have not been determined experimentally. 
All prior published studies reporting characterization of proteinaceous submicron/subvisible 
particles using RMM utilize therefore estimates of the density of these particles, thus 
introducing unknown error into these measurements. In our work, particles created by 
stressing three different proteins (2 different IgG1 monoclonal antibodies and BSA) using 
four different types of stress conditions (heat, solvent-induced precipitation, stirring and 
shaking) were measured after an optimization of the method with commercially available 
standard beads (latex, polymethacrylate and melamine) of defined sizes and densities. Media 
with increasing densities from 1.00 to 1.65 g/cm3 (water, PBS, D2O, CsCl 20%, CsCl 30%, CsCl 
40%, CsCl 50%, CsCl 55% w/w) were used to measure in triplicate the buoyant mass of the 
various samples over selected size ranges. The determinations of particle densities were 
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performed by evaluating the change in the mean buoyant mass of the measured particles 
relative to changes in solution density. The intercept of the linear regression with the Y-axis 
(where the buoyant mass is equal to zero, neutral density) gave the density of the measured 
particles. Interestingly, the measured densities for proteinaceous particles (1.28-1.33 g/cm3) 
originating from three different proteins and various stress conditions (heat, solvent-induced 
precipitation, stirring and shaking) were slightly lower than previous estimates and relatively 
small differences were observed between different proteins and different stress conditions. We 
could observe that using the newly determined density value of 1.28 g/cm3 for mAb-derived 
particles instead of previously suggested 1.32 or 1.35 g/cm3 has a slight impact on the particle 
size distribution measured by RMM. This impact increases as a consequence of increasing 
particle sizes. 
Chapter 2: Comparative evaluation of two methods for preparative fractionation of 
proteinaceous subvisible particles - differential centrifugation and FACS 
Species larger than hundreds of nanometer in diameter are currently difficult to fractionate to 
study their individual physical and biological properties. Recently, fractionation of particles 
using a cell sorter (FACS) was presented to physically separate discrete micrometer size 
fractions of subvisible proteinaceous particles out of a mixture of aggregates encompassing a 
continuous size distribution.11,12 In other studies, rather crude centrifugation was applied to 
obtain mostly two fractions: one pellet (insoluble protein, i.e. particles) and soluble protein 
(including aggregates) present in the supernatant.13 In chapter 2, we describe the method 
development of a differential centrifugation separation strategy for fractionation of 
proteinaceous subvisible particles. Four different fractions were isolated using a first set of 
exploratory experiments in order to identify the critical experimental parameters that might 
have an impact on the process performances. The fractionation strategy was further optimized 
using a DoE-approach, which allowed refinement of all parameters leading to higher purity of 
the selected fractions. The differential centrifugation separation strategy was then compared 
to the fractionation of particles using a cell sorter (FACS). Similar size-fractions of 
proteinaceous subvisible particles were isolated using both methodologies. It was noticed that 
both techniques present advantages and disadvantages regarding the unwanted presence of 
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nanoparticles, the purity [peak sharpness], the final particle concentration, the size range 
applicability, the preparation time and the need of additives to achieve fractionation. Both 
methods will likely find complementary use in the research practice. The new differential 
centrifugation strategy is a valuable addition to the toolbox of methods for researching 
subvisible proteinaceous particles in relevant models. 
Chapter 3: Selective oxidation of methionine and tryptophan residues in a therapeutic 
IgG1 molecule 
In literature, beside the type of stress to generate aggregate and/or particles, it was reported 
that the related oxidation profile also plays an important role for potential induced 
immunogenicity of those species.14 Cysteine, histidine, methionine, phenylalanine, tryptophan 
and tyrosine residues were identified as major oxidation sites in proteins due to the high 
reactivity of sulfur atoms and aromatic rings towards various reactive oxygen species. Most of 
the time after stress or forced oxidation studies, several residues (i.e. amino acids) are 
concurrently oxidized, making the definition of the individual contribution of these 
individual residues to the overall effects difficult to delineate. We could observe that samples 
that were first irradiated with UV light (Atlas Suntest instrument) and were then heat stressed 
to generate large amount of subvisible particles were able to break immune tolerance (whereas 
only heat stressed samples were not able). Those samples presented not only a broad 
oxidation of methionine and tryptophan residues but also non-identified species. It was 
therefore difficult to draw conclusions and to link our observation to individual contribution 
of specific chemical modifications. Thus, we developed a method to selectively oxidize 
methionine and tryptophan in a model mAb in order to improve the understanding of the 
relationship between structure and functional consequences. Using hydrogen peroxide (H2O2) 
or tert-butyl hydroperoxide (t-BHP) in combination with addition of free L-tryptophan (as a 
protective agent) allowed for selective oxidation of methionine. The use of 2,2-azobis(2-
amidinopropane) dihydrochloride (AAPH) in combination with free L-methionine resulted 
in selective tryptophan oxidation. Different reaction conditions such as incubation 
temperature, reaction time and oxidant concentration were evaluated and selected to achieve 
our goal.  
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Chapter 4: Evaluation of the biological effect of proteinaceous particles by using a 
transgenic mouse model 
We assessed the immunogenicity of well-defined size fractions prepared either by differential 
centrifugation or by fluorescence activated cell sorter (FACS) using an in-house transgenic 
mouse model expressing a mini-repertoire of human IgG1 antibodies. The size (mean 
diameter) of these fractions ranged from 1 to 40 m including chemically unmodified 
material as well as oxidized material obtained following different treatments (UV exposure or 
chemical oxidations using methods reported in chapter 3). This study showed that native 
subvisible particles (unfractionated material or well defined fractions, without chemical 
modification) were not immunogenic in our transgenic mouse model whereas corresponding 
highly oxidized samples presenting high levels of chemical modifications in their primary 
structure were immunogenic and showed breakage of tolerance. This response seems to be 
size-dependent and also is most probably dependent on the extent of chemical modifications. 
Those last two points remained as hypothetical for the moment. 
In this last chapter we could show that the use of this transgenic mouse model is appropriate 
and is a very useful tool allowing the identification of potential immunogenicity for subvisible 
particles. However, research needs to be done in order to identify which specific modification 
plays a role in the observed breakage of tolerance. In the future, injections of labeled size 
fractions (with or without chemical modifications in their primary structure) will be 
performed, it will be very useful in order to identify the uptake pathway of subvisible particles 
and assess if the uptake of subvisible particles is size dependent or not. Last but not least, the 
planned experiment for the future will also help to assess if the method of injection and the 
dose have an impact on the level of observed immune responses (especially in the case of large 
subvisible particles).  
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